UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-K10-K/A

(Amendment No. 1)

   Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Fiscal Year Ended December 31, 20202021

or

   Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period from _____ to ______

Commission file number 000-19364

 

 

TIVITY HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

 

 

62-1117144

(State or other jurisdiction of

 

 

 

(I.R.S. Employer

incorporation or organization)

 

 

 

Identification No.)

 

 

 

 

 

701 Cool Springs Boulevard, Franklin, TN  37067

(Address of principal executive offices) (Zip code)

 

 

 

 

 

(800) 869-5311

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock - $.001 par value

TVTY

The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  

 

No  

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.

Yes 

 

No  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes  

 

 

No  

 

 


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes  

 

No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer," “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  

Accelerated filer  

Non-accelerated filer  

Smaller reporting company  

 

 

 

 

Emerging growth company  

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

Indicate by check mark whether the Registrantregistrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes  

 

No  

 

As of June 30, 2020,2021, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $487.1 million$1.2 billion based on the price at which the shares were last sold for such date on The Nasdaq Stock Market LLC.

 

As of February 19, 2021, 49,151,49117, 2022, 49,823,312 shares of common stock were outstanding.

 

Auditor Name:
PricewaterhouseCoopers LLP

Auditor Location:
Nashville, TN

Auditor Firm
PCAOB ID: 238

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.

 


2


Tivity Health, Inc.

Form 10-K10-K/A

 

Table of Contents

 

 

 

 

Page

Part IIII

 

 

 

 

Item 1.

BusinessItem 10.

4Directors, Executive Officers and Corporate Governance

5

 

Item 1A.

Risk FactorsItem 11.

9Executive Compensation

13

 

Item 1B.

Unresolved Staff CommentsItem 12.

18Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

48

 

Item 2.

PropertiesItem 13.

18Certain Relationships and Related Transactions, and Director Independence

52

 

Item 3.

Legal Proceedings

19

 

Item 4.14.

Mine Safety DisclosuresPrincipal Accounting Fees and Services

1955

 

 

 

 

Part IIIV

 

 

 

 

Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

20

Item 6.

Selected Financial Data

22

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

24

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

36

Item 8.

Financial Statements and Supplementary Data

38

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

76

Item 9A.

Controls and Procedures

76

Item 9B.

Other Information

76

Part III

Item 10.

Directors, Executive Officers and Corporate Governance

77

Item 11.

Executive Compensation

77

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

77

Item 13.

Certain Relationships and Related Transactions, and Director Independence

77

Item 14.

Principal Accounting Fees and Services

78

Part IV

 

Item 15.

Exhibits, Financial Statement Schedules

79

Item 16.

Form 10-K Summary

8456

 

3


PART I


Explanatory Note

Tivity Health, Inc. (also referred to herein as the “Company”, “we”, “us” or “our”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Original Form 10-K”) with the United States Securities and Exchange Commission (the “Commission”) on February 25, 2022. The Company is filing this Amendment No. 1 to the Original Form 10-K (this “Form 10-K/A”) solely for the purpose of including in Part III the information that was to be incorporated by reference from the Company’s definitive proxy statement for its 2022 Annual Meeting of Shareholders, because the Company’s definitive proxy statement will not be filed with the Commission within 120 days after the end of the Company’s fiscal year ended December 31, 2021. This Form 10-K/A hereby amends and restates in their entirety Items 10 through 14 of Part III of the Original Form 10-K. Additionally, this Form 10-K/A hereby amends and restates the cover page of the Original Form 10-K to remove the statement that information is being incorporated by reference from the Company’s definitive proxy statement.

Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Form 10-K/A also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV has also been amended and restated in its entirety to include the currently dated certifications as exhibits, and to reference the consolidated financial statements previously filed with the Original Form 10-K. Because no consolidated financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation SK, paragraphs 3, 4 and 5 of the certifications have been omitted.

No attempt has been made in this Form 10-K/A to modify or update the other disclosures presented in the Original Form 10K, including, without limitation, the consolidated financial statements. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or update the disclosures in the Original Form 10-K, except as set forth in this Form 10-K/A, and should be read in conjunction with the Original Form 10-K and the Company’s other filings with the Commission. Terms used but not defined herein are as defined in our Original Form 10-K.  As used throughout this Annual Report on Form 10-K (this “Report”), unless the context otherwise indicates, the terms “we,” “us,” “our,” “Tivity Health,” or the “Company” refer collectively to Tivity Health, Inc. and its wholly owned subsidiaries.

Item 1. Business

OverviewCautionary Statement Regarding Forward-Looking Statements

 

The Company cautions that certain information contained or incorporated by reference in this Report and our other filings with the Commission, in our press releases, and in statements made by or with the approval of authorized personnel is forward-looking information that involves risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements contained herein. Forward-looking statements discuss our current expectations and projections relating to our financial conditions, results of operations, plans, objectives, future performance, and business. ForwardTivitylooking statements are typically identified by words or phrases such as “may,” “will,” “would,” “can,” “should,” “likely,” “anticipate,” “potential,” “estimate,” “pro forma,” “continue,” “expect,” “project,” “intend,” “seek,” “plan,” “believe,” “target,” “outlook,” “forecast,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Forward-looking statements include all statements that do not relate solely to historical or current facts, including statements regarding our expectations, intentions, or strategies and regarding the future. We disclaim any intent or obligation to update these forward-looking statements.


PART III

Item 10. Directors, Executive Officers and Corporate Governance

The directors of the Company are as follows:

Name

 

Age

Director Since

Position(s)

Richard M. Ashworth

 

47

2020

Chief Executive Officer and Director

Sara J. Finley

 

62

2018

Director

Robert J. Greczyn, Jr.

 

70

2015

Director

Beth M. Jacob

 

60

2018

Director

Bradley S. Karro

 

60

2014

Director

Stephanie M. Davis (Michelman)

 

47

2022

Director

Erin L. Russell

 

48

2020

Director

Anthony M. Sanfilippo

 

64

2020

Chairman of the Board

Richard M. Ashworth

President and Chief Executive Officer of the Company

AGE: 47

DIRECTOR SINCE: 2020

Board Committees:
None

Mr. Ashworth has served as President and Chief Executive Officer of the Company and as a member of the Board since June 2020. Mr. Ashworth previously served as the President of Walgreen Co. (“Walgreens”), where he was responsible for developing the strategies and plans for all Walgreens operations including leadership, development, operations, and management of the business. Mr. Ashworth served as President of Operations of Walgreens from November 2017 to February 2020 and as President of Pharmacy and Retail Operations from 2014 to 2017. In 2013, Mr. Ashworth also led the development and delivery of the healthcare strategy for the strategic partnership with U.K.-based Alliance Boots, which Walgreens later acquired.

QUALIFICATIONS:

Mr. Ashworth’s specific skills, experience and qualifications to serve as Chief Executive Officer and a director of the Company include 28 years of experience at Walgreens, a global pharmacy-led health and wellness company, including 20 years of strategic and operational experience.  He has extensive knowledge in strategy, operations, product and business development, healthcare, pharmacy, marketing and consumer insights, and successful leadership of teams comprised of several thousand members.

Sara J. Finley

Principal of Threshold Corporate Consulting, LLC

AGE: 62

DIRECTOR SINCE: 2018

Board Committees:
Nominating and
Corporate Governance
(Chair)

Ms. Finley is the Principal of Threshold Corporate Consulting, LLC, a consulting services firm that she founded in 2015.  From 2009 to 2011, Ms. Finley served as Senior Vice President and General Counsel of CVS Health Corporation, formerly known as CVS Caremark Corporation (including its predecessor companies, “CVS Caremark”), a publicly traded pharmacy services company.  From 2007 to 2009, Ms. Finley served as Senior Vice President and General Counsel of the pharmacy benefits management division of CVS Caremark, and from 2011 until her retirement from the company in 2015, Ms. Finley served as a senior legal advisor for CVS Caremark.  From 1998 to 2007, Ms. Finley served as Senior Vice President, Assistant General Counsel and Corporate Secretary of Caremark Rx, Inc., a publicly traded company and a predecessor of CVS Caremark. Previously, she was a partner at the law firm Kutak Rock in Atlanta, Georgia.  Ms. Finley graduated from the University of Alabama and received her law degree from Vanderbilt University.  She currently serves on the board of directors of Preferred Apartment Communities, Inc., a publicly traded real estate investment trust, and she is also chair of its compensation committee and a member of its nominating and governance committee. Ms. Finley also currently serves on the board of directors of Oak Paper Products Company, Inc., a privately-held paper products, packaging and janitorial supply company based in Los Angeles, California, Studio Bank, a community bank based in Nashville, Tennessee, and Vanderbilt University Medical Center, a hospital system with locations primarily in central Tennessee.  Ms. Finley currently serves on several Nashville non-profit boards, including The Center for Nonprofit Management, The Community Foundation of Middle Tennessee, Leadership Nashville, and the Vanderbilt Law School Board of Advisors.

QUALIFICATIONS:

Ms. Finley’s specific skills, experience and qualifications to serve as a director of the Company include over 15 years of executive management experience for industry-leading health care companies; board leadership roles for corporate and nonprofit organizations; and extensive experience as a senior legal advisor for mergers and acquisitions, health care regulatory matters, corporate governance, enterprise risk management, compliance, and other matters.  We believe Ms. Finley’s experience and perspective provides our Board with valuable insight, particularly with respect to strategic, legal, compliance, and risk management matters.


Robert J. Greczyn, Jr.

Former President and Chief Executive Officer of Blue Cross Blue Shield of North Carolina

AGE: 70

DIRECTOR SINCE: 2015

Board Committees:
Compensation; Nominating and Corporate Governance

Mr. Greczyn served as the Interim Chief Executive Officer of the Company from February 18, 2020 through May 31, 2020, during which time he was not a member of any committees of the Company’s Board of Directors.  He was the Chief Executive Officer of Blue Cross Blue Shield of North Carolina (“BCBSNC”) from 2000 until his retirement in 2010, where he also served on the Board of the Blue Cross Blue Shield Association.  Since 2010, Mr. Greczyn has served as Principal Manager of Capital Food Group, LLC and RJG Restaurant Group LLC, privately held restaurant franchise operations.  From August 1998 until September 1999 he was the Chief Operating Officer of BCBSNC and became its President in September 1999.  From 1990 to 1998, he was the President and CEO of Carolina Physicians Health Plan, a health maintenance organization, which was partially acquired by Healthsource, Inc. in 1991 and fully acquired by Healthsource, Inc. in 1994, at which time it became Healthsource North Carolina.  In 1997, Cigna Corporation acquired Healthsource, Inc.  From 1986 to 1990, Mr. Greczyn was President and CEO of Health Plan of Delaware, Ltd. (which was acquired by Principal Health Care, Inc. in 1988, at which time it became Principal Health Care of Delaware, Inc.).  From March 2011 to November 2014, Mr. Greczyn served on the Board of Directors of Liposcience, Inc., a publicly traded (until its acquisition by Laboratory Corporation of America in November 2014) clinical diagnostic company, where he chaired the compensation committee and was a member of the audit committee.  He also served as the interim President and Chief Executive Officer of Liposcience, Inc. from August 2013 until February 2014, during which time he resigned from his positions on the audit and compensation committees.  From October 2011 until August 2012, Mr. Greczyn served as a director of M*Modal Inc., a publicly traded (until its acquisition August 2012 by One Equity Partners) provider of interactive clinical documentation and speech understanding technology, where he was a member of the compensation and audit committees.  From 2006 to 2008, Mr. Greczyn was Chairman of the Board of the Council for Affordable Quality Care, an alliance of chief executive officers of the nation’s leading health insurers working to simplify healthcare transactions.  Mr. Greczyn also serves as vice chair of the board of Vidant Health (now ECU Health), of which he is also a member of the compensation committee, the quality committee, and the executive committee.  He formerly served as a board member of Vidant Medical Center, a not for profit large hospital.  Mr. Greczyn received an M.P.H. degree in health policy from the University of North Carolina at Chapel Hill and a B.A. degree in psychology from East Carolina University.

QUALIFICATIONS:

Mr. Greczyn’s specific skills, experience and qualifications to serve as a director of the Company include over 20 years of experience as Chief Executive Officer of three health insurance companies as well as service on the compensation and audit committees of publicly traded companies.  We believe his extensive management experience and knowledge of the managed care industry and his prior public company board experience provides critical insight to our Board.


Beth M. Jacob

Former Senior Vice President, Strategic Advisor and Leadership Coach of SPS Commerce

AGE: 60

DIRECTOR SINCE: 2018

Board Committees:
Audit; Nominating and Corporate Governance

After serving in senior leadership roles since 2015 with SPS Commerce, Inc. (“SPS Commerce”), a global leader in cloud-based supply chain management solutions, Ms. Jacob retired in April 2019 from her position as Senior Vice President, Strategic Advisor and Leadership Coach of SPS Commerce, which began in March 2018, and supported the work of SPS Commerce as an independent consultant through August 2019.  From 2015 to March 2018, Ms. Jacob was the Senior Vice President, Chief Customer Success Officer, at SPS Commerce, where she created a high energy and innovative customer success organization that delivers new services and value to drive retention and growth.  From 2002 to 2014, Ms. Jacob was an executive with Target Corporation (“Target”), a leading upscale discount retailer that provides high-quality merchandise with a guest-friendly experience across store and digital channels.  At Target, she was Executive Vice President and Chief Information Officer from 2010 to 2014 and Senior Vice President and Chief Information Officer from 2008 to 2010. Ms. Jacob also was responsible for the global operations of Target India from 2011 to 2014.  From 2006 to 2008, Ms. Jacob was the Vice President of Target Financial Services, Guest Operations, leading the contact center and collection operations team that provided services to Target’s customers.  From 2003 to 2006, Ms. Jacob was Vice President of Target Financial Services, Guest Contact Centers, and from 2002 to 2003, she was the Director of Target Financial Services, Guest Contact Centers.  Prior to joining Target, Ms. Jacob spent 15 years at Ameriprise Financial, Inc. (formerly known as American Express Financial Advisors), a leading diversified financial services firm dedicated to helping customers achieve their financial goals.   Ms. Jacob graduated with a B.S. degree from the University of Minnesota in 1984 and received her Master of Business Administration degree from the University of Minnesota Carlson School of Management in 1989.  Ms. Jacob has served on several non-profit boards.

QUALIFICATIONS:

Ms. Jacob’s specific skills, experience and qualifications to serve as a director of the Company include more than 30 years of consumer-focused business experience with a broad range of responsibilities, spanning customer strategy and service, global operations, technology and data capabilities, scaling strategies for growth, and successful leadership and engagement of teams comprised of several thousand members. We believe Ms. Jacob’s experience and perspective provide our Board with valuable insight, particularly with respect to the Company’s developing digital platforms, expanded operational footprint, and strategy.


Bradley S. Karro

Principal of Hillcote Advisors

AGE: 60

DIRECTOR SINCE: 2014

Board Committees:
Compensation (Chair)

Mr. Karro is a principal of Hillcote Advisors, a firm focused on investing in and restructuring healthcare companies that Mr. Karro founded in May 2007. Prior to starting Hillcote Advisors, Mr. Karro held a number of senior executive positions in the healthcare industry, including serving as Executive Vice President of Caremark Rx, a prescription benefit management company. Mr. Karro joined Medpartners (which changed its name to Caremark Rx) in 1998 and served at Caremark Rx through 2007.  During his time at Caremark Rx, Mr. Karro was responsible for mergers and acquisitions, integration planning, information technology and Medicare product development. Mr. Karro was also appointed as a charter member of the Governor’s e-Health Advisory Council in Tennessee, an organization established to coordinate Tennessee’s initiatives leading towards the adoption of electronic medical records.  He served on the Board of Directors of Sharecare, a digital health company, from 2020 until July 2021. From October 2013 to March 2017, Mr. Karro served as a member of the Board of Directors of Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, where he chaired the Audit Committee. Mr. Karro previously served on the Board of Directors of Emageon Inc., an information technology systems provider for hospitals, healthcare networks, and imaging facilities, from 2008 through 2009.

QUALIFICATIONS:

Mr. Karro’s specific skills, experience and qualifications to serve as a director of the Company are evidenced by his more than 25 years of healthcare industry experience, extensive knowledge of the healthcare industry, executive management experience, and prior public board experience.


Stephanie M. Davis (Michelman)

Global Chief Marketing Officer of Benefit Cosmetics

AGE: 47

DIRECTOR SINCE: 2022

Board Committees:
Nominating and
Corporate Governance

Ms. Michelman has served as the Global Chief Marketing Officer of Benefit Cosmetics, a brand within the Moet Hennessy Louis Vuitton (LVMH) portfolio, since April 2022.  She served as the General Manager of Bobbi Brown Cosmetics, a subsidiary of Estee Lauder Companies, Inc., from July 2019 to March 2022. From February 2015 to April 2019, she was the Chief Marketing Officer of NEST New York, a home fragrance and perfume company. She has also served as a member of the Board of Directors of M.M.LaFleur since January 2021. Ms. Michelman graduated with a B.A. degree from the University of Virginia in 1997 and received her MBA from Northwestern University, Kellogg School of Management in 2004.

QUALIFICATIONS:

Ms. Michelman’s specific skills, experience and qualifications to serve as a director of the Company include her extensive operational and marketing experience in the retail industry as well as her expertise in consumer research, insights, and mapping, data analytics, ecommerce, and digital marketing. Her understanding of the dynamics of technology and online platforms and her financial literacy are a valuable asset to our Board.


Erin L. Russell*

Former Principal of Vestar Capital Partners, LP

AGE: 48

DIRECTOR SINCE: 2020

Board Committees:
Audit (Chair)

Compensation

Since July 2021, Ms. Russell has served on the board of directors of eHealth, Inc., a publicly traded online health insurance marketplace, where she serves as a member of the audit committee.  Since January 2019, she has served as a member of the board of directors of Kadant, Inc., a global supplier of engineered systems, where she is a member of the audit and nominating and corporate governance committees and serves as the chair of the risk oversight and sustainability committee.  From August 2001 until April 2017, she was a principal of Vestar Capital Partners, LP (“Vestar”), a private equity firm specializing in management buyouts, recapitalizations, and growth equity investments. While at Vestar, Ms. Russell served on the boards of directors of a number of companies, including most recently as a director of DeVilbiss Healthcare LLC, a company that designs, manufactures and markets respiratory medical products, from 2012 until July 2015 and as a director and a member of the audit committee of 21st Century Oncology Inc., a provider of state-of-the-art radiation therapy and integrated cancer treatments, from 2008 until September 2016, including as the chair of the audit committee until 2014. She also served as a director of DynaVox Inc., a communications device manufacturer, from 2004 until 2014, including serving as the chair of its audit committee until its initial public offering in 2010. Ms. Russell is currently a member of the school advisory board of St. Thomas Aquinas Catholic School, where she has served since June 2018, and has served on the advisory boards of McIntire School of Commerce since June 2016 and the Jefferson Scholars Foundation at the University of Virginia since April 2008. Ms. Russell holds a Bachelor’s degree in commerce with a concentration in accounting from McIntire School of Commerce, University of Virginia and a Master’s in Business Administration from Harvard Business School.

QUALIFICATIONS:

Ms. Russell’s specific skills, experience and qualifications to serve as a director of the Company are evidenced by her experience with capital and credit markets, as well as her extensive experience serving on the boards of directors of companies in the healthcare sector.  We believe her financial literacy and extensive public and private company board experience provide critical insight to our Board.

Anthony M. Sanfilippo*

Co-founder of Sorelle Capital, Sorelle Entertainment, and Sorelle Hospitality

AGE: 64

DIRECTOR SINCE: 2020

Board Committees:
Audit

Mr. Sanfilippo has been Chairman of the Board since April 2020.  He is the co-founder of Sorelle Capital, Sorelle Entertainment and Sorelle Hospitality, a series of firms focused on investing in and helping grow companies with entrepreneurs in hospitality sectors and related real estate ventures.  Mr. Sanfilippo served as Chief Executive Officer and member of the board of directors (including chairman of the board from May 2017 until October 2018) of Pinnacle Entertainment Inc. (“Pinnacle”), a publicly traded gaming hospitality company with 16 casino locations in 10 states across the U.S., from March 2010 until October 2018, at which time Pinnacle was acquired by Penn National Gaming.  Prior to joining Pinnacle, Mr. Sanfilippo served as President, Chief Executive Officer and board member of Multimedia Games Inc., a publicly traded creator and supplier of comprehensive technology systems, content and electronic gaming devices for various segments of the gaming industry.  Prior to joining Multimedia Games, Inc., he served as Division President at Harrah’s Entertainment Inc., currently known as Caesars Entertainment Inc., including serving as President and Chief Operating Officer for Harrah’s New Orleans and a board member of Jazz Casino Corporation.  Mr. Sanfilippo is a member of the board of directors of Papa John’s International, where he chairs the compensation committee and also serves on its corporate governance and nominating committee.

QUALIFICATIONS:

Mr. Sanfilippo’s specific skills, experience and qualifications to serve as a director of the Company include his extensive operational, strategic, and senior leadership experience in the hospitality industry, including casinos, hotels, restaurants and entertainment businesses.  We believe his leadership and board experience provides our Board with valuable insight.


*Ms. Russell andMr. Sanfilippo were appointed to the Board in connection with a cooperation agreement the Company entered into with HG Vora Capital Management, LLC (“HG Vora”) on February 25, 2020 (the “Company”“HG Vora Agreement”), .  Pursuant to the HG Vora Agreement, HG Vora had the right to appoint two individuals (“New Directors”) to the Board with a term expiring at the 2020 Annual Meeting of Stockholders. HG Vora appointed Mr. Sanfilippo and Ms. Russell, each of whom was founded and incorporatedre-elected at the 2020 Annual Meeting of Stockholders. During the term of the HG Vora Agreement, at least one New Director was to serve on each of the Audit Committee of the Board, the Strategic Review Committee of the Board (dissolved in Delaware in 1981.  Through our four programs, SilverSneakers®senior fitness, Prime® Fitness, WholeHealth LivingTMApril 2020), and Wisely WellTM, we are focused on becoming the modern destination for healthy living, especially for seniorsCEO Search Committee (dissolved upon Mr. Ashworth’s appointment as President and older adultsCEO). The HG Vora Agreement expired pursuant to its terms in January 2021.

 

Executive Officers

Pursuant to General Instruction G(3) of Form 10-K, information concerning our executive officers is included in Part I of the Original Form 10-K, under the caption "Information about our Executive Officers."


Corporate Governance

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Commission.  Officers, directors, and greater than 10% stockholders are required by regulation of the Commission to furnish us with copies of all Section 16(a) forms they file.

Based solely on a review of the Forms 3, 4, and 5 and amendments thereto and certain written representations furnished to us, to our knowledge, all Section 16 reporting requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with during 2021, except for (i) late Form 3 filings for Messrs. Lewis and Bilbao filed on April 13, 2021 related to each of them being designated as Section 16 officers of the Company effective March 31, 2021; and (ii) late Form 4 filings for Messrs. Holland, Lewis, Bilbao, and Wagers on November 12, 2021 related to a certification by the Compensation Committee on February 3, 2021 that certain performance metrics under previously granted performance stock units had been satisfied.  

Code of Conduct

Our Code of Business Conduct applies to all employees (including officers) and non-employee directors (collectively, “colleagues”).  The purpose of the Code of Business Conduct is to provide written standards that are reasonably designed to promote: honest and ethical conduct; full, fair, accurate, timely and understandable disclosure in reports and documents we file with the Commission and other public communications we make; compliance with applicable governmental laws, rules and regulations; prompt internal reporting of violations of the Code of Business Conduct; and accountability for adherence to the Code of Business Conduct, and to deter wrongdoing.  A copy of our Code of Business Conduct, as well as any amendments thereto, is available on our website at www.tivityhealth.com. We offer SilverSneakersintend to post any waiver of a provision of the Code of Business Conduct granted to any principal executive, financial, or accounting officer or any material amendment to the Code of Business Conduct on our website. We did not grant any waivers to the Code of Business Conduct in 2021.

Audit Committee

During 2021, the Audit Committee was composed of Mss. Jacob and Russell for the entire year.  In addition, Dr. Peter Hudson was a member of the Audit Committee from the beginning of the year until the 2021 Annual Meeting of Stockholders (at which time he did not stand for re-election to the Board), and Mr. Sanfilippo has been a member of the Audit Committee since the 2021 Annual Meeting of Stockholders.  It was chaired by Ms. Russell. All of the directors on the Audit Committee are “independent directors” as defined under the Nasdaq listing standards, and satisfy the heightened independence criteria applicable to members of Medicare Advantage, Medicare Supplement,the Audit Committee under the Nasdaq listing standards and group retiree plans.Rule 10A-3(b)(1) under the Exchange Act.  We also offer Prime Fitness, a fitness facility access program, through commercial health plans, employers, and other sponsoring organizations.  Our national network of fitness centers delivers both SilverSneakers and Prime Fitness.  Our fitness networks encompass approximately 16,000 partner locations and nearly 1,000 alternative locations that provide classes outside of traditional fitness centers. We also offer virtual fitness experiences, including live instructor-led classes. Through our WholeHealth Living program, which we sell primarily to health plans, we offer a continuum of services related to complementary, alternative, and physical medicine.  Our WholeHealth Living network includes relationships with approximately 18,000 complementary, alternative, and physical medicine practitioner locations to serve individuals through health plans and employers who seek health services such as chiropractic care, acupuncture, physical therapy, occupational therapy, massage therapy, and more.  Finally, through our Wisely Well brand, we offer meals designed to support individuals and caregivers who are seeking meal convenience as well as those recovering after a hospitalization or living with chronic conditions.

Effective as of December 9, 2020, we completed the sale of Nutrisystem, Inc. (“Nutrisystem”), a wholly owned subsidiaryhave at least one member of the CompanyAudit Committee who has past employment experience in finance or accounting and requisite professional certification in accounting or other comparable experience that includedresults in the Nutrisystem® individual’s financial sophistication.  The Board has determined that each of Ms. Russell and South Beach Diet® programs, to KNS Acquisition Corp. (“Kainos”) pursuant to terms of a Stock Purchase Agreement (the “Purchase Agreement”)Mr. Sanfilippo qualifies as an “audit committee financial expert”, dated October 18, 2020,as defined by and among the Company, Kainos, and Kainos NS Holdings LP.  At the closing (the “Closing”)regulations of the transactions contemplated by the Purchase Agreement (the “Transactions”), NutrisystemCommission.  The Audit Committee meets with our independent registered public accounting firm and its subsidiaries were acquired by, and became wholly owned subsidiaries of, Kainos.  Pursuantmanagement to the terms of the Purchase Agreement, Kainos paid to the Company an aggregate purchase price, after giving effect to customary indebtedness and cash adjustments, of approximately $559 million, which amount is subject to a customary working capital adjustment post-Closing.  We used the significant majority of the net proceeds from the divestiture to pay down $519 million of principal on the term loans underreview our Credit Agreement (as defined below).  Results of operations for Nutrisystem have been classified as discontinued operations for all periods presented in the consolidated financial statements, the quality and all related assetsintegrity of our accounting, auditing and liabilities have been classified as discontinued operationsfinancial reporting process, and our systems of internal controls.  The Audit Committee’s Charter, which is reviewed annually by the Audit Committee and is available on our website at December 31, 2019.

The Company is headquartered at 701 Cool Springs Boulevard, Franklin, Tennessee 37067.

COVID-19www.tivityhealth.com, provides a detailed description of the Audit Committee’s duties and responsibilities.

 

In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus, which causes the disease known as “COVID-19.”  In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic, and COVID-19 continues to spread throughout the United States and other countries.  Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. Such measures have resulted in significantly reduced demand for many businesses that have continued in operation.  


Item 11. Executive Compensation

 

By March 31, 2020, substantiallyCOMPENSATION DISCUSSION AND ANALYSIS

EXECUTIVE SUMMARY

In 2021, our Named Executive Officers (“NEOs”) were as follows:

Name

Position

Richard Ashworth

President and Chief Executive Officer

Adam Holland

Chief Financial Officer

Thomas Lewis (1)

Chief Operating Officer

Raymond Bilbao (1)

Chief Legal Officer

Ryan Wagers

Chief Accounting Officer

(1)

Messrs. Lewis and Bilbao were appointed as executive officers of the Company effective March 31, 2021.  Each of them was employed by the Company for all of fiscal 2021.

Key Compensation Actions for 2021

The Committee believes that the fitness centersCompany’s 2021 executive compensation program was effective in attracting, retaining, and providing appropriate incentives for our national network were temporarily closed, which had an adverse impact on our results from continuing operations forNEOs.  After considering the first quarter of 2020 because a significant portion of revenuespositive say-on-pay vote received from our SilverSneakersstockholders at the 2021 Annual Meeting of Stockholders regarding our 2020 executive compensation program, is based on member visits to a fitness partner location. A substantial number of our fitness partner locations remained closed through April, with some locations

4


reopening in May and additional locations reopening in June and throughout the third quarter of 2020. Due to a resurgence of COVID-19 cases throughout the country, some fitness partner locations were closed again during the fourth quarter of 2020.  For the month of December 2020, approximately 74% of our fitness partner locations reported at least one visitinput from our SilverSneakers program.  From April through December 2020,independent compensation consultant Frederic W. Cook & Co., Inc. (“FW Cook”), pay relative to the average monthly total participation levels of our SilverSneakers members were significantly below historical levels,market and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues from continuing operations.  We are unable to predict with certainty how many of our fitness partner locations will be subject to any operational restrictions in the future and for what duration, or the level of member participation at our fitness partner locations.  

Customer and Partner Contracts

Except for Prime Fitness, our customer contracts generally have initial terms of approximately three years.  Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs.For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while individuals who purchase the Prime Fitness program through these organizations may cancel at any time (on a monthly basis) after an initial period of one to three months. Our fitness partner location contracts generally have initial terms ranging from one to three years and auto-renew for successive one-year renewal terms.

Business Strategy

Our strategy is to become the modern destination for healthy living.  We will expand beyond fitness by establishing an engagement platform that enables personalized member interaction with all of our offerings, and we will partner with other payors and service providers to aggregate services to members under the SilverSneakers umbrella.  The continued development of our suite of digital offerings will enable a more tailored, interactive, and impactful experience across a variety of areas, including fitness, social connection, community involvement, volunteering, and enrichment.  In addition, we plan to accelerate growth in our WholeHealth Living offering through market share expansion and improved technology.  

Segment and Major Customer Information

Following the sale of Nutrisystem in December 2020, we have one operating and reportable segment.  

During 2020, Humana, Inc. (“Humana”), United Healthcare, Inc. (“United Healthcare”)2021 Peer Group (if applicable), and Blue Cross Blue Shield Association (“BCBSA”, which relates to our Prime Fitness business) each comprised more than 10%, and together comprised 39%, of our revenues from continuing operations. Our primary contracts with each of Humana, United Healthcare, and BCBSA continue through December 31, 2022.  No other customer accounted for 10% or more of our revenues from continuing operations in 2020. See Note 17of the notes to consolidated financial statements included in this report relating to revenues from external customers and customer concentration.

Competition

The healthcare industry is highly competitive and best practices, the manner in which services are provided is subjectCommittee made the following key decisions with respect to continual change. Other entities, whose financial and marketing resources may exceed our resources, may choose to initiate or expand programs in competition with our offerings.

We believe we have certain advantages over our competitors such as:executive compensation for 2021:

 

Effective February 2021, the brand recognitionCommittee approved base salary merit increases for each of our programsMessrs. Holland and Wagers, and the CEO approved and informed the Committee of base salary merit increases for each of Messrs. Lewis and Bilbao, who were not executive officers of the Company at the time of such as SilverSneakers;approval.

 

our long-term relationships with health plans;In February 2021, the Committee approved the short-term incentive program for 2021, which was based solely on the achievement of adjusted EBITDA.  Based on actual adjusted EBITDA for 2021, each NEO earned a short-term incentive award equal to 115% of target.

 

our proprietary class programming, including our growing digital programming;In March 2021, the Committee approved annual LTI awards to be granted effective March 22, 2021.  (Mr. Ashworth did not receive an annual LTI award in 2021 due to having received an equity award in June 2020 intended as compensation for fiscal years 2020 through 2022). The Committee designed the LTI program to be generally consistent with the 2020 LTI program, such that 50% of the grant date fair value of each eligible NEO’s LTI grant consisted of “premium priced” stock options having an exercise price equal to 110% of the closing price of the Common Stock on the grant date and becoming exercisable on the third anniversary of the grant date.The remaining 50% of the grant date fair value of each eligible NEO’s LTI grant consisted of RSUs that vest one-third per year on each anniversary of the grant date.

 

In September 2021, the depthCommittee adopted a separation benefits program (the “Separation Benefits Program”) applicable to the Company’s Section 16 Officers, including the NEOs.  

The Committee is committed to designing and maintaining an executive compensation program that is performance-based, competitive, and clear in its design and objectives, and that aligns the interests of management with those of the Company’s stockholders.  The Committee considers the results of the previous year’s “say-on-pay” advisory vote on executive compensation and other feedback the Company


receives from its stockholders in determining the Company’s executive compensation policies and decisions.  

Summary of Compensation Practices

Below are the key features of our executive compensation program that we believe drive sustainable results, encourage executive retention, and align executive and stockholder interests.  We also highlight certain practices we do not do because we believe they do not align with our stockholders’ long-term interests.

What We Do

What We Don’t Do

  Reinforce our pay-for-performance philosophy by designing the majority of total target executive compensation to be variable, through linkage to our financial or market results

  Mitigate undue risk by having caps on incentive awards and breadtha recoupment policy with respect to all performance-based compensation, including performance-based equity

  Maintain meaningful stock ownership and retention requirements

  Engage an independent compensation consultant who reports directly to the Committee and does not provide any other services to the Company

  Require double trigger change in control provisions for acceleration of equity awards in all equity awards for executive officers

  Balance incentives to reward the achievement of short-term operating goals and long-term stockholder value creation

  Periodically, and at least annually, seek stockholder feedback on our fitness center network relationships, which encompass approximately 16,000 partner locations;executive compensation

    No excise tax gross-ups upon a change in control for employment agreements

    No tax gross-ups on ongoing benefits (which do not include benefits associated with one-time events such as relocation) for current or future executive officers

    No granting of discounted stock options

    No repricing of stock options without stockholder approval

    No hedging or short sales of Company securities

    No pledging of Company securities   

Impact of Say-on-Pay Vote Results

At the 2021 Annual Meeting of Stockholders, 76.8% of the shares that were actually voted on the proposal to approve the compensation of the Company’s NEOs were in support of our executive compensation program as disclosed in the proxy statement relating to that meeting. The Committee has considered the outcome of the vote on executive compensation and believes it affirms our stockholders’ support of our overall approach to executive compensation. Accordingly, we have endeavored, to the extent possible in light of the changes in our business and our senior leadership and evaluation of the Company’s strategy, to maintain that overall approach to executive compensation.


The Committee’s Processes and Analyses

Role of Compensation Committee

The Committee sets and administers the policies that govern compensation of our executive officers, including:

Annually evaluating the performance of the CEO and other executive officers and determining the compensation level, including short- and long-term incentive compensation, for each such person based on this evaluation;

Reviewing and approving any changes in executive officer incentive compensation plans and equity-based compensation plans; and

 

Reviewing and approving all equity-based compensation plans of the trusting connections with our members developed over more than 25 years.  Company and granting equity-based awards pursuant to such plans.

5


However, we cannot assure you that we can compete effectively with other entities who provide similar services.

Industry Integration and Consolidation

Consolidation remains an important factor in all aspectsOnly independent directors serve on the Committee. Based on the Committee’s charter, the Committee may delegate any of the healthcare industry.  While we believe the size of our membership base provides us with the economies of scale to compete even in a consolidating market, we cannot assure you that we can effectively compete with companies formed as a result of industry consolidation or that we can retain existing customers if they are acquired by other entities that already have or contract for programs similar to ours or are not interested in our programs.

Governmental Regulation

Governmental regulation impacts us in a number of ways in addition to those regulatory risks presented under Item 1A. “Risk Factors” below.

Health Reform

In recent years, Congress and certain state governments have passed a large number of laws and regulations intended to result in major changes within the healthcare system. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”), the most prominent of these efforts, changes how healthcare services are covered, delivered, and reimbursed through, among other things, expanded health insurance coverage, reduced growth in Medicare program spending and the establishment of programs that tie reimbursement to care quality and value.

The ACA contains provisions that affect our customers, including commercial health plans and Medicare Advantage programs. Since 2010, when the ACA was enacted, the ACA has decreased the number of uninsured individuals, and expanded coverage through the expansion of public programs and private sector health insurance. However, the ACA also may increase costs and/or reduce the revenues of our customers or prospective customers. For example, the ACA prohibits commercial health plans from using gender, health status, family history, or occupation to set premium rates, eliminates pre-existing condition exclusions, and bans annual benefit limits. In addition, the ACA established uniform minimum medical loss ratios (“MLRs”) for health plans, requiring a minimum percentage of health coverage premium revenue to be spent on healthcare medical costs and quality improvement expenses. The ACA also reduced premium payments to Medicare Advantage plans such that the managed care per capita payments paid by HHS to Medicare Advantage plans are now, on average, approximately equal to those for traditional Medicare.  There is substantial uncertainty regarding the ongoing effects of the ACA because the Trump administration and Congress have made significant changes to the ACA, its implementation and its interpretation. Final rules issued in 2018 expand the availability of association health plans and allow the sale of short-term, limited-duration health plans, neither of which are required to cover all of the essential benefits mandated by the ACA.  Effective January 2019, Congress eliminated the financial penalty associated with the ACA’s individual mandate. In December 2018, a federal court in Texas ruled that the individual mandate was unconstitutional as a result of this change and determined that the rest of the ACA was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. On November 10, 2020, the Supreme Court heard oral arguments regarding this case, and the law remains in place pending the appeals process. It is difficult to predict whether, when or how the ACA will be further changed, what alternative provisions, if any, will be enacted, the timing of implementation of any alternative provisions, the impact of alternative provisions on providers and other healthcare industry participants, and the ultimate outcome and impact of court challenges. The healthcare industry remains subject to ongoing health reform initiatives. For example, beginning in 2020, the Creating High-quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2018 (“Chronic Care Act”) allows Medicare Advantage plans to cover supplemental benefits that are not primarily health-related, but that have the reasonable expectation of improving or maintaining health.  Additionally, some members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor proposals (often referred to as "Medicare for All"). Further, the potential impact of the 2020 federal election on health reform efforts is unknown.

Other Laws

While many of the governmental and regulatory requirements affecting healthcare delivery generally do not directly apply to us, our customers must comply with a variety of regulations including those governing Medicare

6


Advantage plans and their marketing and the licensing and reimbursement requirements of federal, state and local agencies. Certain of our services, including health service utilization management and certain claims payment functions, require licensure by state government agencies. We are subjectresponsibilities to a variety of legal requirements in order to obtain and maintain such licenses.

Federal privacy regulations issued pursuant to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) extensively restrict the use and disclosure of individually-identifiable health information by health plans, most healthcare providers, and certain other entities (collectively, “covered entities”). Federal security regulations issued pursuant to HIPAA require covered entities to implement and maintain administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic individually-identifiable health information. Because we handle individually-identifiable health information on behalf of covered entities, we are considered a "business associate" and are required to comply with most aspects of the HIPAA privacy and security regulations. Violations of HIPAA and its implementing regulations may result in criminal penalties and in substantial civil penalties for each violation. These penalties are updated annually based on changes to the consumer price index.

In the event of a data breach involving individually-identifiable health information, we are subject to contractual obligations and state and federal requirements that require us to notify our customers. These requirements may also require us or our customers to notify affected individuals, regulatory agencies, and the media of the data breach. Under HIPAA, non-permitted uses and disclosures of unsecured individually identifiable health information are presumed to be breaches for which notice is required, unless it can be demonstrated that there is a low probability the information has been compromised.

In addition, there are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing the confidentiality and security of confidential personal information that may apply to us directly or us contractually. These laws vary, are subject to frequent changes and updates in regulations, and could impose additional penalties and other legal liability. For example, the potential effects of the CCPA (as defined under Item 1A “Risk Factors”) are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. In addition, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to data use and data breaches. If we fail to comply with these or other applicable laws and regulations, we could be subject to liabilities, including civil penalties, money damages, and criminal penalties.

Federal law contains various prohibitions related to false statements and false claims, some of which apply to private payors as well as federal programs. Our contracts with Medicare Advantage plans may subject us to a number of obligations, including billing and reimbursement requirements, prohibitions on fraudulent and abusive conduct and related training and screening obligations. Actions may be brought under the federal False Claims Act by the government as well as by private individuals, known as “whistleblowers,” who are permitted to share in any settlement or judgment. Liability under the federal False Claims Act arises when an entity knowingly submits a false claim for reimbursement to the federal government. The federal False Claims Act defines the term “knowingly” broadly. There are many other potential bases for liability under the federal False Claims Act, including knowingly and improperly avoiding repayment of an overpayment received from the government and the knowing failure to report and return an overpayment within 60 days of identifying the overpayment. The submission of claims for services or items generated in violation of certain “fraud and abuse” provisions of the Social Security Act, including the anti-kickback provisions, constitutes a false or fraudulent claim under the federal False Claims Act. In some cases, whistleblowers, the federal government, and some courts have taken the position that entities that allegedly have violated other statutes, such as the federal self-referral prohibition commonly known as the Stark Law, have thereby submitted false claims under the federal False Claims Act.

From time to time, participants in the healthcare industry, including the Company and our customers, may be subject to actions under the federal False Claims Act or other fraud and abuse laws, including similar state statutes, and it is not possible to predict the impact of such actions. Violations of applicable laws may result in significant civil and criminal penalties. For example, violations of the federal False Claims Act may result in penalties of three times the actual damages sustained by the government, plus substantial mandatory civil penalties for each separate false claim. These penalties are updated annually based on changes to the consumer price index.

7


Because of the international operations previously conducted as part of our total population health services (“TPHS”) business that we sold to Sharecare, Inc. in July 2016, we were subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”) and similar anti-bribery laws of other countries in which we provided services prior to the sale. The FCPA and similar antibribery laws generally prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business or gaining any business advantage. Failure to comply with the FCPA and similar legislation prior to the sale of our TPHS business could result in the imposition of civil or criminal fines and penalties.

Intellectual Property

We own numerous trademarks and other proprietary rights that are important to our business. Depending upon the jurisdiction, trademarks are validsubcommittee as long as theysuch subcommittee is solely composed of one or more members of the Committee.  The Committee may also delegate to one or more executive officers the authority to make grants of equity-based awards to individuals who are used in the regular course of trade and/or their registrations are properly maintained. We believe the protection of our trademarks, copyrights, domain names, trade dress,not executive officers.

Executive Compensation Philosophy and trade secrets is important to our success. We protect our intellectual property rights by relying on a combination of watch services and trademark, copyright, trade dress and trade secret laws, and through the domain name dispute resolution system.

Human Capital Resources

Employee Profile

As of February 22, 2021, we had approximately 350 employees, comprised of 35% male and 65% female.  Of our total employees, 54% were based out of our office in Chandler, Arizona, 13% were based out of our office in Franklin, Tennessee, and the remaining 33% were based off-campus within the United States.  We believe we have good relationships with our employees, and we encourage open and candid communication to ensure we maintain positive relationships.

Health and Safety

Objectives

We seek to attract, retain, and motivate talented individuals who are committed to the healthCompany’s mission and safetycore values.  The Committee is committed to designing and maintaining an executive compensation program that is performance-based, competitive, clear in its design and objectives, and aligns the interests of management with those of the Company’s stockholders by rewarding executive officers when the Company achieves financial success.

The Committee believes that performance-based pay is key to achieving our employees.financial and strategic objectives and meeting stockholder expectations.  The direct effect of this performance-based philosophy is that a majority of the total target compensation (excluding benefits and perquisites) that is set at the beginning of the year for an NEO is variable.  We have implemented healthconsider compensation to be variable if the ultimate value realized may differ from the intended target compensation.  Variable compensation includes both our annual short-term incentive awards and safety policieslong-term incentive awards.

The Committee strives to align executive compensation with the unique talent and practices, taking into account CDC guidancebusiness needs of the Company, without encouraging excessive or unnecessary risk-taking, through the following objectives:

To attract, retain and motivate talented executives by providing overall compensation that is performance-based, fair to the executives and the stockholders, and takes into consideration both individual contribution and corporate performance;

To closely align the interests of executives with the long-term interests of the Company and its stockholders through a significant portion of each executive’s total compensation opportunity based on long-term equity incentives tied to financial performance, stock price performance, and/or operational performance; and

To provide appropriate incentives for executives to work toward the achievement of our overall business goals with payouts tied directly to the successful achievement of such goals.


The Committee strives to design total compensation opportunities for the Company’s executives that are competitive, but not excessive, as compared to market practice.  Market practice is generally defined as median compensation levels found among companies of comparable size and any applicable statebusiness relative to the Company.  Individual compensation targets may be above or local requirements, to reducebelow market based on the transmissionfollowing factors:

The individual skills and experience of the executive;

The difficulty of attracting or replacing the executive; and

The importance of the position to the Company’s success.

In addition, actual compensation earned may be above or below market levels depending on the performance of COVID-19, including adopting flexible work-from-home arrangements, imposing travel restrictions, promoting social distancing, and increasing cleaning protocols at our two office locations.  Since March 2020, we have not required our employees to work in the office; in June 2020, we began allowing employees to work in the office at their election, with increased office sanitation measuresexecutive and the expectation that employees are adhering to social distancing and mask protocols.

Diversity and Inclusion

Company as a whole.  

We embrace diversityuse the following compensation vehicles to meet the above-described objectives:

Base salaries;

Short-term incentives, based upon achieving clearly-defined financial and/or operational targets; and

Long-term incentives based on the achievement of financial performance, stock price performance, and/or operational performance. To focus our executives on the Company’s sustained performance over the long term, a majority of our target executive compensation is weighted toward long-term incentives.

The compensation vehicles may vary by executive based on role, responsibilities, and inclusionthe executive’s ability to influence Company performance and believe in creatingthe achievement of key short- and long-term objectives.

On an inclusiveannual basis, or more frequently as needed, the Committee reviews:

The Company’s compensation philosophy, ensuring proper alignment with the Company’s principal business objectives;

Our executive compensation policies in light of our financial performance, annual budget, long-term objectives, and competitive and best practices; and

The compensation of each individual executive in light of such executive’s contribution and performance, market practice for the executive’s role, and the Committee’s executive compensation policies for that year.

The Committee believes that our executive compensation program and equitable environment that represents a broad spectrum of backgrounds and cultures.  Our CEO has pledged his commitmentgovernance policies do not encourage our management or colleagues to the CEO Action for Diversity & InclusionTM, which outlines a specific set of actions the CEO will take to cultivate a trusting environment where all ideas are welcomed, and employees feel comfortable and empowered to have discussions about diversity and inclusion.  To further this effort and in addition to our existing communication vehicles, we have created an internal diversity and inclusion council, launched a diversity-focused listening series, and conducted unconscious bias training sessions with our employees. With the assistance of our diversity and inclusion council, we continue to explore additional diversity and inclusion initiatives.

Employee Engagement

We regularly conduct anonymous surveys to seek feedback from our employees on a variety of topics, including but not limited to, confidence in Company leadership, competitiveness of our compensation and benefits package, career growth opportunities and improvements on how we could make our Company an employer of choice. The results are shared with the entire organization and are reviewed by senior leadership, who analyze areas of progress or deterioration and prioritize actions and activities in response to this feedback to drive meaningful improvements in employee engagement.  We have also established regular communication between the CEO and employees.  Finally, we monitor employee turnover, with a particular emphasis on regretted turnover, and conduct exit interviews with departing employees.

8


Available Information

Our Internet address is www.tivityhealth.com. We make available free of charge, on or through our Internet website, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon asrisks reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the “SEC”). The SEC maintains an Internet site that contains periodic reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.

Item 1A. Risk Factors

In the execution of our business strategy, our operations and financial condition are subject to certain risks.  A summary of certain material risks is provided below, and you should take such risks into account in evaluating any investment decision involving the Company. This section does not describe all risks applicable to us and is intended only as a summary of certain material factors that could impact our operations in the industry in which we operate. Other sections of this report contain additional information concerning these and other risks.

Risks Relating to Our Business Generally

The COVID-19 pandemic has had, and is expected to continuelikely to have a material adverse effect on our business and results of operations.

As a result of the COVID-19 pandemic, by March 31, 2020, substantially all of the fitness centers in our national network were temporarily closed.  A substantial number of our fitness partner locations remained closed through April 2020.  Although some locations reopened in May 2020 and additional locations reopened in June and throughout the third quarter of 2020, the average monthly total participation levels of our members after such locations reopened were significantly below historical levels, thus adversely impacting our revenues during the second, third and fourth quarters of 2020.  There is considerable uncertainty regarding the extent to which COVID-19 will continue to spread and the extent and duration of measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place orders and business and government shutdowns. Although some restrictions have eased in some jurisdictions, rates of COVID-19 infection in regions across the United States and the world have remained high in recent months, and some areas are re-imposing closures and other restrictions due to such high rates of COVID-19 cases. As a result, the COVID-19 pandemic is significantly affecting, and is likely to continue to affect, overall economic conditions in the United States.

We have faced and may continue to face reclosures and/or long-term closures and other operational restrictions with respect to some or all of our fitness partner locations for prolonged periods of time due to, among other factors, evolving governmental restrictions including public health directives, quarantine policies, or social distancing measures.  Additionally, even if fitness partner locations are open, members may avoid public gathering places because of a perceived risk of infection or risk to health, which could reduce overall demand and adversely impact their use of our services.  Because a significantportion of our revenues from our SilverSneakers programbusiness.  This belief is based on member visitsthe following factors: our balance of short- and long-term incentives; our use of different types of equity compensation awards that provide a balance of incentives; our cap on incentive awards; our recoupment policy (which permits the Committee, in its discretion, to recover incentive-based compensation from our executive officers in the event of a fitness partner location, this decrease in member participation has affectedrestatement of our financial results or non-compliance with our Code of Business Conduct to the material detriment of the Company); our anti-hedging and could further adversely affectanti-pledging policies; and our business and results of operations.

stock ownership guidelines.

The extent toCommittee also believes that our compensation strategies are aligned with our compensation philosophy, long-term performance, and Company culture, which COVID-19 continues to affect our results will dependplaces significant value on future developments, including whether there are additional outbreaks, mutations, variants, or related strainshigh-performing individuals, and that those strategies promote individual responsibility for collective long-term success of the virus in locations where we operate, and the availability of, and prevalence of access to, effective medical treatments and vaccines for COVID-19, which are highly uncertain and cannot be predicted.Company.

Consumer spending generally may also be negatively impacted by adverse general macroeconomic conditions and reduced consumer confidence, including the impacts of any recession resulting from the COVID-19 pandemic. This has negatively impacted, and may further negatively impact, the number of paid subscribers in our Prime Fitness program.

9



As a result ofdiscussed in further detail throughout this Compensation Discussion and Analysis section, the COVID-19 pandemic, including related governmental guidance or requirements, we have implemented a work-from-home policy for our employees, which may negatively impact productivityCommittee believes that the 2021 executive compensation program was reasonable and cause other disruptions to our business.  We closed our corporate offices and/or call centers from mid-March through May and began reopening our corporate offices on a limited basis in June as we continue to prioritize the safety and well-being of our employees.  We have incurred, and may incur in the future, costs related to implementing our work-from-home policy as well as additional cleaning fees and supplies related to the COVID-19 pandemic.  appropriate.

We are uncertain of the potential long-term impacts of the COVID-19 pandemic on our business, and the severity, duration, and timing of the business and economic impacts from the continuing, unprecedented public health effort to contain and combat the spread of COVID-19, which has previously included, and may in the future include, among other things, significant volatility in financial markets and a sharp decrease in the value of equity securities, including our common stock.

Our business strategy relating to the development and introduction of new products and services exposes us to risks such as limited customer and/or market acceptance and additional expenditures that may not result in additional net revenue.

An important component of our business strategy is to focus on new products and services that enable us to provide immediate value to our customers.  We cannot predict whether customers and/or the market will accept these new products and services, and if we fail to execute successfully on this strategy or to adapt this strategy as market conditions evolve, our ability to grow revenue and our results of operations may be adversely affected.

If we fail to successfully implement our business strategy, our financial performance and our growth could be materially and adversely affected.

Our future financial performance and success are dependent in large part upon our ability to implement our business strategy successfully. Implementation of our strategy will require effective management of our operational, financial and human resources and will place significant demands on those resources. See Part I, Item 1. “Business – Business Strategy" in this report for more information regarding our business strategy.  There are risks involved in pursuing our strategy, including the ability to hire or retain the personnel necessary to manage our strategy effectively.

Setting Compensation

In addition to its annual review of executive compensation, the risksCommittee retains an independent compensation consultant to review the Company’s executive compensation practices.  The Committee has engaged FW Cook since 2013 to provide independent executive compensation advisory services.  The independent compensation consultant reports directly to the Committee and provides no other services to the Company.  The Committee also employs several tools to set forth above, implementation of our business strategy could be affected by a number of factors beyond our control, such as epidemics and pandemics,executive compensation targets that meet the Company’s objectives, including the ongoing COVID-19 pandemic (including responses of governmental authorities to contain such epidemics and pandemics), increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses, and changes in industry trends. We may decide to alter or discontinue certain aspects of our business strategy at any time. If we are not able to implement our business strategy successfully, our long-term growth and profitability may be adversely affected. Even if we are able to implement some or all of the initiatives of our business strategy successfully, our operating results may not improve to the extent we anticipate, or at all.

We may experience difficulties associated with the implementation and/or integration of new businesses, services (including outsourced services), technologies, solutions, or products.

We may face difficulties, costs, and delays in effectively implementing and/or integrating acquired businesses, services (including outsourced services), technologies, solutions, or products into our business.  Implementing internally-developed solutions and products, and/or integrating newly acquired businesses, services (including outsourced services), and technologies could be time-consuming and may strain our resources. Consequently, we may not be successful in implementing and/or integrating these new businesses, services, technologies, solutions, or products and may not achieve anticipated revenue and cost benefits.

Changes in macroeconomic conditions and certain market risks may adversely affect our business.

Economic difficulties and other macroeconomic conditions (including any downturn or recession caused by the COVID-19 pandemic) could reduce the demand and/or the timing of purchases for certain of our services from customers and potential customers.  In addition, changes in economic conditions could create liquidity and credit constraints. We cannot assure you that we would be able to secure additional financing if needed and, if such funds were available, that the terms and conditions would be acceptable to us.

10


Certain of our interest rate swap agreements do not qualify for hedge accounting treatment, which may result in volatility in our U.S. GAAP earnings.

We maintain five interest rate swap agreements with current notional amounts totaling $311.1 million that do not qualify for hedge accounting treatment (“de-designated swaps”).  The de-designated swaps are recorded at their estimated fair value in the consolidated balance sheet, with changes in fair value recognized each period in current earnings.  Such changes may result in volatility in our U.S. GAAP earnings and may adversely affect the price of our common stock.

We have a significant amount of goodwill and intangible assets, the value of which could become further impaired.

We have recorded significant portions of the purchase price of certain acquisitions as goodwill and/or intangible assets. We review goodwill and intangible assets not subject to amortization for impairment on an annual basis (during the fourth quarter) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company.  In March 2020, we experienced a significant decline in the Company’s market capitalization and in our actual and forecasted operating results, in addition to the unfavorable change in market conditions.  As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets (which consist of the Nutrisystem tradename and the SilverSneakers tradename).  Following these evaluations, we recorded a total impairment loss of $199.5 million related to the Nutrisystem goodwill and tradename during the first quarter of 2020, which amount is reflected in loss from discontinued operations.  We determined there was no impairment related to the SilverSneakers tradename or the carrying value of goodwill related to continuing operations.  During the third and fourth quarters of 2020, we recorded additional impairment losses of $66.2 million and $24.0 million related to the Nutrition business, each of which is reflected in loss from discontinued operations. At December 31, 2020, we had approximately $334.7 million and $29.0 million of goodwill and intangible assets, respectively, remaining.  If we determine that the carrying values of our goodwill and/or intangible assets related to continuing operations should be impaired, we may incur non-cash charges to earnings, which could have a material adverse effect on our results of continuing operations for the period in which the impairment occurs.

In order to be successful, we must attract, engage, retain and integrate key employees and have adequate succession plans in place, and failure to do so could have an adverse effect on our ability to manage our business.

Our success depends, in large part, on our ability to attract, engage, retain and integrate qualified executives and other key employees throughout all areas of our business. Identifying, developing internally or hiring externally, training and retaining highly skilled managerial and other personnel are critical to our future, and competition for experienced employees can be intense. Failure to successfully recruit executives and key employees or the loss of any executives and key employees could have a significant impact on our operations. The loss of services of any key personnel, the inability to retain and attract qualified personnel in the future, or delays in hiring may harm our business and results of operations. Further, changes in our management team may be disruptive to our business, and any failure to successfully integrate key newly hired employees could adversely affect our business and results of operations.

We face competition for staffing, which may increase our labor costs and reduce profitability.

We compete with other healthcare and services providers in recruiting qualified management, including executives with the required skills and experience to operate and grow our business, and staff personnel for the day-to-day operations of our business. These challenges may require us to enhance wages and benefits to recruit and retain qualified management and other professionals. Difficulties in attracting and retaining qualified management and other professionals, or in controlling labor costs, could have a material adverse effect on our profitability.

We are or may become a party to litigation that could potentially force us to pay significant damages and/or harm our reputation.

We are subject to certain legal proceedings, which potentially involve large claims and significant defense costs

11


(see Note 11 of the notes to consolidated financial statements included in this report). These legal proceedings and any other claims that we may face in the future, whether with or without merit, could result in costly litigation, and divert the time, attention, and resources of our management. The coverage limits of our insurance policies may not be adequate to cover all such claims and some claims may not be covered by insurance. Additionally, insurance coverage with respect to some claims against us or our directors and officers may not be available on terms that would be favorable to us.  The cost of such coverage has increased in recent years and could further increase in the future.  Further, although we believe that we have conducted our operations in compliance with applicable statutory and contractual requirements and that we have meritorious defenses to outstanding claims, it is possible that resolution of these legal matters could have a material adverse effect on our results of operations.  In addition, legal expenses associated with the defense of these matters may be material to our results of operations in a particular financial reporting period.

Damage to our reputation could harm our business, including our competitive position and business prospects.

Our ability to attract and retain customers, members and employees is impacted by our reputation. Harm to our reputation can arise from various sources, including employee misconduct, cyber security breaches, unethical behavior, litigation or regulatory outcomes, which could, among other consequences, increase the size and number of litigation claims and damages asserted or subject us to enforcement actions, fines and penalties and cause us to incur related costs and expenses.

Our results of operations could be adversely affected by severe or unexpected weather, epidemics, pandemics or outbreaks of disease.

Adverse weather conditions or other extreme changes in the weather may cause people to refrain, or prevent people, from visiting fitness partner locations and using our services.  Additionally, widespread health epidemics or outbreaks of disease, such as influenza or COVID-19, may cause members to avoid public gathering places and negatively impact their use of our services.  As some of the fees that we charge our customers are based on member participation, a decrease in member participation could adversely affect our business and results of operations.

If our customers or fitness center partners experience financial distress, or seek to change or delay payment terms, it could negatively affect our financial position and results.

At any given time, one or more of our customers or fitness center partners may experience financial difficulty, file for bankruptcy protection or go out of business. Unfavorable economic and financial conditions, such as the current events surrounding the COVID-19 pandemic, could result in an increase in our customers’ or fitness center partners’ financial difficulties that then affect us.  The direct impact on us could include reduced revenues and write-offs of accounts receivable and could negatively impact our operating cash flow. While we currently cannot estimate what those effects will be, if they are severe, the indirect impact could include impairments of intangible assets and reduced liquidity, among others.

If our efforts to attract and retain paying subscribers for our Prime Fitness program are not successful, our business will be adversely affected.

Our ability to continue to attract paying subscribers for our Prime Fitness program will depend in part on our ability to offer convenience and value to our Prime Fitness subscribers and our partners’ ability to effectively market the program. Our ability to attract and retain paying subscribers may be adversely affected by our competitors' relative offerings, pricing, and other factors, as well as other fitness programs (including digital offerings) in the marketplace. If our Prime Fitness subscribers do not perceive our products to be of value, we may not be able to attract and retain Prime Fitness subscribers. Additionally, COVID-19 has adversely impacted and may continue to adversely impact our ability to attract and retain subscribers for our Prime Fitness program. We must continually add new Prime Fitness paying subscribers both to replace canceled subscriptions and to grow our Prime Fitness program beyond our current subscriber base. Further, if excessive numbers of our Prime Fitness subscribers cancel their subscriptions, in connection with COVID-19 or otherwise, our results of operations will be adversely affected.

We could be adversely affected by violations of the FCPA and similar anti-bribery laws of other countries in

12


which we provided services prior to the sale of our TPHS business.

Because of the international operations that we previously conducted as part of our TPHS business that we sold to Sharecare, Inc. in July 2016, we could be adversely affected by violations of the FCPA and similar anti-bribery laws of other countries in which we provided services prior to the sale. The FCPA and similar anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business or gaining any business advantage. While our policies mandated compliance with these anti-bribery laws, we cannot provide assurance that our internal control policies and procedures always protected us from reckless or criminal acts committed by our employees, contractors or agents. Failure to comply with the FCPA and similar legislation prior to the sale of our TPHS business could result in the imposition of civil or criminal fines and penalties and could disrupt our business and adversely affect our results of operations, cash flows and financial condition.

Risks Relating to the Healthcare Industry

A significant percentage of our revenues is derived from health plan customers.

A significant percentage of our revenues is derived from health plan customers. The health plan industry may continue to consolidate, and we cannot assure you that we will be able to retain health plan customers, or continue to provide our products and services to such health plan customers on terms at least as favorable to us as currently provided, if they are acquired by other health plans that already participate in competing programs or are not interested in our programs. Increasing vertical integration efforts involving health plans and healthcare providers or entities that provide wellness services may increase these challenges. Our health plan customers that are part of larger healthcare enterprises may have greater bargaining power, which may lead to further pressure on the prices for our products and services. In addition, a reduction in the number of covered lives enrolled with our health plan customers or in the payments we receive could adversely affect our results of operations. Our health plan customers are subject to continuing competition and reduced reimbursement rates from governmental and private sources, which could lead current or prospective customers to seek reduced fees or choose to reduce or delay the purchase of our services. Finally, health plan customers could offer (and in some cases are offering) services themselves that compete directly with our offerings, stop providing our offerings to certain or all of their members (as one of our customers, United Healthcare, has done), or offer fitness benefits in addition to SilverSneakers and Prime Fitness, which could adversely affect our business and results of operations.

We currently derive a significant percentage of our revenues from three customers.

For the year ended December 31, 2020, three customers each comprised more than 10%, and together comprised approximately 39%, of our revenues from continuing operations. Our primary contracts with these customers continue through December 31, 2022. The loss or restructuring of a contract with any of these customers or any of our other significant customers could have a material adverse effect on our business and results of operations.  None of these three contracts allows the customer to terminate for convenience prior to the expiration of the contract.

Our inability to renew and/or maintain contracts with our customers and/or fitness partner locations under existing terms or restructure these contracts under favorable terms could adversely affect our business and results of operations.

If our customers and/or fitness partner locations choose not to renew their contracts with us (which occurs from time to time), our business and results of operations could be materially adversely affected.  Loss of a significant fitness partner or health plan customer or a reduction in a health plan customer's enrolled lives (including as a result of increased unemployment and the resulting loss of health insurance coverage) could have a material adverse effect on our business and results of operations.  In addition, a restructuring of a contract with a health plan customer and/or fitness partner on terms that aren’t favorable to us could adversely affect our business and results of operations. Moreover, the businesses of our fitness partner locations have been and will likely continue to be adversely affected by the closure of locations, any public health directives, or social distancing measures applicable upon reopening of locations and reduced overall consumer demand for fitness center use as a result of the COVID-19 pandemic.  If a significant portion of our fitness partner network is unable to return to normal operations within a reasonable period of time as a result of financial or operational stresses brought on by the COVID-19 pandemic, we may be unable to make alternative arrangements with substitute fitness partners on favorable terms or at all.

13


Reductions in Medicare Advantage health plan reimbursement rates or changes in plan designs may negatively impact our business and results of operations.

A significant portion of our revenue is indirectly derived from the monthly premium payments paid by the U.S. Department of Health and Human Services to our health plan customers for services they provide to Medicare Advantage beneficiaries.  As a result, our results of operations are, in part, dependent on government funding levels for Medicare Advantage programs. An executive order issued in October 2019 seeks to encourage innovative Medicare Advantage benefit structures and plan designs, including through changes to supplemental benefits.  Any changes that limit or reduce Medicare Advantage reimbursement levels, such as reductions in or limitations of reimbursement amounts or rates under these programs, reductions in funding of these programs, expansion of benefits without adequate funding, elimination of coverage for certain benefits, or elimination of coverage affecting the services that we provide, could have a material adverse effect on our health plan customers, and as a result, on our business and results of operations.

Compliance with existing or newly adopted federal and state laws and regulations or new or revised interpretations of such requirements could adversely affect our results of operations or may require us to spend substantial amounts, and the failure to comply with applicable laws and regulations could subject us to penalties or negatively impact our ability to provide services.

Our customers are subject to considerable state and federal government regulation, and a substantial majority of our business involves providing services to Medicare Advantage beneficiaries. As a result, we are subject directly to various federal laws and regulations, including the federal False Claims Act, billing and reimbursement requirements and other provisions related to fraud and abuse. In addition, our contracts with Medicare Advantage plans require us to comply with a number of regulatory provisions and to permit these health plan customers to perform compliance audits of our processes and programs. Many of these regulations are vaguely written and subject to differing interpretations that may, in certain cases, result in unintended consequences that could impact our ability to effectively deliver services. Further, we are required to comply with most requirements of the HIPAA privacy and security laws and regulations and may be subject to criminal or civil penalties for violations of these regulations. Certain of our services, including health utilization management and certain claims payment functions, require licensure and may be regulated by government agencies. We are subject to a variety of legal requirements in order to obtain and maintain such licenses, but little guidance is available to determine the scope of some of these requirements.

We continually monitor the extent to which federal and state legislation and regulations govern our operations. New federal or state laws or regulations or new interpretations of existing requirements that affect our operations could have a material adverse effect on our results of operations. If we are found to have violated applicable laws, to have caused any of our customers to submit false claims or make false statements, or to have failed to comply with our contractual compliance obligations, we could be required to restructure our operations, be subject to contractual penalties, including termination of our customer agreements, and be subject to significant civil and criminal penalties.

Healthcare reform efforts may result in a reduction to our revenues from government health programs and private insurance companies or otherwise directly or indirectly impact our business.

The healthcare industry is subject to various political, regulatory, scientific, and technological influences. Efforts at federal and state levels of government have resulted in laws and regulations intended to effect significant change within the healthcare system. The ACA, the most prominent of these efforts, affects coverage, delivery, and reimbursement of healthcare services. Among other effects, several of its provisions may increase the costs and/or reduce the revenues of our customers or prospective customers. For example, the ACA eliminates pre-existing condition exclusions by commercial health plans, bans annual benefit limits, and mandates minimum medical loss ratios for health plans.

However, there is substantial uncertainty regarding the net effect and future of the ACA. The Trump administration and Congress have made significant changes to the ACA, its implementation and its interpretation.  Effective January 2019, Congress eliminated the penalty associated with the ACA’s individual mandate.  As a result, a federal court in Texas ruled in December 2018 that the individual mandate was unconstitutional and determined that the rest of the ACA was, therefore, invalid.  In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. On November 10, 2020, the Supreme Court heard oral arguments regarding this case,

14


and the law remains in place pending the appeals process.  It is possible that the reforms imposed by the ACA or uncertainty regarding significant changes or court challenges to the law will adversely affect the profitability of our customers and cause our customers or prospective customers to reduce or delay the purchase of our services or to demand reduced fees. Because of this uncertainty and many other variables, including the ACA’s complexity and the difficulty of predicting the impact of changes on other healthcare industry participants and the ultimate outcome of court challenges, we are unable to predict all of the ways in which the ACA could impact us. Furthermore, we could also be impacted by other legislative and regulatory healthcare reform initiatives.  For example, the Chronic Care Act of 2018 allows Medicare Advantage plans, starting in 2020, to cover supplemental benefits that are not primarily health-related, but that have the reasonable expectation of improving or maintaining health. Additionally, some members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor proposals (often referred to as "Medicare for All"). Further, the potential impact of the 2020 federal election on health reform efforts is unknown.

Risks Relating to Information Technology, Data Privacy and Intellectual Property

A failure of our information technology or systems could adversely affect our business.

Our ability to deliver our products and services depends on effectively using information technology.  We rely upon our information technology and systems, employees, and third parties for operating and monitoring all major aspects of our business. These technologies and systems and, therefore, our operations could be damaged or interrupted by natural disasters, power loss, network failure, improper operation by our employees, data privacy or security breaches, computer viruses, computer hacking, network penetration or other illegal intrusions, epidemics or pandemics (such as the COVID-19 pandemic), or other unexpected events. Any disruption in the operation of our information technology or systems, regardless of the cause, could adversely impact our operations, which may adversely affect our financial condition, results of operations and cash flows.

A cybersecurity incident could result in the loss of confidential data, give rise to remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, common law theories or other laws, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business.

The nature of our business involves the receipt, storage and use of personal data about the participants in our programs, including individually identifiable health information, as well as employees and customers. Additionally, we rely upon third parties that are not directly under our control to store and use portions of that personal data as well.  The secure maintenance of this and other confidential information or other proprietary information is critical to our business operations. To protect our information systems from attack, damage and unauthorized use or disclosure, we have implemented multiple layers of security, including technical safeguards, processes, and our people. Our defenses are monitored and routinely tested internally and by external parties. In addition, we are Health Information Trust Alliance (“HITRUST”) certified, which enables us to demonstrate compliance with industry-defined risk management and data protection requirements based on a standardized framework. Despite these efforts, threats from malicious persons and groups, new vulnerabilities, technology failures, and advanced attacks against information systems create risk of cybersecurity incidents, which are rapidly evolving and increasingly sophisticated. Personnel error or malfeasance, faulty password management, social engineering or other vulnerabilities and irregularities may also result in a defeat of our or our third-party service providers' security measures and a breach of our or their information systems. Moreover, hardware, software or applications we use may have inherent vulnerabilities or defects of design, manufacture or operations or could be inadvertently or intentionally implemented or used in a manner that could compromise information security. Therefore, we cannot provide assurance that we or our third-party vendors or other service providers will not be subject to cybersecurity incidents or occurrences, which may result in unauthorized access by third parties, loss, modification, misappropriation, disclosure or corruption of customer, employee, or our information; member protected health information; or other data subject to privacy laws, or that otherwise disable or degrade our systems, disrupt our customers’ experience and our ability to efficiently operate our business. In addition, COVID-19 may have an adverse impact on our information technology systems and our ability to securely preserve confidential information, including as a result of telecommuting issues associated with our employees working remotely. Such cybersecurity incidents or delays in responding to or remedying damage caused by such incidents may lead to a disruption in our systems or business, costs to modify, enhance, or remediate our cybersecurity measures, liability under privacy, security and consumer protection laws or litigation under these or other laws,

15


including common law theories, and subject us to enforcement actions, fines, regulatory proceedings or litigation against us, damage to our business reputation, a reduction in participation and sales of our products and services, and legal obligations to notify customers or other affected individuals about an incident, which could cause us to incur substantial costs and negative publicity, any of which could have a material adverse effect on our financial condition and results of operations and harm our business reputation.

As a result, cybersecurity and the continued development and enhancement of our controls, processes and practices remain a priority for us. We may be required to expend significant additional resources in our efforts to modify or enhance our protective measures against evolving threats or to investigate and remediate any cybersecurity vulnerabilities.

Our business is subject to new and changing federal and state privacy and security laws, rules and regulations, which impact our operating costs and for which failure to adhere could negatively impact our business.

Our business is subject to various federal and state privacy and data security laws, rules and regulations. Some state laws and regulations may be inconsistent across jurisdictions and subject to evolving and differing (sometimes conflicting) interpretations and applications. While we are using internal and external resources to monitor compliance with and to continue to modify our data practices and policies in order to comply with evolving privacy laws, relevant regulatory authorities could determine that our data practices fail to address all the requirements of certain new or changing laws, which could subject us to penalties and/or litigation. Government regulators, privacy advocates and class action attorneys are increasingly scrutinizing how companies collect, process, use, store, share and transmit personal data. For example, the California Consumer Privacy Act of 2018 (“CCPA”), went into effect on January 1, 2020, and it applies broadly to information that identifies or is associated with any California household or individual, and compliance with the new law requires that we implement several operational changes, including processes to respond to individuals’ requests.  Moreover, the California Privacy Rights Act (“CPRA”) was recently approved by California voters as a ballot initiative and will take effect January 1, 2023, and significantly modifies the CCPA. Failure to comply with the CCPA and, after July 2023, the CPRA, may result in governmental enforcement actions, private claims, including class action lawsuits, and damage to our reputation. In addition, the CPRA creates a new enforcement agency charged with enforcing the CPRA and imposes additional requirements including privacy risk assessments and audits as well as vendor contractual requirements for data sharing, license and access arrangements. The CCPA and CPRA also provide for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. We may also be exposed to litigation, regulatory fines, penalties or other sanctions if the personal, confidential or proprietary information of our customers is mishandled or misused by any of our suppliers, counterparties or other third parties, or if such third-parties do not have appropriate controls in place to protect such personal, confidential or proprietary information.  Additionally, the Federal Trade Commission (“FTC”) and many state attorneys general are interpreting federal and state consumer protection laws to impose standards for the collection, use, dissemination and security of data.  The obligations imposed by the CCPA and other similar laws that may be enacted at the federal and state level may require us to modify our business practices and policies and to incur substantial expenditures in order to comply.

Further, our marketing and member engagement activities may be subject to communications privacy laws such as the Telephone Consumer Protection Act, CAN-SPAM Act and FTC and Federal Communications Commission (“FCC”) rules and regulations. While we strive to adhere to strict policies and procedures that comply with such laws and regulations, we may be subjected to class action lawsuit settlements or penalties, and regulators and courts may disagree with our interpretation of these laws and regulations and subject us to penalties and other consequences for noncompliance. Determination by a court or regulatory agency that our marketing practices violate communications privacy laws could subject us to civil penalties and could require us to change some portions of our business. Even an unsuccessful challenge by consumers or regulatory authorities of our activities could result in adverse publicity and could require a costly response from and defense or settlement by us.

The impact of new laws, regulations and policies and the related interpretations, as well as changes in enforcement practices or regulatory scrutiny generally cannot be predicted, and changes in applicable laws, regulations and policies and the related interpretations and enforcement practices may require extensive system and operational changes, be difficult to implement, increase our operating costs, require significant capital

16


expenditures, or adversely impact the cost or attractiveness of the products or services we offer, or result in adverse publicity and harm our reputation.

Third parties may infringe on our brands, trademarks and other intellectual property rights, which may have an adverse impact on our business.

We currently rely on a combination of trademark and other intellectual property laws and confidentiality procedures to establish and protect our proprietary rights, including our brands. If we fail to successfully enforce our intellectual property rights, the value of our brands, services and products could be diminished and our business may suffer. Our precautions may not prevent misappropriation of our intellectual property. Any legal action that we may bring to protect our brands and other intellectual property could be unsuccessful and expensive and could divert management’s attention from other business concerns. In addition, legal standards relating to the validity, enforceability and scope of protection of intellectual property, especially in Internet-related businesses, are uncertain and evolving. We cannot assure you that these evolving legal standards will sufficiently protect our intellectual property rights in the future.

We may be subject to intellectual property rights claims.

Third parties may make claims against us alleging infringement of their intellectual property rights. Any intellectual property claims, regardless of merit, could be time-consuming and expensive to litigate or settle and could significantly divert management’s attention from other business concerns. In addition, if we were unable to successfully defend against such claims, we may have to pay damages, stop selling the service or product or stop using the software, technology or content found to be in violation of a third party’s rights, seek a license for the infringing service, product, software, technology or content or develop alternative non-infringing services, products, software, technology or content. If we cannot license on reasonable terms, develop alternatives or stop using the service, product, software, technology or content for any infringing aspects of our business, we may be forced to limit our service and product offerings. Any of these results could reduce our revenue and our ability to compete effectively, increase our costs or harm our business.

Risks Relating to our Credit Facility

The performance of our business (as it could further be affected by the COVID-19 pandemic) and the level of our indebtedness could prevent us from meeting the obligations under our Credit Agreement or have an adverse effect on our future financial condition, our ability to raise additional capital, or our ability to react to changes in the economy or our industry.

In connection with the consummation of the acquisition of Nutrisystem, on March 8, 2019, we entered into the Credit Agreement.  As of December 31, 2020, outstanding debt under the Credit Agreement was $466.7 million, which represented $496.3 million of principal on the term loans under the Credit Agreement less deferred loan costs and original issue discount.

Our ability to service our indebtedness will depend on our ability to generate cash in the future.  We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available in an amount sufficient to enable us to service our indebtedness or to fund other liquidity needs.  If there are prolonged or worsening effects of the COVID-19 pandemic, such as long-term closures of our fitness partner locations, we could be unable to generate revenues and cash flows sufficient to conduct our business, service our outstanding debt, and comply with the covenants under the Credit Agreement.  This could, among other things, exhaust our available liquidity (and ability to access liquidity sources) and/or result in an acceleration of the maturity of a significant portion or all of our then-outstanding debt obligations, which we may be unable to repay or refinance.

The Credit Agreement contains various affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on us and certain of our subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of

17


business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year.

Our indebtedness could adversely affect our future financial condition or our ability to react to changes in the economy or industry by, among other things:

following:

 

increasing our vulnerability to a downturn in general economic conditions (including any downturn or recession caused by the COVID-19 pandemic), lossAssessment of revenue and/or profit margins in our business, or to increases in interest rates, particularly with respect to the portion of our outstanding debt that is subject to variable interest rates;individual performance

 

o

potentially limiting our abilityAt least once per year, the Committee meets with the CEO to obtain additional financing orreview and approve performance objectives for the upcoming year for each NEO.  After the end of the year, the CEO delivers to obtainthe Committee individual performance evaluations and compensation recommendations for each NEO, excluding himself (“other NEOs”).  The Committee determines compensation adjustments for each other NEO based on a variety of factors, such financingas a competitive compensation analysis; the Committee’s assessment of each other NEO’s individual performance, taking into account the CEO’s input; the Company’s performance; and the Committee’s judgment based on favorable terms;such NEO’s interactions with the Board.

 

causing uso

After the end of the year, the CEO also presents to dedicatethe Committee a self-assessment of his performance for the year based on his established performance objectives.  The Committee conducts a confidential review of the CEO’s performance for the previous year and discusses any compensation adjustment based on the competitive compensation analysis, its assessment of the CEO’s performance in light of the pre-approved performance objectives, the Company’s performance, and the level of CEO compensation relative to the other NEOs.

Assessment of Company performance

o

In addition to each NEO’s individual performance, the Committee also considers the Company’s overall performance in determining executive compensation.  When evaluating the relationship between the CEO’s pay and Company performance, the Committee considers both reported pay (as reflected in the Summary Compensation Table) and realized pay for the CEO in recent years (as applicable).

Compensation market data

o

The Committee reviews NEO compensation against external references to help guide compensation decisions.  The Committee does not use particular formulas or target specific market pay positions when determining compensation levels of a particular officer position but instead uses external comparisons to provide a point of reference.  The external references may include peer group analysis (see below) and/or commercially available, broad-based, comparative market compensation survey reports developed by independent professional organizations (collectively, the “Survey Reports”).  The Survey Reports cover a significant number of companies across a broad range of industries.  To support the Committee’s review and evaluation, management, and if applicable, an independent compensation consultant, provides the Committee with information compiled from the Survey Reports.

o

The Committee recognizes that the Company competes locally and nationally for talent with companies much larger than those included in our compensation peer group.  These larger companies aggressively recruit for the best qualified talent in particularly critical functions.  As a result, to attract and retain talent, the Committee may from time to time


determine that it isin the best interests of the Company and its stockholders to provide compensation packages that deviate from the external market references.

Executive Compensation for 2021

Program Elements

The 2021 executive compensation program consisted of:

Base salaries;

Short-term cash incentive awards, based on achieving clearly-defined financial, operational, or financial reporting targets; and

LTI awards that are based on service and/or Company performance.  To focus our executives on the Company’s sustained performance over the long term, a meaningful portion of future cash flow from operations to service or pay down our debt, which reduces the cash available for other purposes, such as operations, capital expenditures, and future business opportunities; andtarget executive compensation is weighted toward long-term incentives.

2021 Peer Group

In late 2020, FW Cook conducted a review of our peer group in light of our business and size.  FW Cook applied certain criteria in developing the 2021 Peer Group (as defined below) such as industry sectors, revenues, enterprise value, and our historical peers.  With regard to revenue and enterprise value, FW Cook evaluated comparable companies with revenues ranging from approximately one-fourth to four times our pro-forma annual revenues and favored companies with 12-month average enterprise values ranging from approximately one-fourth to four times our enterprise value.  Our 2021 peer group consists of the following companies (the “2021 Peer Group”), whose compensation levels were used as competitive comparisons when reviewing our NEO compensation for 2021.  

 

 

possibly limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to competitors who may be less leveraged.

Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly, and changes in LIBOR reporting practices could lead to an increase in the cost of our indebtedness and adversely affect our results of operations.

Borrowings under our Credit Agreement are at variable rates of interest, generally using LIBOR as the benchmark, and expose us to interest rate risk.  Interest rates are currently at historically low levels, but if interest rates increase, our debt service obligations with respect to our variable rate indebtedness would increase even if the amount borrowed remained the same, and our net income and cash flows would correspondingly decrease.

To mitigate our exposure to future interest rate volatility with respect to our variable rate indebtedness, we have entered into interest rate swaps and may in the future enter into additional interest rate swaps, which involve the exchange of floating for fixed rate interest payments. Considering hedging gains and losses and cash settlement costs, we may not elect to maintain such interest rate swaps, and any swaps may not fully mitigate our interest rate risk.

A transition away from LIBOR as a benchmark for establishing the applicable interest rate may adversely affect our variable rate debt and interest rate swaps.  The Financial Conduct Authority of the United Kingdom has announced that by the end of calendar year 2021 it will no longer require LIBOR submissions, resulting in the possible unavailability or lack of suitability of LIBOR as a benchmark rate. Discussions among the Financial Conduct Authority, the ICE Benchmark Administration and others regarding LIBOR cessation are ongoing, and a number of uncertainties remain. While our borrowing arrangements provide for alternative base rates as well as a method for selecting a benchmark replacement for LIBOR, the consequences of LIBOR becoming unavailable or not suitable at some point cannot be predicted with confidence at this time. Use of an alternative base rate or a benchmark replacement for LIBOR as a basis for calculating interest with respect to our outstanding variable rate indebtedness or interest rate swap agreements could lead to an increase in the interest we pay and a corresponding increase in the cost of our indebtedness, and could affect our ability to refinance some or all of our existing indebtedness or otherwise have a material adverse impact on our business, financial condition and results of operations.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

As of December 31, 2020, we leased the following facilities:

18


Description of Use

 

Leased Square Footage

 

 

Square Footage Subleased to Other Tenants

 

Location

Office space

 

 

263,598

 

 

 

218,769

 

Franklin, Tennessee

Office space

 

 

45,085

 

 

 

 

Chandler, Arizona

Office space

 

 

6,361

 

 

 

 

Ashburn, Virginia

Total

 

 

315,044

 

 

 

218,769

 

 

For a description of material pending legal proceedings, see Note 11of the notes to consolidated financial statements included in this report.

Item 4. Mine Safety Disclosures

Not applicable.

Information about our Executive Officers

The following table sets forth certain information regarding our executive officers as of March 2, 2021.  Executive officers of the Company serve at the pleasure of the Board of Directors of the Company.

OfficerAddus HomeCare, Inc.

 

AgeCorVel Corporation

 

PositionPlanet Fitness, Inc.

 

 

 

 

 

Richard M. Ashworth

Allscripts Healthcare Solutions, Inc.

 

46Evolent Health, Inc.

 

Chief Executive Officer of the Company since June 2020.  President of Walgreen Co. (���Walgreens”) from February 2020 to June 2020.  President of Operations of Walgreens from November 2017 to February 2020 and President of Pharmacy and Retail Operations of Walgreens from 2014 to 2017.Premier, Inc.

 

 

 

 

 

Adam C. Holland

Apollo Medical Holdings, Inc.

 

42HMS Holdings Corp.

 

Chief Financial Officer of the Company since June 2017.  Chief Financial Officer of Kirkland’s, Inc. (“Kirkland’s”) from February 2015 to June 2017, Chief Accounting Officer of Kirkland’s from August 2014 to February 2015 and Vice President of Finance of Kirkland’s from August 2008 to February 2015.Providence Service Corp.

 

 

 

 

 

Ryan M. Wagers

BioTelemetry, Inc.

 

43NextGen Healthcare, Inc.

 

Chief Accounting OfficerTabula Rasa HealthCare, Inc.

Computer Programs and Systems, Inc.

Omnicell, Inc.

U.S. Physical Therapy, Inc.

The median revenue for the latest four quarters and the median 12-month average enterprise value as of September 30, 2020 for companies in our 2021 Peer Group were $0.6 million and $1.4 billion, respectively.

Compensation Decisions for 2021

Based on the positive say-on-pay support received from our stockholders at the 2021 Annual Meeting of Stockholders regarding our 2020 executive compensation program, input from our independent compensation consultant FW Cook, and competitive and best practices, the Committee maintained a performance-based compensation philosophy when designing the 2021 executive compensation program.  

The Committee believes that the Company’s 2021 executive compensation program was instrumental in attracting, retaining, and providing appropriate incentives for our NEOs.  The Committee remains committed to designing and maintaining an executive compensation program that is performance-based, competitive, and clear in its design and objectives, and that aligns the interests of management with those of the Company’s stockholders.


In general, and based on the methodology described under the heading “Compensation market data”, the Committee believes compensation levels for the NEOs were appropriate.

Base Salary

In establishing base salaries for 2021, the Committee considered each NEO's performance and responsibilities, recommendations of the CEO, internal pay equity, pay relative to the market, and the date of each NEO’s last salary increase.      

Effective February 22, 2021, each of the NEOs except for Mr. Ashworth received a merit increase in his base salary.  Base salaries for the NEOs were as follows:

Annualized Base Salary ($000s)

Name

 

 

2021

Base Salary

 

 

 

 

2020

Base Salary

(at end of year)

 

 

 

 

Percentage

Increase

 

 

 

 

Date of

Previous

Increase

Richard Ashworth

 

 

$

900

 

 

 

 

$

900

 

 

 

 

0.0%

 

 

 

 

n/a

Adam Holland

 

 

$

424

 

 

 

 

$

412

 

 

 

 

3.0%

 

 

 

 

02/2020

Thomas Lewis

 

 

$

425

 

 

 

 

$

380

 

 

 

 

11.8%

 

 

 

 

12/2020

Ray Bilbao

 

 

$

309

 

 

 

 

$

300

 

 

 

 

3.0%

 

 

 

 

12/2020

Ryan Wagers

 

 

$

300

 

 

 

 

$

283

 

 

 

 

5.9%

 

 

 

 

02/2020

Short-term Cash Incentive Awards

We offer short-term cash incentive awards to NEOs to align their annual compensation with the Company’s financial and operational objectives for the current year.  For fiscal year 2021, the performance factor for the short-term cash incentive award was Adjusted EBITDA (weighted 100%). Actual payouts were calculated using the following formula: (Base Salary * Bonus Target Percentage * Performance Factor Achievement). The maximum amount that each NEO could earn for the full year was 200% of target.  Short-term cash incentive awards earned are described in further detail below and were paid in mid-March 2022.

Short-Term Cash Incentive Target Percentages

Short-term cash incentive targets (expressed as a percentage of base salary) were set based on target percentages that correspond with each NEO’s internal job grade and/or market comparisons.  The Committee believes that the short-term cash incentive targets are market competitive and that they establish the appropriate level of at-risk annual cash incentive and drive the achievement of annual performance goals.

Short-term Cash Incentive Targets (as a percentage of base salary)

 

 

As of December 31,

 

Name

 

2021

 

 

2020

 

Richard Ashworth

 

100%

 

 

100%

 

Adam Holland

 

50%

 

 

50%

 

Thomas Lewis

 

50%

 

 

50%

 

Raymond Bilbao

 

50%

 

 

50%

 

Ryan Wagers

 

40%

 

 

40%

 


Adjusted EBITDA (100% of Total Bonus Target)

Generally consistent with 2014 through 2020, the predominant performance metric for short-term cash incentive awards for 2021 was Adjusted EBITDA, which was used as a metric for both earning and funding short-term cash incentive awards (the “Adjusted EBITDA Bonus”).  “Adjusted EBITDA” was defined as earnings from continuing operations before interest, taxes, depreciation, and amortization excluding certain pre-defined costs, losses, and expenses, including but not limited to loss on extinguishment and modification of debt, other income (loss) related to the Company’s investment in Sharecare, Inc., other income (loss) related to mark-to-market adjustments on certain interest rate swaps that do not qualify for hedge accounting treatment, and integration and CEO transition costs.  The Committee believes that Adjusted EBITDA provides a specific measure of operating and financial performance and aligns our executives with our short-term business goals for EBITDA growth.  The Adjusted EBITDA Bonus comprised 100% of each NEO’s total bonus target for 2021.

Each NEO’s Adjusted EBITDA Bonus was based on the Company’s achievement of Adjusted EBITDA from continuing operations.  The short-term cash incentive pool for the NEOs (“NEO Bonus Pool”) began funding when Adjusted EBITDA from continuing operations exceeded $156 million (the “Adjusted EBITDA Threshold”).  The following table outlines the threshold and target Adjusted EBITDA goals, along with the Adjusted EBITDA achieved and the corresponding payout as a percent of target for each NEO.

 

Threshold

 

 

Target

 

 

Actual

 

 

Payout (% of

Target)

 

Adjusted EBITDA ($mil.)

$

156.0

 

 

$

162.3

 

 

$

166.1

 

 

 

115.0

%

Based on actual Adjusted EBITDA (before accruing the Adjusted EBITDA Bonus described herein) of $166.1 million for 2021, each NEO earned an Adjusted EBITDA Bonus of 115% of the target applicable to such NEO.  

Short-Term Cash Incentive Payouts for 2021 ($000s)

 

Name

 

2021

at

Target

 

 

2021

Actual

Payout

 

Richard Ashworth

 

$

900

 

 

$

1,037

 

Adam Holland

 

$

211

 

 

$

243

 

Thomas Lewis

 

$

209

 

 

$

241

 

Raymond Bilbao

 

$

154

 

 

$

177

 

Ryan Wagers

 

$

119

 

 

$

137

 

Long-Term Incentive Awards

The Committee believes that our LTI compensation is a key component of our retention strategy and is integral to our ability to achieve our performance goals.  LTI awards are generally granted annually to eligible employees, including our NEOs.  LTI awards are typically made during the first quarter or shortly thereafter once the Committee has had the opportunity to review the previous year’s full year results, expected performance for the current year, and the Company’s long-range business plan (to the extent a sufficient number of shares is available under the Company’s equity incentive plan).  The Committee may also approve additional equity-based awards in certain special circumstances, such as upon an officer’s initial employment with the Company, the promotion of an officer to a new position or in recognition of special contributions made by an officer.


The table below summarizes the types of long-term incentives granted to the NEOs in recent years intended to incentivize performance and the objective for using each of the incentives in supporting the interests of the stockholders.

Incentive

Objective

RSUs

Encourage executive retention and align management and stockholder interests

MSUs

Align management and stockholder interests and reward achievement of certain total shareholder return goals

PSUs

Align management and stockholder interests and reward achievement of the Company since October 2018.  Company’s financial goals

Stock options

Reward share price appreciation

Annual Equity Awards

As described above, one of our key compensation objectives is to provide long-term incentive compensation to strengthen and align the interests of our NEOs with those of our stockholders.  Each NEO’s target LTI value was set based on the NEO’s internal job grade and/or market comparisons.  To meet this objective, the Committee designed the LTI program for 2021 such that 50% of the grant date fair value of each eligible NEO’s LTI grant consisted of “premium priced” stock options having an exercise price equal to 110% of the closing price of the Common Stock on the grant date.  The remaining 50% of the grant date fair value of each eligible NEO’s LTI grant consisted of RSUs. Effective March 22, 2021, each NEO except for Mr. Ashworth received an annual equity award. Mr. Ashworth was not eligible for an LTI grant in 2021 due to having received an equity award effective June 2020 granted as compensation for fiscal years 2020 through 2022.  

Name

 

 

RSUs (1)

 

 

 

Grant Date

Fair Value

of RSUs

 

 

 

Premium

Priced

Stock

Options (2)

 

 

 

Grant Date

Fair Value

of Premium

Priced Stock

Options

 

Adam Holland

 

 

 

13,598

 

 

 

$

324,992

 

 

 

 

24,603

 

 

 

$

325,006

 

Thomas Lewis

 

 

 

9,937

 

 

 

$

237,494

 

 

 

 

17,979

 

 

 

$

237,503

 

Raymond Bilbao

 

 

 

5,126

 

 

 

$

122,511

 

 

 

 

9,273

 

 

 

$

122,496

 

Ryan Wagers

 

 

 

3,661

 

 

 

$

87,498

 

 

 

 

6,624

 

 

 

$

87,503

 

SVP, Chief Accounting Officer and Treasurer of Sitel Worldwide Corporation (“Sitel”) from November 2016 to October 2018.  SVP, Shared Services of Sitel, from February 2016 until November 2016 and Chief Accounting Officer of Sitel from 2011 to February 2016.(1)

The RSUs vest in three equal annual installments over three years.

(2)

Premium priced stock options become exercisable on March 22, 2024.

Stock Ownership and Retention Guidelines

Our stock ownership and retention guidelines require currently employed NEOs to maintain a minimum ownership in the Company’s stock calculated as a multiple of their base salary aligned with their job responsibility (for 2021, at least 3.75 times base salary for Mr. Ashworth, 2.0 times base salary for Messrs. Holland and Lewis, 1.8 times base salary for Mr. Bilbao, and 1.2 times base salary for Mr. Wagers). NEOs must retain 75% of the net number of shares acquired (after payment of exercise price, if any, and taxes) upon the exercise of all stock options and upon the vesting of all RSUs, PSUs, and MSUs granted until they achieve the required multiple of base salary.  NEOs who do not comply with the guidelines may not be eligible for future equity awards.  All of the NEOs are currently in compliance with the guidelines.


401(k) Plan

The Committee believes that an important aspect of attracting and retaining qualified individuals to serve as NEOs involves providing a means to save for retirement.  As part of the Company’s Retirement Savings Plan (the “401(k) Plan”), which is based on a calendar year, during 2021 the Company matched 50 cents of each dollar of a participant’s voluntary salary contributions (up to a maximum of 6% of base salary).  The annual maximum participant voluntary salary contribution, which is established by the Internal Revenue Service, was $19,500 for 2021, plus a “catch-up” contribution limit for those over 50 years old of $6,500.  With respect to the 2021 plan year, all of the Company’s matching contributions were in cash.  Employees are credited with approximately 33% vesting in Company contributions each year during their first three years of service such that after three years of service, employees are fully vested in all prior and future Company matching contributions to the 401(k) Plan.  All of the NEOs were eligible to participate in the 401(k) Plan during 2021.

Severance and Change in Control Benefits

The Committee believes that reasonable severance and change in control benefits are necessary in order to recruit and retain effective executives and compete for executive talent within our industry.  In addition, the Committee also believes that a change in control arrangement provides an appropriate level of security to an executive that will likely reduce the reluctance of that executive to pursue a change in control transaction that could be in the best interests of our stockholders.  Although the Committee independently reviews the potential severance and change in control payments in light of their reasonableness as part of negotiating employment agreements or offer letters with our executive officers, the Committee typically does not consider the value of potential severance and change in control payments when assessing annual compensation because severance payments as a result of a change in control are contingent in nature and have primary purposes unrelated to ordinary compensation.  For a detailed discussion of potential severance and change in control benefits as well as an estimate of the amounts that would have been payable had they been triggered as of the end of 2021, see “Potential Payments Upon Termination or Change in Control of the Company”.

Perquisites and Other Benefits

NEOs are eligible for benefits generally available to and on the same terms as the Company’s employees who are categorized as exempt for purposes of the Fair Labor Standards Act.  Those benefits include health, disability, dental and life insurance. These payments are discussed in the footnotes to the Summary Compensation Table.

Tax Deductibility of Compensation

Prior to the Tax Cuts and Jobs Act enacted in December 2017 (the “Tax Act”), Section 162(m) of the Internal Revenue Code limited the Company’s ability to deduct on its tax return compensation over $1 million to the NEOs, other than the CFO, serving at the end of the year unless, in general, the compensation was paid pursuant to a plan that was performance-related, non-discretionary, and approved by the Company’s stockholders (“performance-based compensation”).

The Tax Act substantially modified Section 162(m) and, among other things, eliminated the performance-based compensation exception to the $1 million deduction limit with respect to taxable years beginning after December 31, 2017.  Accordingly, effective beginning in fiscal 2018, compensation paid to our NEOs (including our CFO) will be subject to the limitations on deductibility under Section 162(m) for any year in which compensation is paid to them (even years following their separation from service), and we will no longer be able to deduct “performance-based compensation” to such officers who receive annual compensation in excess of $1 million.  However, the Tax Act


provides that awards that were made and subject to binding written contracts in effect on November 2, 2017 are “grandfathered” under prior law and can still qualify as deductible “performance-based compensation,” even if paid in future years. The Committee will continue to monitor these awards and Internal Revenue Service guidance to determine whether they are deductible if and when paid.  The Committee has determined, however, that the Company will not necessarily seek to limit executive compensation to amounts deductible under Section 162(m) if the Committee believes such limitation is not in the best interest of the Company’s stockholders. While considering the tax implications of its compensation decisions, the Committee believes its primary focus should be to attract, retain, and motivate executives, and align the executives’ interest with those of the Company’s stockholders.

Compensation Decisions for 2022

For 2022 and beyond, the Committee remains committed to designing and maintaining an executive compensation program that is performance-based, competitive, and clear in its design and objectives, and that aligns the interests of management with those of the Company’s stockholders. The Committee will continue to evaluate the executive compensation program each year in light of market competitiveness and new facts and circumstances to ensure that our executive compensation strategies are aligned with our pay-for-performance compensation philosophy and our business objectives.

2022 Peer Group

In September 2021, FW Cook conducted a review of our peer group.  FW Cook applied certain criteria in developing the 2022 Peer Group (as defined below) such as industry sectors, revenues, enterprise value, and our historical peers.  With regard to revenue and enterprise value, FW Cook evaluated comparable companies with revenues ranging from approximately one-fourth to four times our pro-forma annual revenues and favored companies with 12-month average enterprise values ranging from approximately one-fourth to four times our enterprise value.  Our 2022 peer group consists of the following companies (the “2022 Peer Group”), whose compensation levels were used as competitive comparisons when reviewing our NEO compensation for 2022.  The median revenue for the latest four quarters and the median enterprise value as of August 31, 2021 for companies in our 2022 Peer Group were $0.7 million and $2.2 billion, respectively.

Addus HomeCare, Inc.

Evolent Health, Inc.

Planet Fitness, Inc.

Allscripts Healthcare Solutions, Inc.

Hanger, Inc.

Premier, Inc.

Apollo Medical Holdings, Inc.

ModivCare Inc.

Progyny, Inc.

Computer Programs and Systems, Inc.

NextGen Healthcare, Inc.

Tabula Rasa HealthCare, Inc.

CorVel Corporation

Omnicell, Inc.

U.S. Physical Therapy, Inc.

 

 

 

 

 

 

19


PART IIFollowing is a summary of compensation decisions with respect to the NEOs for 2022:

Item 5. Market forRegistrant's Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities

Market Information

OurcommonstockistradedonTheNasdaqGlobal SelectMarket(“Nasdaq”)underthesymbol"TVTY".Base Salaries

 

PerformanceGraphIn establishing base salaries for 2022, the Committee considered each NEO’s performance and responsibilities, CEO recommendations, internal pay equity, pay relative to the market and the 2022 Peer Group, and date of the last salary increase.  The Committee determined that the NEOs’ base salaries would be equal to the amounts set forth below effective February 21, 2022:


The followinggraphcompares the totalstockholder returnof $100 investedonDecember 31, 2015in(a) theCompany, (b) the Nasdaq U.S. StocksBenchmark index and (c) the NasdaqHealth Care index, assuming the reinvestment of all dividends.Annualized Base Salary ($000s)

Name

 

 

2022

Base Salary

 

 

 

2021

Base Salary

(at end of year)

 

 

 

Percentage

Increase

 

 

 

Date of

Previous

Increase

Richard Ashworth

 

 

$

900

 

 

 

$

900

 

 

 

0.0%

 

 

 

n/a

Adam Holland

 

 

$

438

 

 

 

$

424

 

 

 

3.2%

 

 

 

02/2021

Thomas Lewis

 

 

$

445

 

 

 

$

425

 

 

 

4.7%

 

 

 

02/2021

Ray Bilbao

 

 

$

330

 

 

 

$

309

 

 

 

6.8%

 

 

 

02/2021

Ryan Wagers

 

 

$

311

 

 

 

$

300

 

 

 

3.5%

 

 

 

02/2021

The stock price performance shown onthis graphisnotnecessarily indicativeoffuture priceperformance.

 

HoldersShort-Term Incentive Awards

For 2022, 80% of Common Stock

At Februaeach NEO’s short-term incentive target is based on Company achievement of financial goals, specifically Adjusted EBITDA.  The remaining 20% of each NEO’s short-term incentive target is based on Company achievement of an operational and strategic goal, specifically virtual visits.ry 22, 2021, there  There were approximately 10,400 holders of our commonstock, including274 stockholders of record.

20


Dividends

We have never declared or paid a cash dividend on our commonstock.  We intendno changes to retain any earnings to finance the growth and development of our business and do not expect to declare or pay any cash dividends in the foreseeable future.Our Board of Directorsreviews our dividend policy from time to time and maydeclare dividends at its discretion; however, our Credit Agreement placesrestrictions on the payment of dividends.For further discussion of the Credit Agreement, see Item 7. "Management's Discussion and AnalysisNEOs’ individual short-term incentive targets from the levels established at the end of Financi2021.  al Condition andResultsThe NEOs’ potential award payouts are capped at 190% of Operation- Liquidity and Capital Resources."the target award amount.

Securities AuthorizedShort-Term Incentive Targets for Issu2022 (as ance Under Equity Compensation Plans

See Part III,Item 12. "Security Ownership percentage of Certain Beneficial Owners and Management and Related Stockholder Matters," for information regarding securities authorized for issuance under ourequity compensation plans, which is incorporated herein by reference.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

The stock repurchase activity for the fourth quarter of 2020 was as follows:base salary)

 

ISSUER PURCHASES OF EQUITY SECURITIES

 

Period

 

Total Number of Shares Purchased (1)

 

 

Average Price Paid per Share

 

 

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)

 

 

Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)

 

10/1/2020 - 10/31/2020

 

 

 

 

 

 

 

 

 

 

 

 

11/1/2020 - 11/30/2020

 

 

 

 

 

 

 

 

 

 

 

 

12/1/2020 - 12/31/2020

 

 

8,513

 

 

$

19.70

 

 

 

 

 

 

 

Total

 

 

8,513

 

 

$

19.70

 

 

 

 

 

 

 

Name

 

(1)Short-term

Incentive

Total shares purchased include shares attributable to the withholding of shares by Tivity Health to satisfy the payment of tax obligations related to the vesting of restricted shares.

Richard Ashworth

 

(2)100%

We had no publicly announced plans or open market repurchase programs for shares of our common stock during the three months ended December 31, 2020.

Adam Holland

50%

Thomas Lewis

50%

Raymond Bilbao

50%

Ryan Wagers

40%

AnnualLong-Term Incentive Awards

The Committee granted annual equity awards in March 2022.  Similar to 2020 and 2021, the Committee designed the LTI program for 2021 such that 50% of the grant date fair value of each NEO’s LTI grant consisted of “premium priced” stock options having an exercise price equal to 110% of the closing price of the Common Stock on the grant date.  The stock options become exercisable on the third anniversary of the grant date.  The remaining 50% of the grant date fair value of each NEO’s LTI grant consisted of RSUs that are subject to vesting in three equal installments over three years.  Mr. Ashworth was not eligible for an annual LTI grant in 2021 due to having received an equity award in June 2020 granted ascompensation for fiscal years 2020 through 2022.

Special Incentive Bonus Award

On February 11, 2022, the Company entered into a Special Incentive Bonus Award Agreement (the “Special Incentive Bonus Award Agreement”) with Mr. Ashworth, pursuant to which Mr. Ashworth will be entitled to a cash payment in the amount of $5,000,000 on February 11, 2027 (the “Vesting Date”), as long as Mr. Ashworth is serving as an employee of the Company on the Vesting Date.  


If Mr. Ashworth’s employment with the Company is involuntarily terminated by the Company for any reason other than termination for cause, or is terminated by Mr. Ashworth for good reason, then, subject to Mr. Ashworth’s execution of the release of claims in favor of the Company, any portion of the Special Incentive Bonus Award that has not vested prior to the date of termination of Mr. Ashworth’s employment will immediately vest. If Mr. Ashworth’s employment with the Company terminates by reason of death or disability, then any portion of the Special Incentive Bonus Award that has not vested prior to the date of termination of Mr. Ashworth’s employment will immediately vest. If Mr. Ashworth’s employment with the Company is involuntarily terminated for cause or Mr. Ashworth is terminated for any other reason not already described above, then any portion of the Special Incentive Bonus Award that has not vested prior to the date on which Mr. Ashworth’s employment is terminated will immediately be forfeited and Mr. Ashworth shall have no further rights with respect to such Special Incentive Bonus Award. In the event of a change in control, the Special Incentive Bonus Award will vest as follows: (a) 50% of the Special Incentive Bonus Award will immediately vest on the date of the change in control, and (b) 50% of the Special Incentive Bonus Award will vest on the first anniversary of the date of the change in control.  

Compensation Committee Report

A copy of the Tivity Health, Inc. AnnualReport onForm 10-K for 2020 filed with the Securities and Exchange Commission is available onthe Company's website,www.tivityhealth.com.It is alsoavailable from the Company (withoutexhibits) atno charge. Theserequests shouldThe following Report of the Compensation Committee does not constitute soliciting material and should not bedirected deemed filed for any purpose, including for purposes of Section 18 of the Exchange Act, or otherwise subject to Jill Meyer, Vice President – Corporate Communications,the liabilities of that Section, or Adam Holland, Chief Financial Officerincorporated by reference into any other Company filing under the Securities Act of 1933, as amended (the “Securities Act”), ator theCompany'scorporateoffice. Exchange Act, except to the extent the Company specifically incorporates this Report by reference therein.


21


Item 6. Selected Financial DataThe Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis section with management and, based on such review and discussions, recommended to the Board that the Compensation Discussion and Analysis section be included in this Form 10-K/A.

 

Respectfully submitted,

Bradley S. Karro, Chair

Robert J. Greczyn, Jr.

Erin L. Russell

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

During 2021, the Compensation Committee was composed of Messrs. Karro and Greczyn for the entire year.  Ms. Jacob was a member of the Committee from the beginning of the year until the 2021 Annual Meeting of Stockholders.  Ms. Russell has been a member of the Committee since the 2021 Annual Meeting of Stockholders. Except for Mr. Greczyn, who served as the interim CEO of the Company from February 2020 through May 2020, none of these persons has at any time been an officer or employee of the Company or any of the Company’s subsidiaries.  In addition, there are no relationships among the Company’s executive officers, members of the Committee or entities whose executives serve on the Board or the Committee that require disclosure under applicable Commission regulations.


Summary Compensation Table

The following table represents selected consolidated financial data. The table should be read in conjunction with Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Item 8. "Financial Statements and Supplementary Data" of this report.  As further discussed in Note 1provides information regarding compensation to the notes to the consolidated financial statements included in this report, our results from continuing operations do not include the results of the Nutrisystem and TPHS businesses, which we sold effective December 9, 2020 and July 31, 2016, respectively.NEOs.

 

(In thousands, except per share data)

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

2017

 

 

2016

 

Operating Results:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

437,714

 

 

$

633,066

 

 

$

606,299

 

 

$

556,942

 

 

$

500,998

 

Cost of revenue (exclusive of depreciation and

   amortization included below)

 

 

250,362

 

 

 

445,817

 

 

 

418,333

 

 

 

390,261

 

 

 

353,451

 

Marketing expenses

 

 

12,197

 

 

 

17,720

 

 

 

14,417

 

 

 

5,541

 

 

 

3,669

 

Selling, general and administrative expenses

 

 

42,991

 

 

 

53,198

 

 

 

35,077

 

 

 

34,164

 

 

 

39,478

 

Depreciation and amortization

 

 

9,930

 

 

 

7,137

 

 

 

4,667

 

 

 

3,357

 

 

 

4,085

 

Restructuring and related charges

 

 

4,358

 

 

 

1,881

 

 

 

124

 

 

 

3,223

 

 

 

4,933

 

Operating income

 

$

117,876

 

 

$

107,313

 

 

$

133,681

 

 

$

120,396

 

 

$

95,382

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

43,477

 

(1)

 

41,803

 

(1)

 

8,733

 

 

 

15,613

 

 

 

17,318

 

Income before income taxes

 

$

74,399

 

 

$

65,510

 

 

$

124,948

 

 

$

104,783

 

 

$

78,064

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

17,530

 

(2)

 

20,293

 

(2)

 

27,046

 

(2)

 

43,553

 

(2)

 

21,973

 

Income from continuing operations

 

$

56,869

 

 

$

45,217

 

 

$

97,902

 

 

$

61,230

 

 

$

56,091

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from discontinued operations, net of

   income tax

 

 

(280,500

)

 

 

(332,038

)

 

 

901

 

 

 

2,485

 

 

 

(184,706

)

Net income (loss)

 

$

(223,631

)

 

$

(286,821

)

 

$

98,803

 

 

$

63,715

 

 

$

(128,615

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less: net income attributable to

   non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

496

 

Net income (loss) attributable to Tivity Health

 

$

(223,631

)

 

$

(286,821

)

 

$

98,803

 

 

$

63,715

 

 

$

(129,111

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic income (loss) per share attributable to

   Tivity Health:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.17

 

 

$

0.97

 

 

$

2.44

 

 

$

1.56

 

 

$

1.52

 

Discontinued operations

 

 

(5.75

)

 

 

(7.14

)

 

 

0.02

 

 

 

0.06

 

 

 

(5.01

)

Net income (loss) (3)

 

$

(4.59

)

 

$

(6.17

)

 

$

2.47

 

 

$

1.62

 

 

$

(3.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted income (loss) per share attributable to

   Tivity Health:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.16

 

 

$

0.96

 

 

$

2.27

 

 

$

1.44

 

 

$

1.47

 

Discontinued operations

 

 

(5.70

)

 

 

(7.05

)

 

 

0.02

 

 

 

0.06

 

 

 

(4.86

)

Net income (loss)

 

$

(4.54

)

 

$

(6.09

)

 

$

2.29

 

 

$

1.50

 

 

$

(3.39

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares and equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

48,746

 

 

 

46,509

 

 

 

40,078

 

 

 

39,357

 

 

 

36,999

 

Diluted

 

 

49,217

 

 

 

47,103

 

 

 

43,073

 

 

 

42,547

 

 

 

38,075

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selected Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets (4)

 

 

578,983

 

 

 

1,630,883

 

 

 

482,079

 

 

 

636,163

 

 

 

544,782

 

Long-term obligations (5)

 

 

470,744

 

 

 

1,079,528

 

 

 

30,589

 

 

 

 

 

 

164,297

 

Name and

Principal

Position

Year

 

Salary

($)

 

Bonus

($)

 

Stock

Awards

($)

 

Option

Awards

($)

 

Non-Equity

Incentive Plan

Compensation

($)

 

All Other

Compensation ($)

 

Total

($)

 

 

 

 

 

 

 

 

(1)

 

(1)

 

(2)

 

(3)

 

 

 

Richard Ashworth

2021

 

 

$

900,000

 

 

 

 

$

 

 

 

 

$

 

 

 

 

$

 

 

 

 

$

1,036,894

 

 

 

 

$

10,779

 

 

 

 

$

1,947,673

 

President and Chief Executive Officer

2020

 

 

$

421,247

 

 

 

 

$

 

 

 

 

$

10,154,429

 

 

 

 

$

 

 

 

 

$

900,000

 

 

 

 

$

77,288

 

 

 

 

$

11,552,964

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

2021

 

 

$

422,696

 

 

 

 

$

 

 

 

 

$

324,992

 

 

 

 

$

325,006

 

 

 

 

$

243,495

 

 

 

 

$

10,779

 

 

 

 

$

1,326,968

 

Chief Financial Officer

2020

 

 

$

338,186

 

 

 

 

$

 

 

 

 

$

669,540

 

 

 

 

$

324,999

 

 

 

 

$

63,787

 

 

 

 

$

9,937

 

 

 

 

$

1,406,449

 

 

2019

 

 

$

389,231

 

 

 

 

$

 

 

 

 

$

874,996

 

 

 

 

$

 

 

 

 

$

127,566

 

 

 

 

$

10,364

 

 

 

 

$

1,402,157

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

2021

 

 

$

418,942

 

 

 

 

$

 

 

 

 

$

237,494

 

 

 

 

$

237,503

 

 

 

 

$

241,333

 

 

 

 

$

11,779

 

 

 

 

$

1,147,051

 

Chief Operating Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

2021

 

 

$

307,789

 

 

 

 

$

 

 

 

 

$

122,511

 

 

 

 

$

122,496

 

 

 

 

$

177,302

 

 

 

 

$

1,930

 

 

 

 

$

732,028

 

Chief Legal Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

2021

 

 

$

297,745

 

 

 

 

$

 

 

 

 

$

87,498

 

 

 

 

$

87,503

 

 

 

 

$

137,213

 

 

 

 

$

10,607

 

 

 

 

$

620,566

 

Chief Accounting Officer

2020

 

 

$

232,503

 

 

 

 

$

 

 

 

 

$

249,155

 

 

 

 

$

87,502

 

 

 

 

$

54,275

 

 

 

 

$

7,385

 

 

 

 

$

630,820

 

 

2019

 

 

$

272,365

 

 

 

 

$

10,000

 

 

 

 

$

275,002

 

 

 

 

$

 

 

 

 

$

69,314

 

 

 

 

$

10,918

 

 

 

 

$

637,599

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

In December 2020, we usedReflects the significant majorityaggregate grant date fair value of stock and option awards granted during the respective period calculated in accordance with FASB ASC Topic 718, consistent with our estimate of the net proceeds fromaggregate compensation cost to be recognized for performance-based and market-based stock awards assuming 100% of target shares are earned. For additional detail regarding the divestitureassumptions used in the calculation of Nutrisystemthese fair value amounts, see Note 7 to pay down $519.0 million of principalour audited financial statements for the fiscal year ended December 31, 2021, included in the Form 10-K filed with the Commission on the term loans under our Credit Agreement.  February 25, 2022.We allocated interest expense to discontinued operations for 2019 and 2020 based on the interest expense incurred from March 8, 2019 through December 8, 2020 based on such principal amount of $519.0 million and our historical interest rates.

 

22In 2020, stock awards for Mr. Ashworth included an inducement award consisting of 500,000 RSUs vesting 50%, 25%, and 25% on each of the first, second, and third anniversaries of the grant date, respectively, to replace compensation forfeited from Mr. Ashworth’s former employer and to induce Mr. Ashworth to join the Company (“CEO Inducement Award”).  The CEO Inducement Award had a grant date fair value of $5,550,000. In addition, in 2020 Mr. Ashworth was granted 150,000 RSUs (“CEO RSU Award”) and 150,000 MSUs (at target performance) (“CEO MSU Award”), each of which were intended as compensation for fiscal years 2020 through 2022, and which had an aggregate grant date fair value of $4,491,000.  With respect to the MSUs, the table above includes the aggregate compensation cost ($2,826,000) to be recognized for the MSU award based on the Monte Carlo valuation of the award.  Assuming the highest level of performance conditions will be achieved, the value of the award at the grant date (i.e., the maximum potential shares multiplied by the fair value per share of $11.10 on the grant date) is $4,995,000. 


In 2019, stock awards for Mr. Holland include $687,501 aggregate compensation costs to be recognized for PSU awards assuming 100% would be earned at the end of the two-year performance period. Based on actual performance as measured following the end of the performance period, the aggregate compensation cost to be recognized for PSU awards granted to Mr. Holland in 2019 is $443,493.  

In 2019, stock awards for Mr. Wagers include $231,249 aggregate compensation costs to be recognized for PSU awards assuming 100% would be earned at the end of the two-year performance period. Based on actual performance as measured following the end of the performance period, the aggregate compensation cost to be recognized for PSU awards granted to Mr. Wagers in 2019 is $163,915.


(2)

Non-equity incentive plan compensation in 2021 includes short-term cash incentive awards.  

See the section titled “Short-term Cash Incentive Awards” in the “Compensation Discussion and Analysis” section for details on the short-term cash incentive awards.  

(3)

The Tax Cutsamounts in this column for 2021 reflect Company contributions to the 401(k) Plan and Jobs Act (the “Tax Act”), which was signed into lawthe NEO’s health savings account and insurance premiums the Company paid with respect to life insurance for the benefit of each NEO.

The table does not include medical benefits coverage and disability insurance that are offered through programs available to substantially all of our salaried employees.



Grants of Plan-Based Awards in 2021

The following table sets forth the plan-based awards granted to the Company’s NEOs during 2021.

 

 

 

Estimated Future Payouts

Under Non-Equity Incentive

Plan Awards

(2)

 

 

 

Estimated Future Payouts

Under Equity Incentive Plan

Awards

 

All Other

Stock

Awards:

Number of

Shares of

 

 

All Other

Option

Awards:

Number of

Securities of

 

 

Exercise

or Base

Price of

 

 

Grant Date

Fair Value

of Stock

and

 

Name

Grant

Type

(1)

Grant

Date (3)

Threshold

($)

 

 

Target

($)

 

 

Maximum

($)

 

 

 

Threshold

(#)

 

Target

(#)

 

Max-

imum

(#)

 

Stock or

Units

(#)

 

 

Underlying

Options

(#)

 

 

Option

Awards

($/Sh)

 

 

Option

Awards

($)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4)

 

 

(5)

 

 

 

 

 

 

(6)

 

Richard Ashworth (7)

STC

 

$

 

 

$

900,000

 

 

$

1,800,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland (7)

STC

 

$

 

 

$

211,348

 

 

$

422,696

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

RSU

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13,598

 

 

 

 

 

 

 

 

 

 

$

324,992

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

NQ

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24,603

 

 

$

26.29

 

 

$

325,006

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis (7)

STC

 

 

 

 

 

$

209,471

 

 

$

418,942

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

RSU

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,937

 

 

 

 

 

 

 

 

 

 

$

237,494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

NQ

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17,979

 

 

$

26.29

 

 

$

237,503

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao (7)

STC

 

 

 

 

 

$

153,894

 

 

$

307,788

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

RSU

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,126

 

 

 

 

 

 

 

 

 

 

$

122,511

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

NQ

03/22/21

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,273

 

 

$

26.29

 

 

$

122,496

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers (7)

STC

 

 

 

 

 

$

119,098

 

 

$

238,196

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

RSU

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,661

 

 

 

 

 

 

 

 

 

 

$

87,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

NQ

03/22/21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,624

 

 

$

26.29

 

 

$

87,503

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

STC: Represents cash awards under the short-term cash incentive program discussed in December 2017, resultedfootnote (7) below.

RSU: Represents RSUs granted under the Second Amended and Restated 2014 Plan.

NQ: Represents premium-priced, non-qualified stock options granted under the Second Amended and Restated 2014 Plan.


(2)

Non-equity incentive plan awards include short-term cash incentive awards.  These columns set forth the target and maximum payouts for performance under these awards.  

Under the short-term cash incentive program, potential bonus payouts range from 0% to 200% of the target.  There was no threshold amount for the short-term cash incentive awards.  See the section titled “Short-term Cash Incentive Awards” in the “Compensation Discussion and Analysis” section for details of actual payouts compared to the target.

(3)

Grant approval occurred on the grant date.

(4)

RSUs vest in three equal annual installments.    

(5)

a reductionStock options vest on the three-year anniversary of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017grant date.

(6)

.  In 2017, we incurred a non-cash charge to income tax expenseThese amounts represent the aggregate grant date fair value of $7.4 million related to the Tax Act.  This charge related to both the re-measurement of our deferred tax assets to the lower tax rate and the requirement to recalculate the impact of repatriation of our foreign earnings, which occurred earlierawards calculated in accordance with FASB ASC Topic 718.  These amounts are reflected in the year, under provisionsSummary Compensation Table in the “Stock Awards” and “Option Awards” columns.

(7)

Under the 2021 short-term cash incentive program, Mr. Ashworth was eligible to receive an award up to 100% of his base earnings, each of Messrs. Holland, Lewis, and Bilbao was eligible to receive an award up to 50% of his base earnings, and Mr. Wagers was eligible to receive an award up to 40% of his base earnings.  The maximum short-term incentive award payout that each NEO could earn for 2021 was equal to 200% of his annual short-term cash incentive target amount.  See the new law. In addition,section titled “Short-term Cash Incentive Awards” in 2017 we adopted Accounting Standards Update ("ASU")the “Compensation Discussion and Analysis” No. 2016-09, "Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), whichsection requires the excess tax benefits from share-based awards to be recognizedfor a detailed discussion of targets and actual payouts.

Compensation Programs for Fiscal 2021

As reflected in the above Summary Compensation Table and Grants of Plan-Based Awards Table, the primary components of our 2021 executive compensation program were base salary, short-term cash incentive compensation, LTI awards, and awards under retirement plans.  For a detailed discussion of each of these components, see the “Compensation Discussion and Analysis” section.


Outstanding Equity Awards at Fiscal Year-End

The following tables provide information with respect to outstanding stock options, MSUs, and RSUs held by the NEOs as of December 31, 2021.

 

 

OPTION AWARDS

 

 

Name

 

Option

Grant

Date

 

 

Number

of

Securities

Underlying

Unexercised

Options

(#)

Exercisable

 

 

Number

of

Securities

Underlying

Unexercised

Options

(#)

Unexercisable

 

 

Option

Exercise

Price

($)

 

 

Option

Expiration

Date

 

 

Richard Ashworth

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

 

6/15/18

 

 

 

10,910

 

 

 

 

 

$

34.42

 

 

6/15/28

 

 

 

 

11/10/20

 

 

 

 

 

39,634 (1)

 

 

$

16.78

 

 

11/10/27

 

 

 

 

3/22/21

 

 

 

 

 

24,603 (2)

 

 

$

26.29

 

 

3/22/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

 

11/10/20

 

 

 

 

 

24,390 (1)

 

 

$

16.78

 

 

11/10/27

 

 

 

 

3/22/21

 

 

 

 

 

19,979 (2)

 

 

$

26.29

 

 

3/22/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

 

7/2/18

 

 

 

1,477

 

 

 

 

 

$

35.75

 

 

7/2/28

 

 

 

 

11/10/20

 

 

 

 

 

14,939 (1)

 

 

$

16.78

 

 

11/10/27

 

 

 

 

3/22/21

 

 

 

 

 

9,273 (2)

 

 

$

26.29

 

 

3/22/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

 

10/17/18

 

 

 

1,266

 

 

 

 

 

$

33.36

 

 

3/31/21

 

 

 

 

11/10/20

 

 

 

 

 

10,671 (1)

 

 

$

16.78

 

 

11/10/27

 

 

 

 

3/22/21

 

 

 

 

 

6,624 (2)

 

 

$

26.29

 

 

3/22/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Options vest in full on a prospective basis in income tax expense, whereas they were previously recorded to stockholders’ equity.May 10, 2023.

 

(3)

Figures may not add due to rounding.

(4)

Includes assets of discontinued operation at December 31, 2019.  In addition, balances at December 31, 2020 and 2019 include right-of-use assets from continuing operations of $18.1 million and $25.6 million, respectively, due to the adoption of ASU No. 2016-02, “Leases”, on January 1, 2019. Prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting policies.

(5)

Balances at December 31, 2020 and 2019 include long-term lease liabilities from continuing operations of $11.5 million and $19.6 million, respectively, due to the adoption of ASU No. 2016-02, “Leases”, on January 1, 2019. Balance at December 31, 2019 includes long-term lease liabilities of discontinued operation of $11.8 million.  Prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting policies.

23


Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Please read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included under Item 8. "Financial Statements and Supplementary Data" of this report.

Overview

Tivity Health, Inc. (the “Company”), was founded and incorporated in Delaware in 1981.  Through our four programs, SilverSneakers®senior fitness, Prime® Fitness, WholeHealth LivingTM, and Wisely WellTM, we are focused on becoming the modern destination for healthy living, especially for seniors and older adults.   

We offer SilverSneakers to members of Medicare Advantage, Medicare Supplement, and group retiree plans.  We also offer Prime Fitness, a fitness facility access program, through commercial health plans, employers, and other sponsoring organizations.  Our national network of fitness centers delivers both SilverSneakers and Prime Fitness.  Our fitness networks encompass approximately 16,000 partner locations and nearly 1,000 alternative locations that provide classes outside of traditional fitness centers. We also offer virtual fitness experiences, including live instructor-led classes. Through our WholeHealth Living program, which we sell primarily to health plans, we offer a continuum of services related to complementary, alternative, and physical medicine.  Our WholeHealth Living network includes relationships with approximately 18,000 complementary, alternative, and physical medicine practitioner locations to serve individuals through health plans and employers who seek health services such as chiropractic care, acupuncture, physical therapy, occupational therapy, massage therapy, and more.  Finally, through our Wisely Well brand, we offer meals designed to support individuals and caregivers who are seeking meal convenience as well as those recovering after a hospitalization or living with chronic conditions.

Effective as of December 9, 2020, we completed the sale of Nutrisystem, Inc. (“Nutrisystem”), a wholly owned subsidiary of the Company that included the Nutrisystem® and South Beach Diet® programs, to KNS Acquisition Corp. (“Kainos”) pursuant to terms of a Stock Purchase Agreement (the “Purchase Agreement”), dated October 18, 2020, by and among the Company, Kainos, and Kainos NS Holdings LP.  At the closing (the “Closing”) of the transactions contemplated by the Purchase Agreement (the “Transactions”), Nutrisystem, Inc. and its subsidiaries were acquired by, and became wholly owned subsidiaries of, Kainos.  Pursuant to the terms of the Purchase Agreement, Kainos paid to the Company an aggregate purchase price, after giving effect to customary indebtedness and cash adjustments, of approximately $559 million, which amount is subject to a customary working capital adjustment post-Closing.  We used the significant majority of the net proceeds from the divestiture to pay down $519 million of principal on the term loans under our Credit Agreement.  Results of operations for Nutrisystem have been classified as discontinued operations for all periods presented in the consolidated financial statements, and all related assets and liabilities have been classified as discontinued operations at December 31, 2019.

The Company is headquartered at 701 Cool Springs Boulevard, Franklin, Tennessee 37067.

COVID-19

In January 2020, the Secretary of HHS declared a national public health emergency due to a novel strain of coronavirus, which causes the disease known as “COVID-19.”  In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic, and COVID-19 continues to spread throughout the United States and other countries.  Many state and local governments, together with public health officials, have recommended and mandated precautions to mitigate the spread of COVID-19, including ordering closure of certain businesses and imposing stay-at-home orders and social distancing guidelines for individuals. Such measures have resulted in significantly reduced demand for many businesses that have continued in operation.  

By March 31, 2020, substantially all of the fitness centers in our national network were temporarily closed, which had an adverse impact on our results from continuing operations for the first quarter of 2020 because a significant portion of revenues from our SilverSneakers program is based on member visits to a fitness partner location. A substantial number of our fitness partner locations remained closed through April, with some locations reopening in May and additional locations reopening in June and throughout the third quarter of 2020. Due to a resurgence of COVID-19 cases throughout the country, some fitness partner locations were closed again during the

24


fourth quarter of 2020.  For the month of December 2020, approximately 74% of our fitness partner locations reported at least one visit from our SilverSneakers program.  From April through December 2020, the average monthly total participation levels of our SilverSneakers members were significantly below historical levels, and we also experienced a decline in paid subscribers for Prime Fitness, each of which adversely impacted revenues from continuing operations.  We are unable to predict with certainty how many of our fitness partner locations will be subject to any operational restrictions in the future and for what duration, or the level of member participation at our fitness partner locations.  

Forward-Looking Statements

This report contains forward-looking statements, which are based upon current expectations, involve a number of risks and uncertainties, and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and those regarding the intent, belief, or expectations of the Company, including, without limitation, all statements regarding the Company's future earnings, revenues, and results of operations.  Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary from those in the forward-looking statements as a result of various factors, including, but not limited to:

impacts from the COVID-19 pandemic (including the response of governmental authorities to combat and contain the pandemic, the closure of fitness centers in our national network (or operational restrictions imposed on such fitness centers), reclosures, and potential additional reclosures as a result of surges in positive COVID-19 cases) on our business, operations or liquidity;

the risks associated with changes in macroeconomic conditions (including the impacts of any recession or changes in consumer spending resulting from the COVID-19 pandemic), widespread epidemics, pandemics (such as the current COVID-19 pandemic) or other outbreaks of disease, geopolitical turmoil, and the continuing threat of domestic or international terrorism;

our ability to collect accounts receivable from our customers and amounts due under our sublease agreements;

the market’s acceptance of our new products and services;

our ability to develop and implement effective strategies and to anticipate and respond to strategic changes, opportunities, and emerging trends in our industry and/or business, as well as to accurately forecast the related impact on our revenues and earnings;

the impact of any impairment of our goodwill, intangible assets, or other long-term assets;

our ability to attract, hire, or retain key personnel or other qualified employees and to control labor costs;

the effectiveness of the reorganization of our business (including the 2020 COVID Restructuring Plan and the 2020 Healthcare Restructuring Plan, each as defined below) and our ability to realize the anticipated benefits;

our ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed our resources;

the impact of legal proceedings involving us and/or our subsidiaries, products, or services, including any claims related to intellectual property rights, as well as our ability to maintain insurance coverage with respect to such legal proceedings and claims on terms that would be favorable to us;

the impact of severe or adverse weather conditions, the current COVID-19 pandemic, and the potential emergence of additional health pandemics or infectious disease outbreaks on member participation in our programs;

25


(2)

the risks associated with deriving a significant concentration of our revenues from a limited number of our customers, many of whom are health plans;Options vest in full on March 22, 2024.

our ability and/or the ability of our customers to enroll participants and to accurately forecast their level of enrollment and participation in our programs in a manner and within the timeframe we anticipate;

our ability to sign, renew and/or maintain contracts with our customers and/or our fitness partner locations under existing terms or to restructure these contracts on terms that would not have a material negative impact on our results of operations;

the ability of our health plan customers to maintain the number of covered lives enrolled in those health plans during the terms of our agreements;

our ability to add and/or retain paid subscribers in our Prime Fitness program;

the impact of a reduction in Medicare Advantage health plan reimbursement rates or changes in plan design;

the impact of any new or proposed legislation, regulations and interpretations relating to Medicare, Medicare Advantage, Medicare Supplement and privacy and security laws;

the impact of healthcare reform on our business;

the risks associated with potential failures of our information systems or those of our third-party vendors, includingStock options granted as a result of telecommuting issues associated with personnel working remotely, which may include a failure to execute on policies and processes in a work-from-home or remote model;

the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of our information systems or those of third-party vendors or other service providers, including those risks that result from the increase in personnel working remotely, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee or our information, or other data subject to privacy laws and may lead to a disruption in our business, costs to modify, enhance, or remediate our cybersecurity measures, enforcement actions, fines or litigation against us, or damage to our business reputation;

the risks associated with changes to traditional office-centered business processes and/or conducting operations out of the office in a work-from-home or remote model by us or our third-party vendors during adverse situations (e.g., during a crisis, disaster, or pandemic), which may result in additional costs and/or may negatively impact productivity and cause other disruptions to our business;

our ability to enforce our intellectual property rights;

the risk that our indebtedness may limit our ability to adapt to changes in the economy or market conditions, expose us to interest rate risk for the variable rate indebtedness and require a substantial portion of cash flows from operations to be dedicated to the payment of indebtedness;

our ability to service our debt, make principal and interest payments as those payments become due, and remain in compliance with our debt covenants;

our ability to obtain adequate financing to provide the capital that may be necessary to support our current or future operations;

counterparty risk associated with our interest rate swap agreements; and

other risks detailed in this report and our other filings with the Securities and Exchange Commission.

We undertake no obligation to update or revise any such forward-looking statements.

26


Critical Accounting Policies

We describe our significant accounting policies in Note 1 of the notes to the consolidated financial statements.  We prepare the consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and related disclosures at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

We believe the following accounting policies are the most critical in understanding the estimates and judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition, and cash flows.

Revenue Recognition

Beginning in 2018, we account for revenue from contracts with customers in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers” (“ASC Topic 606”).  The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract’s transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied.

We earn revenue from continuing operations primarily from threeprograms: SilverSneakers senior fitness, Prime Fitness andWholeHealth Living.  We provide the SilverSneakers senior fitness programto membersof MedicareAdvantage and MedicareSupplement plans through our contracts with those plans.  We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program.  We sell our WholeHealth Living program primarily to health plans.

The significant majority of our customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term.  There are generally no performance obligations that are unsatisfied at the end of a particular month.  There was no material revenue recognized during the year ended December 31, 2020 from performance obligations satisfied in a prior period.

Our fees are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location.  We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month.  We bill for member visits approximately one month in arrears once actual member visits are known.  Payments from customers are typically due within 30 days of invoice date.  When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period.  

Our customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month.  The allocated consideration corresponds directly with the value to our customers of our services completed for the month.  Under the majority of our contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice.  ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient.

Although we evaluate our financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment, we believe the following information depicts how our revenues and cash flows from continuing operations are affected by economic factors.  For the year ended December 31, 2020, revenue from our SilverSneakers program, which is predominantly contracted with Medicare Advantage and Medicare Supplement plans, comprised 72% of revenues from continuing operations, while revenue from our Prime

27


Fitness and WholeHealth Living programs comprised 22% and 5%, respectively, of revenues from continuing operations.

Sales and usage-based taxes are excluded from revenues.

Impairment of Intangible Assets and Goodwill

We reviewgoodwillfor impairment at thereportingunitlevel (operatingsegmentor onelevelbelowanoperatingsegment) on an annualbasis (duringthe fourth quarter of our fiscal year) ormore frequently wheneverevents orcircumstances indicatethat the carryingvalue may not be recoverable.  Following the sale of Nutrisystem in December 2020, we have a single reporting unit.

As part of the annual impairment test, we may electCompany’s LTI program have an exercise price equal to perform a qualitative assessment to determinewhether it is more likely than not that the fair valueof the reportingunit is less thanits carrying value.If we elect not to perform a qualitativeassessment or we determine that it is more likely than not that the fair valueof the reportingunit is less thanits carrying value, we perform a quantitative review as described below.

During a quantitative review of goodwill, we estimate the fairmarket value of the reporting unit based on a discounted cash flow model or a combination of a discounted cash flow model and market-based approaches, and we reconcile the fair value of the reporting unit to our consolidated market capitalization.  If the fair value of the reporting unit exceeds its carrying amount, no impairment is indicated. If the fair value of the reporting unit is less than its carrying amount, impairment of goodwill is measured as the excess of the carrying amount over fair value.  Estimating fair value requires significant judgments, including management's estimate of future cash flows of the reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for the reporting unit, the terminal growth rate of revenue, the tax rate, and determination of the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based approaches.  Changes in these estimates and assumptions could materially affect the estimate of fair value and potential goodwill impairment for the reporting unit.

Except for a tradename that has an indefinite life and is not subject to amortization, we amortize identifiable intangible assets over their estimated useful lives on a straight-line or accelerated basis based on the period for which the economic benefits of the asset are expected to be realized.We assess the potential impairment of intangible assets subject to amortizationwhenever events orchanges in circumstances indicate thatthe carrying values may not be recoverable. If we determine thatthe carrying value of other identifiable intangible assetsmay not be recoverable,we calculateany impairment using an estimate of thasset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between marketparticipants.  

We review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate.  Changes in these estimates and assumptions could materially affect the estimates of fair value for the tradename.

Key Performance Indicators

In managing our business, we regularly review and analyze a number of key performance indicators (“KPIs”), including revenues, adjusted EBITDA (both in dollars and as a percentage of revenues), and free cash flow.  Adjusted EBITDA and free cash flow are not calculated in accordance with U.S. GAAP (“non-GAAP”).  These KPIs help us monitor our performance, identify trends affecting our business, determine the allocation of resources, and assess the quality and potential variability of our cash flows and earnings.  We believe they are useful to investors in evaluating and understanding our business.

Following the divestiture of Nutrisystem, we have only one reportable segment and therefore no longer review and analyze revenues on a segment-level basis or adjusted EBITDA on a segment-level basis as KPIs. Instead, we

28


review and analyze revenues from continuing operations and adjusted EBITDA from continuing operations. Additionally, beginning in 2020, we have revised the definition of free cash flow to exclude settlement on derivatives not designated as hedges, a new item for 2020 that did not exist in prior periods. Settlement on derivatives not designated as hedges arose in 2020 due to the de-designation of certain interest rate swaps in the fourth quarter of 2020 in connection with the repayment of a portion of the principal on the term loans under our Credit Agreement, as further described in Note 13 of the notes to consolidated financial statements included in this report. We believe it is appropriate to exclude settlement on derivatives not designated as hedges from free cash flow because these payments are similar to interest payments (which are reflected in cash flow from operating activities) and they reduce our cash available to repay debt or make other investments.

 

 

Year Ended December 31,

 

(In $000s)

 

2020

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues from continuing operations

 

$

437,714

 

 

$

633,066

 

 

$

606,299

 

Adjusted EBITDA from continuing operations

 

 

147,855

 

 

 

142,561

 

 

 

142,168

 

Adjusted EBITDA as a percentage of

   revenues from continuing operations

 

 

33.8

%

 

 

22.5

%

 

 

23.4

%

Revenues – we review year-over-year changes in revenue from continuing operations as a key measure of our success in growing our business.  In addition to measuring revenue in total, we also measure and report revenue by program type or source of revenue, as detailed in Note 4 of the notes to the consolidated financial statements included in this report, i.e., SilverSneakers, Prime Fitness, WholeHealth Living, and Other.  Evaluating revenue by program type or source helps us identify and address changes in product mix, broad market factors that may affect our revenues, and opportunities for future growth.

Adjusted EBITDA is a non-GAAP measure and is defined by the Company as earnings before interest, taxes, depreciation and amortization, acquisition, integration, and project costs, CEO transition costs, and restructuring charges.  We believe adjusted EBITDA provides investors a helpful measure for comparing our operating performance with our historical operating results as well as the performance of other companies that may have different financing and capital structures or tax rates. We believe it is a useful indicator of the operational strength and performance of our business.  Because adjusted EBITDA may be defined differently by other companies in our industry, the financial measure presented herein may not be comparable to similarly titled measures of other companies.  A reconciliation of adjusted EBITDA to net income (the most comparable U.S. GAAP measure) is set forth below.

 

 

Year Ended December 31,

 

(In thousands)

 

2020

 

 

2019

 

 

2018

 

Income from continuing operations, GAAP basis

 

$

56,869

 

 

$

45,217

 

 

$

97,902

 

Income tax expense

 

 

17,530

 

 

 

20,293

 

 

 

27,046

 

Interest expense

 

 

43,477

 

 

 

41,803

 

 

 

8,733

 

Depreciation expense

 

 

9,930

 

 

 

7,137

 

 

 

4,667

 

EBITDA, non-GAAP basis (1)

 

$

127,806

 

 

$

114,450

 

 

$

138,348

 

Acquisition, integration, project and CEO transition costs (2)

 

 

15,691

 

 

 

26,230

 

 

 

3,696

 

Restructuring charges (3)

 

 

4,358

 

 

 

1,881

 

 

 

124

 

Adjusted EBITDA, non-GAAP basis (4)

 

$

147,855

 

 

$

142,561

 

 

$

142,168

 


(1)

EBITDA is a non-GAAP financial measure.  We believe it is useful to investors to provide disclosures of our operating results on the same basis as that used by management.  You should not consider EBITDA in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.

(2)

Acquisition, integration, project and CEO transition costs consist of pre-tax charges of $15,691, $26,230, and $3,696 for fiscal 2020, 2019, and 2018, respectively, incurred in connection with the acquisition and integration of Nutrisystem and other strategic projects and with the termination of our former CEO in February 2020 and the hiring of our new CEO in June 2020.

(3)

Restructuring charges in 2020 consist of pre-tax charges of $4,358 related to the 2020 COVID Restructuring Plan and the 2020 Restructuring Plan (each as further defined below).  Restructuring charges for 2019 consist of pre-tax charges of $1,881 related to the 2019 Restructuring Plan (as defined below).  Restructuring charges for 2018 consist of pre-tax charges of $124 primarily due to additional costs related to a prior restructuring.

(4)

Adjusted EBITDA is a non-GAAP financial measure.  We exclude acquisition, integration, project and CEO transition costs and restructuring charges from this measure because of its comparability to our historical operating results. We believe it is useful to investors to provide disclosures of our operating results on the same basis as that used by management.  You should not consider Adjusted EBITDA in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.  Additionally, because Adjusted EBITDA may be defined differently by other companies in the Company’s industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

Free cash flow is a non-GAAP measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges.  We believe free cash flow is useful to management and investors to measure (i) our performance, (ii) the strength of the Company and its ability to generate cash, and (iii) the amount of cash that is available to repay debt or make other investments.  A reconciliation of free cash flow to cash flows from operating activities (the most comparable U.S. GAAP measure) is set forth below.  The amounts shown below represent consolidated figures that include the effects of owning Nutrisystem.

 

 

Year Ended December 31,

 

(In thousands)

 

2020

 

 

2019

 

 

2018

 

Net cash flows provided by operating activities

 

$

169,447

 

 

$

82,305

 

 

$

108,739

 

Acquisition of property and equipment

 

 

(15,525

)

 

 

(24,713

)

 

 

(9,053

)

Settlement on derivatives not designated as hedges

 

 

(1,499

)

 

 

 

 

 

 

Free cash flow

 

$

152,423

 

 

$

57,592

 

 

$

99,686

 

Outlook

Although there is significant uncertainty relating to the potential impacts of the COVID-19 pandemic on our business going forward, including the duration of the outbreak, the timing and duration of any operational restrictions applicable to our fitness partner locations, the impact on member participation in our SilverSneakers programs, our ability to continue to attract paying subscribers for our Prime Fitness program, and the ultimate medium- and long-term impact of the pandemic on the global economy, we expect our results from continuing operations for the short term to continue to be adversely impacted by COVID-19.

Executive Overview of Results

The key financial results for the year ended December 31, 2020 are:

Revenues of $437.7 million for the year ended December 31, 2020 compared to $633.1 million for the year ended December 31, 2019; and

Pre-tax income from continuing operations of $74.4 million for the year ended December 31, 2020 compared to $65.5 million for the year ended December 31, 2019. Pre-tax income from continuing operations for 2020 includes:

30


o

$43.5 million of interest expense compared to $41.8 million for 2019;

o

$12.2 million of marketing expenses, compared to $17.7 million for 2019;

o

$6.6 million of CEO transition costs compared to $0 for 2019;

o

$5.7 million of transition, acquisition, and integration costs compared to $26.2 million for 2019;

o

$4.4 million of restructuring and related charges compared to $1.9 million for 2019;

o

$3.4 million of strategic project costs compared to $0 for 2019.

Loss from discontinued operations, net of income tax benefit, of $280.5 million for the year ended December 31, 2020 compared to $332.0 million for the year ended December 31, 2019.

Results of Operations

The following table sets forth the components of the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018 expressed as a percentage of revenues from continuing operations.  

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Revenues

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Cost of revenue (exclusive of depreciation included below)

 

 

57.2

%

 

 

70.4

%

 

 

69.0

%

Marketing

 

 

2.8

%

 

 

2.8

%

 

 

2.4

%

Selling, general and administrative expenses

 

 

9.8

%

 

 

8.4

%

 

 

5.8

%

Depreciation expense

 

 

2.3

%

 

 

1.1

%

 

 

0.8

%

Restructuring and related charges

 

 

1.0

%

 

 

0.3

%

 

 

0.0

%

Operating income (loss) (1)

 

 

26.9

%

 

 

17.0

%

 

 

22.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

9.9

%

 

 

6.6

%

 

 

1.4

%

Income before income taxes (1)

 

 

17.0

%

 

 

10.3

%

 

 

20.6

%

Income tax expense

 

 

4.0

%

 

 

3.2

%

 

 

4.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations (1)

 

 

13.0

%

 

 

7.1

%

 

 

16.1

%

Income (loss) from discontinued operations, net of income tax

 

 

(64.1

)%

 

 

(52.4

)%

 

 

0.1

%

Net income (loss) (1)

 

 

(51.1

)%

 

 

(45.3

)%

 

 

16.3

%

(1)

Figures may not add due to rounding.

Following is a discussion of the Company’s results of operations and financial condition for 2020 compared to 2019 and for 2019 compared to 2018.  

Revenues

Revenues from continuing operations were $437.7 million for 2020compared to $633.1 million for 2019, a decrease of $195.4 million, primarily as a result of a net decrease in SilverSneakers revenue of $179.2 million driven by a decrease in revenue-generating visits in 2020 due to the COVID-19 pandemic, which resulted in the closure of substantially all of our fitness partner locations beginning in March 2020. While some of these locations reopened in May and additional locations reopened in June and throughout the remainder of 2020, the average participation level of our members after such locations reopened was significantly lower than in the comparable periods in 2019.  As a result, revenues from PMPM fees represented 54% of SilverSneakers revenue for 2020, compared to 33% for 2019.  In addition, revenue from Prime Fitness decreased by $25.9 million due to a decrease in paid subscribers for 2020 compared to 2019. These decreases were partially offset by an increase of $6.8 million from a program during the second quarter of 2020 with a large employer seeking to improve its employees’ well-being during the COVID-19 pandemic. We do not expect revenue from this program to recur at this level.

31


Revenues from continuing operations for 2019 increased to $633.1 million compared to $606.3 million for 2018, primarily due to (i) an increase in Prime Fitness revenue of $19.6 million driven by an increase in average subscribers for 2019 compared to 2018 and (ii) a net increase in SilverSneakers revenue of $5.2 million, primarily due to an increase in revenue-generating visits somewhat offset by a decrease in the number of eligible lives.

Cost of Revenue

Cost of revenue from continuing operations (excluding depreciation) as a percentage of revenues decreased from 2019 (70.4%) to 2020 (57.2%), primarily due to a higher mix of revenues from PMPM fees in 2020, as noted above, coupled with a decrease in visit costs due to the temporary closure of fitness partner locations and a decline in average monthly total participation levels (compared to 2019) after such locations reopened.  

Cost of revenue from continuing operations (excluding depreciation) as a percentage of revenues increased from 2018 (69.0%) to 2019 (70.4%), primarily due to (i) an increase in cost per visit due to certain contract renegotiations, as well as a higher number of average visits per member per month in 2019 compared to 2018 and (ii) acquisition and integration costs in 2019 related to the acquisition of Nutrisystem.

MarketingExpenses

Marketing expenses from continuing operations as a percentage of revenues did not change materially from 2018 (2.4%) to 2019 (2.8%) to 2020 (2.8%).

Selling, General and Administrative Expenses

Selling, general and administrative expenses from continuing operations as a percentage of revenues increased from 2019 (8.4%) to 2020 (9.8%) primarily due to (i) the fixed nature of certain costs that cannot be reduced proportionately with reductions in revenue, (ii) costs incurred in 2020 associated with developing our new strategy, and (iii) CEO transition-related expenses associated with the termination of our former CEO in February 2020 and the hiring of a new CEO in June 2020.  These increases were partially offset by (i) savings in employee compensation resulting from temporary salary reductions and furloughs, as described under “COVID-19” above, and (ii) a decrease in acquisition, integration, and project costs from $23.3 million in 2019 to $3.6 million in 2020.

Selling, general and administrative expenses from continuing operations as a percentage of revenues increased from 2018 (5.8%) to 2020 (9.8%) primarily due to acquisition, integration, and project costs of $23.3 million during 2019, primarily related to the acquisition of Nutrisystem

Depreciation Expense

Depreciation expense from continuing operations increased by $2.8 million from 2019 to 2020 and by $2.5 million from 2018 to 2019, primarily due to an increase in the amount of depreciable computer software.

Restructuring and Related Charges

2019 Restructuring Plan

During the first quarter of 2019, we began a reorganization primarily related to integrating the Nutrisystem business and streamlining our corporate and operations support (the "2019 Restructuring Plan"). The 2019 Restructuring Plan concluded during the first quarter of 2020.  For the years ended December 31, 2020 and 2019, we incurred restructuring charges from continuing operations of $0.5 million and $1.9 million, respectively, related to the 2019 Restructuring Plan.  To date, we have incurred restructuring charges from continuing operations of $2.4 million related to the 2019 Restructuring Plan. These expenses consist entirely of severance and other employee-related costs.  The 2019 Restructuring Plan resulted in total annualized savings in 2020 of approximately $6.7 million.

2020 COVID Restructuring Plan

During the second quarter of 2020, we began a reorganization plan primarily related to eliminating certain compensation costs in response to the COVID-19 pandemic in order to preserve our liquidity and manage our cash flows (“2020 COVID Restructuring Plan”). The 2020 COVID Restructuring Plan was completed during the third

32


quarter of 2020. To date and for the year ended December 31, 2020, we incurred restructuring charges from continuing operations of $0.8 million related to the 2020 COVID Restructuring Plan. These expenses consist entirely of severance and other employee-related costs.  The 2020 COVID Restructuring Plan is expected to result in total annualized savings at target performance of approximately $6.0 million.

2020 Restructuring Plan

During the third quarter of 2020, we began a reorganization plan primarily related to optimizing our business for growth and executing on our new strategy (“2020 Restructuring Plan”).  To date and for the year ended December 31, 2020, we incurred restructuring charges from continuing operations of $3.1 million related to the 2020 Restructuring Plan, which consisted entirely of severance and other employee-related costs.  Actions taken to date under the 2020 Restructuring Plan are expected to result in total annualized savings at target performance of approximately $6.7 million.

Interest Expense

Interest expense from continuing operations did not change materially from 2019 to 2020.As discussed in Note 2 of the notes to consolidated financial statements in this report, we allocated a portion of historical interest expense for 2019 and 2020 to discontinued operations.

Interest expense from continuing operations increased by $33.1 million from 2018 to 2019, primarily due to our entering into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, as revolving facility agent and swingline lender, on March 8, 2019 in connection with the acquisition of Nutrisystem.    

Income Tax Expense

See Note 8 of the notes to consolidated financial statements in this report for a discussion of income tax expense for fiscal 2020 compared to fiscal 2019.  Our effective tax rate for the fourth quarter of 2020 was 7.3%, which was less than our statutory tax rate and represents a decrease compared to the first three quarters of 2020.  This decrease is primarily due to a decrease in the valuation allowance on certain deferred tax assets reevaluated for realizability after the Nutrisystem divestiture.  

Liquidity and Capital Resources

Overview

As of December 31, 2020, outstanding debt under the Credit Agreement was $466.7 million, which represented $496.3 million of principal on the Term Loans less deferred loan costs and original issue discount, and we had $100.4 million of cash and cash equivalents.

As of December 31, 2020, we had working capital of $75.6 million.  While the COVID-19 pandemic has created significant uncertainty as to general economic and market conditions for the remainder of 2021 and beyond, as of the date of this report, we believe our cash on hand, expected cash flows from operations, and anticipated available credit under the Credit Agreement will be sufficient to fund our operations, principal and interest payments, and capital expenditures for the next 12 months.  We cannot assure you that we will be able to secure additional financing if needed and, if such funds are available, whether the terms or conditions will be favorable to us.  With the uncertainty surrounding COVID-19, our ability to engage in financing transactions may be constrained by (i) volatile or tight economic, capital, credit and/or financial market conditions, (ii) moderated investor and/or lender interest or capacity, (iii) restrictions under our Credit Agreement, and/or (iv) our liquidity, leverage and net worth, and we can provide no assurance as to successfully completing, the costs of, or the operational limitations arising from, any one or series of such transactions. As of December 31, 2020, availability under the Revolving Credit Facility totaled $124.5 million as calculated under the most restrictive covenant.

Credit Facility

In connection with the consummation of the acquisition of Nutrisystem, on March 8, 2019, we entered into the Credit Agreement. The Credit Agreement provides us with (i) a $350.0 million term loan A facility (“Term Loan A”),

33


(ii) an $830.0 million term loan B facility (“Term Loan B” and, together with Term Loan A, the “Term Loans”), (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit (the “Revolving Credit Facility”; Term Loan A, Term Loan B and the Revolving Credit Facility are sometimes herein referred to collectively as the “Credit Facilities”), and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements.

We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full.  

We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable beginning on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full.

We are permitted to make voluntary prepayments of borrowings under the Term Loans at any time without penalty.  From March 8, 2019 through December 31, 2020, we made voluntary prepayments of payments of $164.7 million on the Term Loans, which prepaid all scheduled quarterly installments due through December 31, 2021.  In addition, in December 2020 we used the significant majority of the net proceeds from the divestiture of Nutrisystem to pay $519.0 million of principal on the Term Loans, which was applied to the amount due and payable at  maturity.  In January 2021, we made a voluntary prepayment of $45.0 million on the Term Loans, which prepaid all scheduled quarterly installments due through September 30, 2022.

We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024.  In addition, the Credit Agreement contains provisions that, beginning with fiscal 2019, may require annual excess cash flow (as defined in the Credit Agreement and generally designed to equal cash generated by our business in excess of cash used in the business) to be applied towards the Term Loans.  We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages (such resulting payment an “Excess Cash Flow Payment”) based on our Net Leverage Ratio (as defined in the Credit Agreement) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1.  Any such potential mandatory prepayments are reduced by voluntary prepayments.  We were not required to make an Excess Cash Flow Payment for fiscal 2020.  

The Credit Agreement contains a financial covenant that requires us to maintain maximum ratios or levels of consolidated total net debt to consolidated adjusted EBITDA, calculated as provided in the Credit Agreement, of 5.75:1.00 for all test dates occurring on or after December 31, 2019 but prior to December 31, 2020, 5.25:1.00 for all test dates occurring on or after December 31, 2020 but prior to December 31, 2021, and 4.75:1.00 for all test dates occurring on or after December 31, 2021. As of December 31, 2020, we were in compliance with all of the financial covenant requirements of the Credit Agreement, and our Net Leverage Ratio was equal to 2.36. 

Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, the outstanding principal on the term loans under our Credit Agreement following the repayment of $519.0 million in December 2020 and $45.0 million in January 2021, our fitness partner locations reopening and/or remaining open, and the average monthly total participation levels of our members at such locations, we currently believe we will be in compliance with the Net Leverage Ratio covenant over the next 12 months.  We will continue to monitor our projected ability to comply with all covenants under the Credit Agreement, including the Net Leverage Ratio.

Cash Flows Provided by Operating Activities

Operating activities during the year ended December 31, 2020 provided cash of $169.4 million compared to $82.3 million during the year ended December 31, 2019. The increase in operating cash flowis primarily due to (i) increased collections on accounts receivable, (ii) decreased payments related to acquisition and integration costs,

34


and (iii) decreased payments related to visit costs.  These changes were partially offset by transaction costs related to the sale of Nutrisystem and higher interest payments related to borrowings under the Credit Agreement.

Operating activities during the year ended December 31, 2019 provided cash of $82.3 million compared to $108.7 million during the year ended December 31, 2018. The decrease in operating cash flow is primarily due to payments related to interest and acquisition and integration costs, offset by net cash flows provided by Nutrisystem.

Cash Flows Provided by/Used in Investing Activities

Investing activities during the year ended December 31, 2020 provided cash of $541.0 million, compared to cash used of $1,087.5 million during the year ended December 31, 2019.  This change is primarily due to the acquisition of Nutrisystem in March 2019, followed by the sale of Nutrisystem in December 2020.

Investing activities during the year ended December 31, 2019 used $1,087.5 million in cash, compared to $7.6 million during the year ended December 31, 2018.  This change is primarily due to the acquisition of Nutrisystem.

Cash Flows Provided by/Used in Financing Activities

Financing activities during the year ended December 31, 2020 used $612.6 million in cash, compared to cash provided of $1,005.8 million during the year ended December 31, 2019.  This change is primarily due to net borrowings under the Credit Agreement in 2019, compared to net payments under the Credit Agreement in 2020.

Financing activities during the year ended December 31, 2019 provided $1,005.8 million in cash, compared to cash used of $127.6 million during the year ended December 31, 2018.  This change is primarily due to net borrowings under the Credit Agreement, slightly offset by payment of deferred loan costs.

General

If acquisition or investment opportunities arise, we may need to issue additional debt or equity securities to provide the funding for these increased growth opportunities. We may also issue debt or equity securities in connection with future acquisitions or strategic alliances.  We cannot assure you that we would be able to issue additional debt or equity securities on terms that would be favorable to us.

Any material commitments for capital expenditures are included in the "Contractual Obligations" table below.

Contractual Obligations

The following schedule summarizes our contractual cash obligations as of December 31, 2020:

 

 

Payments due by year ended December 31,

 

(in thousands)

 

2021

 

 

2022-2023

 

 

2024-2025

 

 

2026 and

After

 

 

Total

 

Debt, related interest, and other related

   settlement obligations (1)

 

 

45,770

 

 

 

188,526

 

 

 

139,870

 

 

 

270,133

 

 

 

644,299

 

Operating lease obligations (2)

 

 

2,416

 

 

 

3,786

 

 

 

1,084

 

 

 

 

 

 

7,286

 

Finance lease obligations (3)

 

 

686

 

 

 

403

 

 

 

 

 

 

 

 

 

1,089

 

Severance and employee-related

   obligations

 

 

3,242

 

 

 

587

 

 

 

 

 

 

 

 

 

3,829

 

Total Contractual Cash Obligations

 

$

52,114

 

 

$

193,302

 

 

$

140,954

 

 

$

270,133

 

 

$

656,503

 

(1)

Consists of scheduled principal payments and estimated interest payments on outstanding borrowings under the Credit Agreement. The total term loan principal due during 2021 reflects $7.5 million of additional debt repayment required upon estimated final settlement of the Nutrisystem sale, reduced by $2.8 million additional proceeds expected as a result of the post-Closing working capital adjustment. Total estimated interest payments included in the table above are $34.5 million for 2021, $59.4 million for 2022 and 2023 combined, $37.2 million for 2024 and 2025 combined, and $3.1 million thereafter. Total estimated cash settlements on de-designated interest rate swaps included in the table above are $6.6 million for 2021, $9.4 million for 2022 and 2023 combined, $0.7 million for 2024, and $0 thereafter.

35


(2)

Amounts shown are net of cash receipts from sublease contracts of $5.7 million in 2021, $6.7 million for 2022 and 2023 combined, and $0 thereafter.

(3)

Consists of scheduled payments on finance lease obligations, including estimated interest of $42,000 in 2021 and $6,000 for 2022.  

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as of December 31, 2020.

Recent Relevant Accounting Standards

See Note 3 of the notes to consolidated financial statements included in this report for discussion of recent relevant accounting standards.

Certain Assets

As disclosed in Note 1(e) of the notes to consolidated financial statements included in this report, we own 159,309 shares of common stock of Sharecare, Inc. (“Sharecare”) that we acquired in connection with the sale of our TPHS business to Sharecare in July 2016.  On February 12, 2021, Sharecare announced that it had entered into a merger agreement with Falcon Capital Acquisition Corp. (“FCAC”) and FCAC Merger Sub, Inc. (“Merger Sub”) pursuant to which Sharecare would merge with and into Merger Sub with Sharecare surviving as a wholly owned subsidiary of FCAC (the “Sharecare Transaction”), as further described in the Current Report on Form 8-K filed by FCAC on February 12, 2021 and other filings made by FCAC with the Securities and Exchange Commission, none of which shall constitute a part of this report or be incorporated by reference into this report.  The Sharecare Transaction is subject to customary closing conditions, including the approval of Sharecare’s and FCAC’s shareholders, and may or may not be consummated. The value of any consideration that we may receive as a shareholder of Sharecare in connection with the Sharecare Transaction is speculative, and any equity consideration we may receive in connection with the Sharecare Transaction will be subject to restrictions on resale.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We are subject to market risk related to interest rate changes, primarily as a result of the Credit Agreement and certain interest rate swap agreements that, effective October 2020, no longer qualify for hedge accounting treatment (see further discussion below).

Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than zero, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25%, and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total net leverage ratio. The Base Rate margin for Term Loan A loans is 3.25%, the Base Rate margin for Term Loan B loans is 4.25%, and the Base Rate margin for revolving loans varies between 2.75% and 3.25%, depending on our total net leverage ratio.  Effective May 31, 2019, we maintain eight amortizing interest rate swap agreements with current notional amounts totaling $700.0 million, through which we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread.  Each of these interest rate swap agreements were designated as cash flow hedges from their inception through October 18, 2020.  Upon entering into the Purchase Agreement with Kainos on October 18, 2020, we determined that some of our hedged transactions would not materially occur in the initially identified time period since we expected to use the majority of the net proceeds from the sale to pay down a significant portion of outstanding debt. As a result, we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we discontinued the related hedging designation (“de-designated swaps”).

For the year ended December 31, 2020, we estimate that a 100-basis point increase in LIBOR would have reduced our cash flow from operating activities by $2.4 million, which reflects increased payments on variable rate

36


debt outstanding under the Credit Agreement, partially offset by decreased payments related to the de-designated swaps (for which we pay a fixed interest rate of approximately 2.2% and receive a variable interest rate based on LIBOR).  For the year ended December 31, 2019, we estimate that a 100-basis point increase in LIBOR would have reduced our cash flow from operating activities by $3.9 million based on variable rate debt outstanding under the Credit Agreement.  

37


Item 8. Financial Statements and Supplementary Data

Report of Independent Registered Public Accounting Firm

To theBoard of Directors and Stockholders of Tivity Health, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Tivity Health, Inc.and its subsidiaries(the “Company”) as of December 31, 2020and 2019,and the related consolidated statements of operations, comprehensive income (loss), changes in stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the “consolidated financial statements”).We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework(2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  

In our opinion, the consolidatedfinancial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020and 2019,and the results of itsoperations and itscash flows for each of the three years in the period endedDecember 31, 2020in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework(2013)issued by the COSO.

Change in Accounting Principle

As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidatedfinancial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  

Our audits of the consolidatedfinancial statements included performing procedures to assess the risks of material misstatement of the consolidatedfinancial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidatedfinancial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidatedfinancial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in

38


accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to theconsolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidatedfinancial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

First Quarter Goodwill and Indefinite-Lived Intangible Asset Impairment Assessments – Nutrition Reporting Unit and Nutrisystem Indefinite-Lived Tradename

As described in Notes 1 and 12 to the consolidated financial statements, management reviews goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year or more frequently whenever events or circumstances indicate that the carrying value of goodwill and indefinite-lived intangible assets may not be recoverable. As a result of the COVID-19 pandemic, in March 2020, the Company experienced a significant decline in market capitalization and in the actual and forecasted operating results, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of its goodwill and indefinite-lived intangible assets. Following these evaluations, management recorded a total impairment loss of $199.5 million related to the Nutrisystem goodwill and indefinite-lived tradename during the first quarter of 2020. Fair value of the Nutrition reporting unit was estimated by management using a discounted cash flow model and market-based approaches.  Estimating fair value for the Nutrition reporting unit required significant judgment and assumptions related to management’s estimated future cash flows which is dependent upon internal forecasts of projected income, estimation of the long-term growth rates of future revenues, the terminal growth rate of revenue, the tax rate, and determination of the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based approach used in the valuation of goodwill.  Fair value of the Nutrisystem indefinite-lived tradename was estimated by management using the relief-from-royalty method under the income approach.  Estimating the fair value of the Nutrisystem indefinite-lived tradename required significant assumptions related to the long-term growth rates of future revenues associated with the tradename, the terminal growth rate of revenue, the royalty rate for such revenue, the tax rate, and the discount rate.

The principal considerations for our determination that performing procedures relating to the first quarter goodwill and indefinite-lived intangible asset impairment assessments of the Nutrition reporting unit and the Nutrisystem indefinite-lived tradename is a critical audit matter are (i) the significant judgment applied by management when developing the fair value estimates, (ii) significant auditor judgment, subjectivity, and effort in performing procedures and evaluating  management’s significant assumptions related to internal forecasts of projected income, the long-term growth rates of future revenues, the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the valuation of the goodwill and the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, and the discount rate for the valuation of the Nutrisystem indefinite-lived tradename, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with

39


forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill and indefinite-lived intangible asset impairment assessments, including controls over the development of the assumptions related to the valuation of goodwill and indefinite-lived intangible assets, including internal forecasts of projected income, the long-term growth rates of future revenues, the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for goodwill and the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, and the discount rate for the Nutrisystem indefinite-lived tradename. These procedures also included, among others (i) testing management’s process for developing the fair value estimates, (ii) evaluating the appropriateness of the valuation models, (iii) testing the completeness, accuracy, and relevance of underlying data used in estimating the fair values, and (iv) evaluating the significant assumptions used by management related to internal forecasts of projected income, the long-term growth rates of future revenues, the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the valuation of the goodwill and the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, and the discount rate for the valuation of the Nutrisystem indefinite-lived tradename.  Evaluating management’s assumptions related to internal forecasts of projected income, the long-term growth rates of future revenues, the weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for goodwill and the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, and the discount rate for the Nutrisystem indefinite-lived tradename involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past financial performance, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of the valuation models and evaluating the reasonableness of certain significant assumptions related to the weighted average cost of capital as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for goodwill and the royalty rate for revenues associated with the tradename and the discount rate for the Nutrisystem indefinite-lived tradename.

/s/ PricewaterhouseCoopers LLP

Nashville, Tennessee

March 2, 2021

We have served as the Company’s auditor since 2014.

40


TIVITY HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

 

December 31,

2020

 

 

December 31,

2019

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

100,385

 

 

$

2,486

 

Accounts receivable, net

 

 

25,981

 

 

 

84,194

 

Prepaid expenses

 

 

5,556

 

 

 

7,740

 

Income taxes receivable

 

 

10,996

 

 

 

4,978

 

Other current assets

 

 

11,336

 

 

 

7,155

 

Current assets of discontinued operation

 

 

 

 

 

60,162

 

Total current assets

 

 

154,254

 

 

 

166,715

 

 

 

 

 

 

 

 

 

 

Property and equipment, net of accumulated depreciation of

   $38,188 and $32,532 respectively

 

 

20,959

 

 

 

23,576

 

Right-of-use assets

 

 

18,139

 

 

 

25,575

 

Long-term deferred tax asset

 

 

3,601

 

 

 

 

Intangible assets, net

 

 

29,049

 

 

 

29,049

 

Goodwill, net

 

 

334,680

 

 

 

334,680

 

Other assets

 

 

18,301

 

 

 

22,992

 

Long-term assets of discontinued operation

 

 

 

 

 

1,028,296

 

Total assets

 

$

578,983

 

 

$

1,630,883

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

19,741

 

 

$

28,099

 

Accrued salaries and benefits

 

 

8,949

 

 

 

6,886

 

Accrued liabilities

 

 

18,424

 

 

 

37,640

 

Deferred revenue

 

 

4,460

 

 

 

4,336

 

Current portion of long-term debt

 

 

7,456

 

 

 

 

Current portion of lease liabilities

 

 

8,052

 

 

 

7,898

 

Current portion of other long-term liabilities

 

 

14,753

 

 

 

4,947

 

Current liabilities of discontinued operation

 

 

 

 

 

64,740

 

Total current liabilities

 

 

81,835

 

 

 

154,546

 

 

 

 

 

 

 

 

 

 

Long-term debt

 

 

459,250

 

 

 

1,048,127

 

Long-term lease liabilities

 

 

11,494

 

 

 

19,585

 

Long-term deferred tax liability

 

 

 

 

 

4,222

 

Other long-term liabilities

 

 

22,748

 

 

 

11,292

 

Long-term liabilities of discontinued operation

 

 

 

 

 

169,411

 

 

 

 

 

 

 

 

 

 

Commitments and contingent liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock $.001 par value, 5,000,000 shares authorized, NaN

   outstanding

 

 

 

 

 

 

Common Stock $.001 par value, 120,000,000 shares authorized,

   48,983,735 and 48,156,786 shares outstanding, respectively

 

 

49

 

 

 

48

 

Additional paid-in capital

 

 

513,263

 

 

 

504,419

 

Accumulated deficit

 

 

(464,085

)

 

 

(240,494

)

Treasury stock, at cost, 2,254,953 shares in treasury

 

 

(28,182

)

 

 

(28,182

)

Accumulated other comprehensive loss

 

 

(17,389

)

 

 

(12,091

)

Total stockholders' equity

 

 

3,656

 

 

 

223,700

 

Total liabilities and stockholders' equity

 

$

578,983

 

 

$

1,630,883

 

 

 

 

 

 

 

 

 

 

See accompanying notes to the consolidated financial statements.

41


TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except earnings per share data)

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Revenues

 

$

437,714

 

 

$

633,066

 

 

$

606,299

 

Cost of revenue (exclusive of depreciation of $9,209, $5,920, and

   $4,109, respectively, included below)

 

 

250,362

 

 

 

445,817

 

 

 

418,333

 

Marketing expense

 

 

12,197

 

 

 

17,720

 

 

 

14,417

 

Selling, general and administrative expenses

 

 

42,991

 

 

 

53,198

 

 

 

35,077

 

Depreciation expense

 

 

9,930

 

 

 

7,137

 

 

 

4,667

 

Restructuring and related charges

 

 

4,358

 

 

 

1,881

 

 

 

124

 

Operating income

 

 

117,876

 

 

 

107,313

 

 

 

133,681

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

43,477

 

 

 

41,803

 

 

 

8,733

 

Income before income taxes

 

 

74,399

 

 

 

65,510

 

 

 

124,948

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

17,530

 

 

 

20,293

 

 

 

27,046

 

Income from continuing operations

 

$

56,869

 

 

$

45,217

 

 

$

97,902

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from discontinued operations, net of income tax

   (benefit) of ($46,851), ($59,881) and $325, respectively

 

 

(280,500

)

 

 

(332,038

)

 

 

901

 

Net income (loss)

 

$

(223,631

)

 

$

(286,821

)

 

$

98,803

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share - basic:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.17

 

 

$

0.97

 

 

$

2.44

 

Discontinued operations

 

$

(5.75

)

 

$

(7.14

)

 

$

0.02

 

Net income (loss) (1)

 

$

(4.59

)

 

$

(6.17

)

 

$

2.47

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share – diluted:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.16

 

 

$

0.96

 

 

$

2.27

 

Discontinued operations

 

$

(5.70

)

 

$

(7.05

)

 

$

0.02

 

Net income (loss)

 

$

(4.54

)

 

$

(6.09

)

 

$

2.29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss)

 

$

(228,929

)

 

$

(298,912

)

 

$

98,803

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares and equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

48,746

 

 

 

46,509

 

 

 

40,078

 

Diluted

 

 

49,217

 

 

 

47,103

 

 

 

43,073

 

(1)

Figures may not add due to rounding.

See accompanying notes to the consolidated financial statements.

42


TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Net income (loss)

 

$

(223,631

)

 

$

(286,821

)

 

$

98,803

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in fair value of effective portion of interest rate swaps

   designated as cash flow hedges, net of tax benefit of $5,540

   and $4,147, respectively

 

 

(16,151

)

 

 

(12,091

)

 

 

 

Reclassification adjustment for loss from interest rate swaps de-

   designated as cash flow hedges included in "Income (loss) from

   discontinued operations, net," net of tax of $3,661

 

 

10,675

 

 

 

 

 

 

 

Reclassification adjustment for previously deferred loss from

   interest rate swaps included in "Interest expense," net of

   tax of $61

 

 

178

 

 

 

 

 

 

 

Total other comprehensive loss, net of tax

 

$

(5,298

)

 

$

(12,091

)

 

$

 

Comprehensive income (loss)

 

$

(228,929

)

 

$

(298,912

)

 

$

98,803

 

See accompanying notes to the consolidated financial statements.

43


TIVITY HEALTH, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(In thousands)

 

 

Preferred

Stock

 

 

Common

Stock

 

 

Additional

Paid-in

Capital

 

 

Retained

Earnings (Accumulated Deficit)

 

 

Treasury

Stock

 

 

Accumulated Other

Comprehensive

Income (Loss)

 

 

Total

 

Balance, January 1, 2018

 

$

 

 

$

40

 

 

$

349,243

 

 

$

(52,358

)

 

$

(28,182

)

 

$

 

 

$

268,743

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

98,803

 

 

 

 

 

 

 

 

 

98,803

 

Exercise of stock options and

   Warrants

 

 

 

 

 

1

 

 

 

1,909

 

 

 

 

 

 

 

 

 

 

 

 

1,910

 

Tax withholding for share-based

   compensation

 

 

 

 

 

 

 

 

(9,762

)

 

 

 

 

 

 

 

 

 

 

 

(9,762

)

Share-based employee

   compensation expense

 

 

 

 

 

 

 

 

6,097

 

 

 

 

 

 

 

 

 

 

 

 

6,097

 

Balance, December 31, 2018

 

$

 

 

$

41

 

 

$

347,487

 

 

$

46,445

 

 

$

(28,182

)

 

$

 

 

$

365,791

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

(286,821

)

 

 

 

 

 

(12,091

)

 

 

(298,912

)

Issuance of Common Stock in connection with Merger

 

 

 

 

 

6

 

 

 

132,832

 

 

 

 

 

 

 

 

 

 

 

 

132,838

 

Share-based compensation replacement awards related to merger and attributable to pre-combination services

 

 

 

 

 

 

 

 

9,107

 

 

 

 

 

 

 

 

 

 

 

 

9,107

 

Exercise of stock options

 

 

 

 

 

1

 

 

 

988

 

 

 

 

 

 

 

 

 

 

 

 

989

 

Tax withholding for share-based

   compensation

 

 

 

 

 

 

 

 

(4,733

)

 

 

 

 

 

 

 

 

 

 

 

(4,733

)

Share-based employee

   compensation expense

 

 

 

 

 

 

 

 

18,832

 

 

 

 

 

 

 

 

 

 

 

 

18,832

 

Other

 

 

 

 

 

 

 

 

(94

)

 

 

(118

)

 

 

 

 

 

 

 

 

(212

)

Balance, December 31, 2019

 

$

 

 

$

48

 

 

$

504,419

 

 

$

(240,494

)

 

$

(28,182

)

 

$

(12,091

)

 

$

223,700

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

(223,631

)

 

 

 

 

 

(5,298

)

 

 

(228,929

)

Exercise of stock options

 

 

 

 

 

1

 

 

 

1,024

 

 

 

 

 

 

 

 

 

 

 

 

1,025

 

Tax withholding for share-based

   compensation

 

 

 

 

 

 

 

 

(6,257

)

 

 

 

 

 

 

 

 

 

 

 

(6,257

)

Share-based employee

   compensation expense

 

 

 

 

 

 

 

 

14,077

 

 

 

 

 

 

 

 

 

 

 

 

14,077

 

Other

 

 

 

 

 

 

 

 

 

 

 

40

 

 

 

 

 

 

 

 

 

40

 

Balance, December 31, 2020

 

$

 

 

$

49

 

 

$

513,263

 

 

$

(464,085

)

 

$

(28,182

)

 

$

(17,389

)

 

$

3,656

 

See accompanying notes to the consolidated financial statements.

44


TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

56,869

 

 

$

45,217

 

 

$

97,902

 

Income (loss) from discontinued operations

 

 

(280,500

)

 

 

(332,038

)

 

 

901

 

Adjustments to reconcile net income (loss) to net cash

   provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

45,887

 

 

 

50,775

 

 

 

4,667

 

Amortization and write-off of deferred loan costs

 

 

9,190

 

 

 

4,487

 

 

 

1,152

 

Amortization and write-off of debt discount

 

 

8,604

 

 

 

3,711

 

 

 

4,140

 

Share-based employee compensation expense

 

 

14,077

 

 

 

18,832

 

 

 

6,097

 

Loss on derivatives

 

 

14,544

 

 

 

 

 

 

 

Impairment of goodwill and intangible assets of discontinued operation

 

 

199,500

 

 

 

377,100

 

 

 

 

Loss (gain) on sale of business

 

 

90,163

 

 

 

 

 

 

(1,304

)

Deferred income taxes

 

 

(38,438

)

 

 

(52,076

)

 

 

25,485

 

Decrease (increase) in accounts receivable, net

 

 

63,239

 

 

 

(8,283

)

 

 

(12,311

)

Decrease in other current assets

 

 

1,129

 

 

 

1,661

 

 

 

1,610

 

Decrease in accounts payable

 

 

(3,182

)

 

 

(10,052

)

 

 

(95

)

Increase (decrease) in accrued salaries and benefits

 

 

128

 

 

 

3,608

 

 

 

(10,314

)

Decrease in other current liabilities

 

 

(19,152

)

 

 

(21,495

)

 

 

(11,802

)

Increase (decrease) in deferred revenue

 

 

686

 

 

 

(1,198

)

 

 

 

Other

 

 

6,703

 

 

 

2,056

 

 

 

2,611

 

Net cash flows provided by operating activities

 

$

169,447

 

 

$

82,305

 

 

$

108,739

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition of property and equipment

 

$

(15,525

)

 

$

(24,713

)

 

$

(9,053

)

Proceeds from sale of business, net of cash transferred

 

 

558,067

 

 

 

 

 

 

1,416

 

Settlement on derivatives not designated as hedges

 

 

(1,499

)

 

 

��

 

 

 

 

Business acquisitions, net of cash acquired

 

 

 

 

 

(1,062,818

)

 

 

 

Net cash flows provided by (used in) investing activities

 

$

541,043

 

 

$

(1,087,531

)

 

$

(7,637

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of long-term debt

 

$

196,525

 

 

$

1,611,970

 

 

$

253,425

 

Payments of long-term debt

 

 

(795,100

)

 

 

(574,329

)

 

 

(373,536

)

Proceeds from settlement of cash convertible notes hedges

 

 

 

 

 

 

 

 

141,246

 

Payments related to settlement of cash conversion derivative

 

 

 

 

 

 

 

 

(141,246

)

Payments related to tax withholding for share-based compensation

 

 

(6,257

)

 

 

(4,733

)

 

 

(9,762

)

Exercise of stock options

 

 

1,025

 

 

 

989

 

 

 

1,910

 

Deferred loan costs

 

 

 

 

 

(30,189

)

 

 

 

Change in cash overdraft and other

 

 

(8,784

)

 

 

2,083

 

 

 

410

 

Net cash flows provided by (used in) financing activities

 

$

(612,591

)

 

$

1,005,791

 

 

$

(127,553

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash

 

$

 

 

$

(12

)

 

$

(56

)

Net increase (decrease) in cash and cash equivalents

 

$

97,899

 

 

$

553

 

 

$

(26,507

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

2,486

 

 

 

1,933

 

 

 

28,440

 

Cash and cash equivalents, end of period

 

$

100,385

 

 

$

2,486

 

 

$

1,933

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

71,439

 

 

$

67,717

 

 

$

4,099

 

Cash paid for income taxes, net of refunds

 

$

20,433

 

 

$

8,370

 

 

$

3,339

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Noncash investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net working capital settlement expected from sale of Nutrisystem (see Note 2)

 

$

2,844

 

 

$

 

 

$

 

See accompanying notes to the consolidated financial statements.

45


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years Ended December 31, 2020, 2019, and 2018

1.

Summary of Significant Accounting Policies

Tivity Health, Inc. (the “Company”) was founded and incorporated in Delaware in 1981.  Through our 4 programs, SilverSneakers® senior fitness, Prime® Fitness, WholeHealth LivingTM and Wisely WellTM, we are focused on becoming the modern destination for healthy living, especially for seniors and older adults

Beginning in February 2020, the Board of Directors engaged in a comprehensive review of the Company’s long-term strategy, including reviewing the Company’s core capabilities and ability to best deliver increased shareholder value through actions that would improve our balance sheet and best focus management on the creation of value. On May 6, 2020, we announced that our Board had commenced a process to explore strategic alternatives with respect to the Nutrition business, including a possible transaction.

On October 18, 2020, we entered into aCommon Stock Purchase Agreement (“Purchase Agreement”) with Kainos NS Holdings LP, a Delaware limited partnership (“Parent”), and KNS Acquisition Corp., a Delaware corporation and indirect wholly owned subsidiary of Parent (“Purchaser,” and collectively with Parent, “Kainos”) to sell to Kainos all of the issued and outstanding capital stock of Nutrisystem, Inc. (“Nutrisystem”), a wholly owned subsidiary of the Company that included the Nutrisystem® and South Beach Diet® programs, which would result in the disposition of our Nutrition business. Because management did not have the authority to commit to a plan to sell the Nutrition business at September 30, 2020, we concluded that the held for sale criteria were not met in the third quarter of 2020. Upon obtaining Board approval to sell the Nutrition business on October 18, 2020, we met all of the criteria to classify the Nutrition business as held for sale. We concluded that the disposition of the Nutrition business represents a strategic shift that will have a major effect on our operations and financial results.  Accordingly, results of operations for Nutrisystem have been classified as discontinued operations for all periods presented in the accompanying consolidated financial statements, and all related assets and liabilities have been classified as discontinued operations at December 31, 2019.  Effective as of December 9, 2020, we completed the sale of Nutrisystem to Kainos pursuant to the terms of the Purchase Agreement.  At the closing (the “Closing”) of the transactions contemplated by the Purchase Agreement, Nutrisystem and its subsidiaries were acquired by, and became wholly owned subsidiaries of, Kainos.

Our results from continuing operations also do not include the results of MeYou Health, LLC (“MeYou Health”), which we sold in June 2016.  Results of operations for MeYou Health have been classified as discontinued operations for all periods presented in the accompanying consolidated financial statements.

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).  In our opinion, the accompanying consolidated financial statements of Tivity Health, Inc. and its wholly owned subsidiaries (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement.  We have reclassified certain items in prior periods to conform to current classifications.

In addition, we have recorded a correction to deferred revenue as of January 1, 2018, the earliest date presented in the consolidated financial statements, to reflect additional performance obligations that were unsatisfied at such time.  Such adjustment resulted in a $3.2 million increase to deferred revenue, with a related decrease to retained earnings as of January 1, 2018. We concluded that this adjustment was not material to any prior annual or interimperiod.

a.

Principles of Consolidation – See discussion above regarding Nutrisystem and MeYou Health.  We have eliminated all intercompany profits, transactions, and balances.

b.

Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit.

46


c.

Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts.  Billed receivables represent fees that are contractually due for services performed or products sold, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2020 and 2019, respectively. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis.  Unbilled receivables were $5.7 million and $29.1 million at December 31, 2020 and 2019, respectively, and primarily represent fees recognized for monthly member utilization of fitness facilities under our SilverSneakers fitness solution, billed one month in arrears.

d.

Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and office equipment, and three to five years for equipment.  Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years.  Depreciation expense, including depreciation of assets recorded under finance leases, for the years ended December 31, 2020, 2019, and 2018 was $9.9 million, $7.1 million, and $4.7 million, respectively.

e.

Other Assets - Other assets consist primarily of 159,309 shares of common stock of Sharecare, Inc. which have a carrying value of $10.8 million and are accounted for as a cost method investment, and customer incentives. We have elected the measurement alternative to measure cost method investments that do not have a readily determinable fair value at cost less impairment, adjusted by observable price changes, with any fair value changes recognized in earnings.

f.

Leases – On January 1, 2019, we adopted Accounting Standards Update (“ASU”) No. 2016-02 using the modified retrospective approach. We recognize right-of-use assets and lease liabilities for leases with contractual terms longer than twelve months, and we categorize such leases as either operating or finance. Finance leases are generally those leases that allow us to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. Our leases generally have remaining lease terms of one to 45 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the asset or liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative fair values.

Lease liabilities are recognized at the present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the leases. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term.

Costs associated with right-of-use assets are recognized on a straight-line basis within operating expenses over the term of the lease. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. See Note 9 for further information on leases.

g.

Intangible Assets - Intangible assets subject to amortization include acquired technology and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets related to continuing operations and subject to amortization were fully amortized at December 31, 2020 and 2019.

We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of other identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants.

47


Intangible assets related to continuing operations and not subject to amortization at December 31, 2020 and 2019 consist of a trade name of $29.0 million.

We review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. See Note 6 for further information on intangible assets.

h.

Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire.

We reviewgoodwillfor impairment at thereportingunitlevel (operatingsegmentor onelevelbelowanoperatingsegment) on an annualbasis (duringthe fourth quarter of our fiscal year) ormore frequently wheneverevents orcircumstances indicatethat the carryingvalue may not be recoverable.  Following the sale of our Nutrition business in December 2020, we have a single reporting unit.

As part of the annual impairment test, we may elect to perform a qualitative assessment to determinewhether it is more likely than not that the fair valueof the reportingunit is less thanits carrying value.If we elect not to perform a qualitativeassessment or we determine that it is more likely than not that the fair valueof the reportingunit is less thanits carrying value, we perform a quantitative review as described below.

During a quantitative review of goodwill, we estimate the fair value of the reporting unit based on a discounted cash flow model or a combination of a discounted cash flow model and market-based approaches, and we reconcile the fair value of the reporting unit to our consolidated market capitalization.  If the fair value of the reporting unit exceeds its carrying amount, no impairment is indicated. If the fair value of the reporting unit is less than its carrying amount, impairment of goodwill is measured as the excess of the carrying amount over fair value.  Estimating fair value requires significant judgments, including management's estimate of future cash flows of each reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for our reporting units, the terminal growth rate of revenue, the tax rate, and determination of our weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based approaches.  Changes in these estimates and assumptions could materially affect the estimate of fair value and potential goodwill impairment for each reporting unit. See Note 6 for further information on goodwill.

i.

Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.

j.

Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to fitness network locations (which actual visit data is typically received approximately one month in arrears. Estimated amounts accrued for member visits at December 31, 2020 and 2019 were $10.5 million and $28.8 million, respectively.

k.

Income Taxes - We file a consolidated federal income tax return that includes all of our wholly owned subsidiaries. U.S. GAAP generally requires that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income.

48


l.

Revenue Recognition - On January 1, 2018, we adopted ASU No. 2014-09 using the modified retrospective transition method applied to contracts that were not completed as of January 1, 2018.  See Note 4 for a further discussion of revenue recognition.

m.

Marketing Expense – Marketing expense includes media, advertising production, marketing, and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense from continuing operations was $7.2 million, $7.1 million, and $1.0 million in 2020, 2019, and 2018, respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on a cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or, in the case of production costs, the first time the advertising takes place. At December 31, 2020 and 2019, $0 million and $1.7 million, respectively, of costs have been prepaid for future advertisements and promotions within continuing operations.

n.

Earnings (Loss) Per Share – Beginning in 2019, we use the two-class method to calculate earnings per share (“EPS”) as the unvested restricted stock awards outstanding under our equity incentive plan were participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period.  In applying the two-class method, we allocate undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect is given to the participating securities because they do not share in the losses of the Company. See Note 15 for a reconciliation of basic and diluted earnings (loss) per share.

o.

Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 7 for a further discussion of share-based compensation.     

p.

Derivative Instruments and Hedging Activities – We generally use derivative instruments to add stability to interest expense and to manage our exposure to interest rate movements. We account for derivatives in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. For derivatives that are designated and qualify as effective cash flow hedges, the unrealized gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings as interest expense when the hedged transaction affects earnings. If a derivative instrument ceases to be a highly effective hedge, we will discontinue hedge accounting prospectively for the affected derivative instrument. The application of the authoritative guidance could impact the volatility of earnings. See Note 13 for further information on derivative instruments and hedging activities.

q.

Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

2.Discontinued Operations

Effective as of December 9, 2020, we completed the sale of Nutrisystem to Kainos for an aggregate purchase price, after giving effect to customary indebtedness and cash adjustments, of approximately $558.9 million, which amount is subject to a customary working capital adjustment post-Closing.  We estimate such working capital adjustment will result in additional proceeds to be received in 2021 of $2.8 million, which we have recorded in other current assets at December 31, 2020.Additionally, we incurred $11.2 million of transaction costs directly related to the disposition of Nutrisystem, resulting in estimated net proceeds, after post-Closing adjustment, of $550.5 million.  


In accordance with ASC Topic 205, “Presentation of Financial Statements”, the Nutrition business met the criteria for discontinued operations at December 31, 2020, as it was a component of the Company and the sale represented a strategic shift in the Company’s operations and financial results. Accordingly, the results of operations of the Nutrition business have been classified as discontinued operations for 2019 and 2020, and the assets and liabilities as of December 31, 2019 have been reclassified to discontinued operations.

The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the disposition of the Nutrition business: 

(In thousands)

 

December 31, 2019

 

Accounts receivable, net

 

$

13,402

 

Inventories

 

 

36,150

 

Prepaid expenses

 

 

10,515

 

Other current assets

 

 

95

 

Current assets of discontinued operation

 

 

60,162

 

 

 

 

 

 

Property and equipment, net

 

 

29,333

 

Right-of-use assets

 

 

17,624

 

Intangible assets, net

 

 

660,637

 

Goodwill, net

 

 

319,956

 

Other assets

 

 

746

 

Long-term assets of discontinued operation

 

 

1,028,296

 

Total assets of discontinued operation

 

$

1,088,458

 

 

 

 

 

 

Accounts payable

 

$

18,381

 

Accrued salaries and benefits

 

 

6,184

 

Accrued liabilities

 

 

18,024

 

Deferred revenue

 

 

10,911

 

Income taxes payable

 

 

5,383

 

Current portion of lease liabilities

 

 

5,857

 

Current liabilities of discontinued operation

 

 

64,740

 

 

 

 

 

 

Long-term lease liabilities

 

 

11,816

 

Long-term deferred tax liability

 

 

156,624

 

Other long-term liabilities

 

 

971

 

Long-term liabilities of discontinued operation

 

 

169,411

 

Total liabilities of discontinued operation

 

$

234,151

 


The following table presents financial results of the Nutrition business included in “income (loss) from discontinued operations" for the years ended December 31, 2020 and 2019.  Results of operations for the year ended December 31, 2018 for the Nutrition business are not included as the Company did not acquire the Nutrition business until March 8, 2019, and there is no impact of the sale on the year ended December 31, 2018.

 

 

Year Ended December 31

 

(In thousands)

 

2020 (1)

 

 

2019 (2)

 

Revenues

 

$

617,191

 

 

$

498,091

 

Cost of revenues

 

 

291,097

 

 

 

232,240

 

Marketing expenses

 

 

196,952

 

 

 

140,286

 

Selling, general and administrative expenses

 

 

59,093

 

 

 

56,840

 

Depreciation and amortization

 

 

35,957

 

 

 

43,638

 

Impairment loss

 

 

199,500

 

 

 

377,100

 

Restructuring and related charges

 

 

472

 

 

 

5,143

 

Interest expense (3)

 

 

36,798

 

 

 

34,763

 

Pretax loss from discontinued operations

 

 

(202,678

)

 

 

(391,919

)

Loss on de-designation of cash flow hedges (4)

 

 

(14,336

)

 

 

 

Write-off of deferred loan costs and debt discount (3)

 

 

(8,946

)

 

 

 

Loss on sale of Nutrition business (5)

 

 

(101,391

)

 

 

 

Total pretax loss on discontinued operations

 

$

(327,351

)

 

$

(391,919

)

Income tax benefit

 

 

(46,851

)

 

 

(59,881

)

Loss from discontinued operations, net of income tax benefit

 

$

(280,500

)

 

$

(332,038

)

(1)

Results include the period from January 1, 2020 through December 8, 2020.

(2)

Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019.

(3)

The term loans under our Credit Agreement were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates.

(4)

Represents loss recognized in the fourth quarter of 2020 in connection with the de-designation of cash flow hedging on interest rate swaps (see Note 13).

(5)

Consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 12), which includes post-Closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem.

51


The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows:

 

 

Year Ended December 31

 

(In thousands)

 

2020

 

 

2019

 

Impairment of goodwill and intangible assets

 

$

199,500

 

 

$

377,100

 

Loss on sale of business

 

 

90,163

 

 

 

 

Depreciation and amortization

 

 

35,957

 

 

 

43,638

 

Loss on de-designation of cash flow hedges

 

 

14,336

 

 

 

 

Write-off of deferred loan costs and debt discount (1)

 

 

8,946

 

 

 

 

Capital expenditures on discontinued operations

 

 

6,794

 

 

 

10,168

 

Share-based compensation on discontinued operations

 

 

4,351

 

 

 

13,230

 

Deferred income taxes

 

 

(54,561

)

 

 

(68,488

)

(1)

Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount���.

3.

Recent RelevantAccounting Standards

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”.  ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR.  ASC 848 was effective for the Company as of January 1, 2020.  The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed.  The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level.  The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract.  ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable.  For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis.  In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform.  In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848.  In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument.  We will also apply the aforementioned elections to any future designated cash flow hedging relationship.

In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted.  As of December 31, 2020, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820.  ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively.  The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

52


In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets.  ASU 2016-13 was effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments.  The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

4.  Revenue Recognition

Beginning in 2018, we account for revenue from contracts with customers in accordance with ASC Topic 606.  The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied.

We earn revenue from continuing operations primarily from 3 programs: SilverSneakers senior fitness, Prime Fitness, and WholeHealth Living.  We provide the SilverSneakers senior fitness program to members of Medicare Advantage, Medicare Supplement, and group retiree plans through our contracts with such plans.  We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program.  We sell our WholeHealth Living program primarily to health plans.

Except for Prime Fitness, our customer contracts generally have initial terms of approximately three years.  Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs.  For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while individuals who purchase the Prime Fitness program through these organizations may cancel at any time (on a monthly basis) after an initial period of one to three months.  The significant majority of our customer contracts contain1 performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term.  Unsatisfied performance obligations at the end of a particular month primarily relate to certain monthly memberships for our Prime Fitness program, which are recorded as deferred revenue on the consolidated balance sheet. Deferred revenue was $4.5 million and $4.3 million at December 31, 2020 and 2019, respectively.  During 2020, we recognized $3.6 million of revenue that was included in deferred revenue at December 31, 2019 and increased deferred revenue by $3.8 million, excluding amounts recognized as revenue during 2020.

Our fees are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location.  We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month.  The average monthly total participation levels of our members were significantly lower in fiscal year 2020 than in 2019 due to the COVID-19 pandemic.  As a result, revenues from PMPM fees represented 54% of SilverSneakers revenue for the year ended December 31, 2020, compared to 33% for the year ended December 31, 2019. We bill for member visits approximately one month in arrears once actual member visits are known.  Payments from customers are typically due within 30 days of invoice date.  When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period. At December 31, 2020 and 2019, $0.8 million and $0.5 million, respectively, of such costs were capitalized. During the years ended

53


December 31, 2020 and 2019, amortization expense related tosuch capitalized costs was $0.4 million and $0.1 million, respectively. NaN such capitalized costs were amortized during the year ended December 31, 2018.

Our customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month.  The allocated consideration corresponds directly with the value to our customers of our services completed for the month.  Under the majority of our contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient.

Although we evaluate our financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment, we believe the following information depicts how our revenues and cash flows from continuing operations are affected by economic factors.  

The following table sets forth revenue from continuing operations disaggregated by program.  Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans.

(In thousands)

 

Year Ended December 31

 

 

 

2020

 

 

2019

 

 

2018

 

SilverSneakers

 

$

313,575

 

 

$

492,778

 

 

$

487,559

 

Prime Fitness

 

 

95,015

 

 

 

120,949

 

 

 

101,391

 

WholeHealth Living

 

 

19,776

 

 

 

18,511

 

 

 

16,835

 

Other (1)

 

 

9,348

 

 

 

828

 

 

 

514

 

 

 

$

437,714

 

 

$

633,066

 

 

$

606,299

 

(1)

For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million from our Wisely Well program.

Sales and usage-based taxes are excluded from revenues.

5.

Property and Equipment

Property and equipment at December 31, 2020 and 2019 consisted of the following:

(In thousands)

 

December 31, 2020

 

 

December 31, 2019

 

Leasehold improvements

 

$

7,963

 

 

$

7,659

 

Computer equipment and related software

 

 

45,504

 

 

 

30,256

 

Furniture and office equipment

 

 

4,418

 

 

 

6,173

 

Capital projects in process

 

 

1,262

 

 

 

12,020

 

Total property and equipment at cost

 

$

59,147

 

 

$

56,108

 

Less: accumulated depreciation

 

 

(38,188

)

 

 

(32,532

)

Total property and equipment, net

 

$

20,959

 

 

$

23,576

 

6.

Intangible Assets andGoodwill

There was no change in the carryingamountof goodwill of continuing operations duringtheyears endedDecember 31, 2020 or 2019.  At each of December 31, 2020 and December 31, 2019, the gross amount of goodwill of continuing operations totaled $517.0 million, and we had accumulated impairment losses of $182.4 million.

54


Intangible assets subject to amortization at December 31, 2020 and 2019 consisted of the following:

(In thousands)

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net

 

Acquired technology

 

$

1,483

 

 

$

(1,483

)

 

 

 

Distributor and provider networks

 

 

8,709

 

 

 

(8,709

)

 

 

 

Total

 

$

10,192

 

 

$

(10,192

)

 

$

 

As all intangible assets subject to amortization were fully amortized as of December 31, 2016, 0 amortization was incurred during the years ended December 31, 2020, 2019, and 2018, and 0 amortization expense is expected over the next five years and thereafter.

At December 31, 2020 and 2019, intangible assets not subject to amortization consisted of a tradename of$29.0 million.

7.

Share-Based Compensation

We currently have4 types of share-based awardsoutstandingto our employees and directors:stock options, restricted stock units, performance-based stock units, and market stock units. All restricted stock awards that were outstanding at the beginning of 2020 vested or were forfeited during the year and are 0 longer outstanding as of December 31, 2020. We believethatourshare-basedawards alignthe interests of our employees anddirectors withthoseofourstockholders. 

We grant options under our stock incentive plan at fair value on the date of grant.grant or, in the case of premium-priced options, equal to 110% of the closing price of the Company’s common stock on the grant date. The options generally vest over or at the end of three years based on service conditions and expire seven or ten years from the date of grant.  Restricted stock units generally vest over three or four years. Performance-based stock units have a multi-year performance period and vest approximately two or three years from the grant date. Market stock units granted during 2020 have a three-year performance period and will vest at the end of such period based on total shareholder return.

In March 2019, we granted the following awards related to our assumption of unvested restricted stock awards and performance stock units, respectively, held by Nutrisystem employees (“Replacement Awards”): (i) approximately 258,000time-vesting restricted stock awards at a fair value of $19.42 per share and (ii) approximately 919,000time-vestingrestricted stock units at a fair value of $19.42 per share. During the years ended December 31, 2020 and 2019, $0.9 million and $9.9 million, respectively, of post-combination expense related to the Replacement Awards was recognized in discontinued operations. Effective with the sale of Nutrisystem in December 2020, all outstanding Replacement Awards were accelerated, and other unvested restricted stock units and performance-based stock units held by Nutrisystem employees were accelerated in full or in part.

We recognize share-based compensation expense for options, restricted stock units, performance-based stock units, and restricted stock awards on a straight-line basis over the vesting period. We account for forfeitures as they occur. We recognize share-based compensation expense for market stock units if the requisite service period is rendered, even if the market condition is never satisfied. All awards generally provide for accelerated vesting upon a change in control or normal or early retirement (as defined in the applicable equity award agreement or stock incentive plan). In the fourth quarter of 2020, the compensation committee of the Company’s Board of Directors approved the acceleration of certain unvested stock-based compensation awards in connection with the sale of Nutrisystem. At December 31, 2020, we had reserved approximately 1.4 million shares for future equity grants under our stock incentive plans.

55


Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2020, 2019, and 2018. We did not capitalize any share-based compensation costs during these periods.


 

 

 

Year Ended

 

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

(In millions)

 

2020

 

 

2019

 

 

2018

 

Share-based compensation included in cost of revenue

 

$

2.7

 

 

$

2.2

 

 

$

2.3

 

Share-based compensation included in selling, general and

   administrative expenses

 

 

6.2

 

 

 

3.4

 

 

 

3.8

 

Share-based compensation included in restructuring and related

   charges

 

 

0.8

 

 

 

 

 

 

 

Share-based compensation included in continuing operations

 

$

9.7

 

 

$

5.6

 

 

$

6.1

 

Share-based compensation included in discontinued operations

 

 

4.4

 

 

 

13.2

 

 

 

 

Total share-based compensation

 

$

14.1

 

 

$

18.8

 

 

$

6.1

 

Total income tax benefit recognized in continuing operations

 

 

2.5

 

 

 

1.4

 

 

 

1.6

 

 

STOCK AWARDS

 

 

Name

Stock Award

Grant Date

Number of

Shares or

Units of

Stock That

Have Not

Vested

(#)

 

 

 

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

($)

 

 

 

 

Equity

Incentive

Plan

Awards:

Number of

Unearned

Shares,

Units or

Other

Rights That

Have Not

Vested

(#)

 

 

 

 

Equity

Incentive

Plan

Awards:

Market or

Payout

Value of

Unearned

Shares,

Units or

Other

Rights That

Have Not

Vested

($)

 

 

 

 

 

 

 

 

 

(3)

 

 

 

 

 

 

 

 

 

 

(3)

 

 

Richard Ashworth

6/1/20

 

 

 

 

 

 

 

 

 

 

 

 

150,000

 

(4)

 

 

$

3,966,000

 

 

 

6/1/20

 

100,000

 

(5)

 

$

2,644,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6/1/20

 

250,000

 

(6)

 

$

6,610,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

4/11/19

 

3,070

 

(5)

 

$

81,171

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11/10/20

 

14,207

 

(7)

 

$

375,633

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/22/21

 

13,598

 

(5)

 

$

359,531

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

4/11/19

 

512

 

(5)

 

$

13,537

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11/10/20

 

8,743

 

(7)

 

$

231,165

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/22/21

 

9,937

 

(5)

 

$

262,734

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

4/11/19

 

307

 

(5)

 

$

8,117

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11/10/20

 

5,355

 

(7)

 

$

141,586

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/22/21

 

5,126

 

(5)

 

$

135,531

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

4/11/19

 

717

 

(5)

 

$

18,957

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11/10/20

 

3,825

 

(7)

 

$

101,133

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/22/21

 

3,661

 

(5)

 

$

96,797

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3)

Market value was calculated by multiplying the number of shares underlying the award in the previous column that have not vested as of December 31, 2021 times the closing price of the Common Stock on December 31, 2021 of $26.44 per share.

(4)

Award represents the target number of MSUs granted under the Second Amended and Restated 2014 Plan. Award vests at the end of three years only upon the achievement of certain compounded annual TSR goals over the three-year period from the grant date.

(5)

RSU award vests in three equal annual installments on each of the first three anniversaries of the grant date.

(6)

RSU award vests 50% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 25% on the third anniversary of the grant date.

(7)

RSU award vests one-third on each of the following dates: November 10, 2021; May 10, 2022; and May 10, 2023.


As of December 31, 2020, there was $14.2 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under our stock incentive plan. That total cost is expected to be recognized over a weighted average period of 1.6 years.

Option Exercises and Stock Options

We use a lattice-based binomial option valuation model ("lattice binomial model") to estimate the fair values of stock options. We base expected volatility on historical volatility due to the low volume of traded options on our stock. The expected term of options granted is derived from the output of the lattice binomial model and represents the period of time that options granted are expected to be outstanding.  We used historical data to estimate expected option exercise and post-vesting employment termination behavior within the lattice binomial model.Vested in 2021

The following table sets forth provides information regarding the weighted average grant-date fair valuesvesting of optionsRSUs and PSUs during 2021, and the weighted average assumptions we used to develop the fair value estimates for the years ended December 31, 2020 and 2018.  There were 0 stock options granted during fiscal 2019.

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Weighted average grant-date fair value

   of options per share

 

$

8.20

 

 

$

 

 

$

20.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

Expected volatility

 

 

63.2

%

 

 

 

 

 

56.2

%

Expected dividends

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

 

6.2

 

 

 

 

 

6.7

 

Risk-free rate

 

 

0.7

%

 

 

 

 

 

2.8

%

56


A summary of options as of December 31, 2020 and the activity during the year then ended is presented below:

Options

 

Shares

(In thousands)

 

 

Weighted

Average

Exercise

Price

Per Share

 

 

Weighted

Average

Remaining

Contractual

Term

 

 

Aggregate

Intrinsic Value

(In thousands)

 

Outstanding at January 1, 2020

 

 

319

 

 

$

17.85

 

 

 

 

 

 

 

 

 

Granted

 

 

220

 

 

 

16.78

 

 

 

 

 

 

 

 

 

Exercised

 

 

(81

)

 

 

12.67

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(5

)

 

 

39.55

 

 

 

 

 

 

 

 

 

Expired

 

 

(31

)

 

 

20.76

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

422

 

 

$

17.83

 

 

 

5.2

 

 

$

1,544

 

Exercisable at December 31, 2020

 

 

187

 

 

$

17.54

 

 

 

3.0

 

 

$

927

 

The total intrinsic value, which represents the difference between the market price of the underlying common stock and the option's exercise price, of options exercised during the years ended December 31, 2020, 2019, and 2018 was $0.6 million, $0.6 million, and $3.9 million, respectively.

Cash received from option exercises under all share-based payment arrangements during 2020 was $1.0 million. The actual tax benefit realized during 2020 for the tax deductions from option exercise totaled $0.2 million.   We issue new shares of common stock upon exercise of stock options or vesting of restricted stock units, restricted stock awards, performance-based stock units, and market stock units.

Nonvested Shares

The fair value of restricted stock units and performance-based stock units is determined based on the closing bid price of the Company's common stock on the grant date.  The weighted average grant-date fair value of restricted stock units grantedby our NEOs during the years ended December 31, 2020, 2019, and 2018 was $11.17, $19.68, and $38.12, respectively. The weighted average grant-date fair value of performance-based stock units granted during the years ended December 31, 2020 and 2019 was $21.49 and $20.20, respectively. NaN performance-based stock units were granted during 2018. The Monte Carlo simulation valuation model is used to determine the fair value of market stock units. The weighted average grant-date fair value of all market stock units granted during 2020 was $18.84. NaN market stock units were granted during 2019 or 2018.  

The four tables below set forth a summary of our nonvested shares as of December 31, 2020 as well as activity during the year then ended, including the acceleration of certain shares in connection with the divestiture of Nutrisystem. The total grant-date fair value of shares vested during the years ended December 31, 2020, 2019, and 2018 was $13.6 million, $23.5 million, and $7.6 million, respectively.

The following table shows a summary of our restricted stock awards as of December 31, 2020, as well as activity during the year then ended:2021.

 

 

 

Restricted Stock Awards

 

 

 

Shares

(In thousands)

 

 

Weighted-

Average

Grant Date

Fair Value

 

Nonvested at January 1, 2020

 

 

127

 

 

$

19.42

 

Vested

 

 

(120

)

 

 

19.42

 

Forfeited

 

 

(7

)

 

 

19.42

 

Nonvested at December 31, 2020

 

 

 

 

$

 

 

 

 

Option Awards

 

 

 

 

Stock Awards

 

Name

 

Number of

Shares

Acquired

on Exercise

(#)

 

Value

Realized

on Exercise

($)

 

Number of

Shares

Acquired

on Vesting

(#)

 

Value

Realized

on Vesting

($) (1)

 

Richard Ashworth

 

 

 

 

 

 

 

$

 

 

 

 

 

306,887

 

 

 

 

$

8,035,054

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adam Holland

 

 

 

 

 

 

 

$

 

 

 

 

 

70,480

 

 

 

 

$

1,761,528

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thomas Lewis

 

 

 

 

 

 

 

$

 

 

 

 

 

14,697

 

 

 

 

$

386,568

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Raymond Bilbao

 

 

 

 

 

 

 

$

 

 

 

 

 

21,878

 

 

 

 

$

538,897

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ryan Wagers

 

 

 

 

 

 

 

$

 

 

 

 

 

27,588

 

 

 

 

$

681,937

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

57


The following table shows a summary of our restricted stock units as of December 31, 2020 as well as activity during the year then ended:

 

 

Restricted Stock Units

 

 

 

Shares

(In thousands)

 

 

Weighted-

Average

Grant Date

Fair Value

 

Nonvested at January 1, 2020

 

 

393

 

 

$

21.16

 

Granted

 

 

1,774

 

 

 

11.17

 

Vested

 

 

(692

)

 

 

13.81

 

Forfeited

 

 

(234

)

 

 

17.96

 

Nonvested at December 31, 2020

 

 

1,241

 

 

$

11.58

 

The following table shows a summary of our performance-based stock units as of December 31, 2020, as well as activity during the year then ended:

 

 

Performance Stock Units

 

 

 

Shares

(In thousands)

 

 

Weighted-

Average

Grant Date

Fair Value

 

Nonvested at January 1, 2020

 

 

407

 

 

$

20.29

 

Granted

 

 

4

 

 

 

21.49

 

Shares adjustment for performance (1)

 

 

(74

)

 

 

20.26

 

Vested

 

 

(86

)

 

 

20.42

 

Forfeited

 

 

(165

)

 

 

20.26

 

Nonvested at December 31, 2020

 

 

86

 

 

$

20.30

 

(1)Represents the number of shares at target for certain performance-based stock units that are no longer eligible to be earned as a result of actual performance being below the applicable performance targets. These awards are included in the nonvested balance at January 1, 2020 and the number of shares granted above.

The following table shows a summary of our market stock units as of December 31, 2020 as well as activity during the year then ended:

 

 

Market Stock Units

 

 

 

Shares

(In thousands)

 

 

Weighted-

Average

Grant Date

Fair Value

 

Nonvested at January 1, 2020

 

 

 

 

$

 

Granted

 

 

150

 

 

 

18.84

 

Nonvested at December 31, 2020

 

 

150

 

 

$

18.84

 

58


8.

Income Taxes

Income tax expense is comprised of the following:

 

 

Year Ended December 31,

 

(In thousands)

 

2020

 

 

2019

 

 

2018

 

Current taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

526

 

 

$

3,051

 

 

$

29

 

State

 

 

881

 

 

 

830

 

 

 

1,857

 

Deferred taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

14,114

 

 

 

11,853

 

 

 

20,136

 

State

 

 

2,009

 

 

 

4,559

 

 

 

5,024

 

Total

 

$

17,530

 

 

$

20,293

 

 

$

27,046

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  The following table sets forth the significant components of our net deferred tax asset and liability as of December 31, 2020 and 2019:

(In thousands)

 

December 31,

2020

 

 

December 31,

2019

 

Deferred tax asset:

 

 

 

 

 

 

 

 

Accruals and reserves

 

$

1,137

 

 

$

498

 

Deferred compensation

 

 

604

 

 

 

191

 

Share-based payments

 

 

2,909

 

 

 

2,802

 

Lease liability

 

 

4,993

 

 

 

5,003

 

Section 163(j) interest limitation

 

 

370

 

 

 

5,647

 

Interest rate swap

 

 

5,964

 

 

 

4,147

 

Unrealized losses

 

 

3,720

 

 

 

0

 

Net operating loss carryforwards

 

 

10,608

 

 

 

7,200

 

Capital loss carryforwards

 

 

149,608

 

 

 

7,801

 

 

 

 

179,913

 

 

 

33,289

 

Valuation allowance

 

 

(152,295

)

 

 

(13,147

)

 

 

$

27,618

 

 

$

20,142

 

Deferred tax liability:

 

 

 

 

 

 

 

 

Property and equipment

 

$

(4,516

)

 

$

(3,181

)

Intangible assets

 

 

(14,868

)

 

 

(14,651

)

Right-of-use assets

 

 

(4,633

)

 

 

(6,532

)

 

 

 

(24,017

)

 

 

(24,364

)

Net long-term deferred tax asset (liability)

 

$

3,601

 

 

$

(4,222

)

59


In 2019, upon closing of the acquisition of Nutrisystem, we evaluated the realizability of beginning-of-the-year deferred tax assets and increased the valuation allowance on deferred tax assets related to state net operating loss carryforwards by $1.8 million. We also recorded a $0.9 million reduction in deferred tax assets related to state income tax credits.  These two adjustments increased our income tax expense for 2019 by approximately $2.7 million. In 2020, upon closing of the Nutrisystem divestiture, we evaluated the realizability of beginning-of-the-year deferred tax assets and decreased the valuation allowance on deferred tax assets related to state net operating loss carryforwards by $2.7 million.

At December 31, 2020, we provided valuation allowances for $2.4 million of deferred tax assets associated with our international net operating loss carryforwards, $0.3 million of deferred tax assets associated with our state net operating loss carryforwards, and $149.6 million for deferred tax assets related to capital loss carryforwards generated in the sale of the total population health services business in 2016 and the sale of Nutrisystem in 2020.  Capital loss carryforwards can only be used to offset future capital gains and cannot be used to offset any future operating losses the Company may incur. We recorded a total increase in our valuation allowance of $139.1 million for the year ended December 31, 2020. Our valuation allowance at December 31, 2019 totaled $13.1 million.

At December 31, 2020, we had international net operating loss carryforwards totaling approximately $8.2 million, $8.0 million of which have an indefinite carryforward period, approximately $159.0 million of state net operating loss carryforwards expiring between 2021 and 2036, and approximately $598.4 million of capital loss carryforwards expiring between 2021 and 2025.

We recorded a tax effect of $6.0 million in 2020 related to our interest rate swap agreements to stockholder’s equity as a component of accumulated other comprehensive income (loss).

The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows:

 

 

Year Ended December 31,

 

(In thousands)

 

2020

 

 

2019

 

 

2018

 

Statutory federal income tax

 

$

15,624

 

 

$

13,757

 

 

$

26,239

 

State income taxes, less federal income tax benefit

 

 

3,607

 

 

 

3,048

 

 

 

6,261

 

Permanent items

 

 

1,131

 

 

 

306

 

 

 

1,496

 

Change in valuation allowance

 

 

(2,659

)

 

 

2,509

 

 

 

(1,005

)

Share-based compensation

 

 

426

 

 

 

210

 

 

 

(6,378

)

State income tax credits

 

 

 

 

 

954

 

 

 

677

 

Change in uncertain tax position liability

 

 

 

 

 

 

 

 

(644

)

Prior year tax adjustments

 

 

(592

)

 

 

(464

)

 

 

(590

)

Net impact of foreign operations

 

 

3

 

 

 

(9

)

 

 

990

 

Other

 

 

(10

)

 

 

(18

)

 

 

 

Income tax expense

 

$

17,530

 

 

$

20,293

 

 

$

27,046

 

Uncertain Tax Positions

During 2020, we recorded a $1.1 million decrease to unrecognized tax benefits primarily related to the unrecognized tax benefits divested in the sale of Nutrisystem. As of December 31, 2020, we had 0 unrecognized tax benefits that would affect our effective tax rate. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.

60


The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows:

(In thousands)

 

 

 

 

Unrecognized tax benefits at December 31, 2018

 

$

0

 

Increases related to acquisition of Nutrisystem

 

 

1,006

 

Increases related to current year tax positions

 

 

8

 

Increases related to prior year tax positions

 

 

66

 

Decreases due to lapse of statute of limitations

 

 

(19

)

Unrecognized tax benefits at December 31, 2019

 

$

1,061

 

Increases related to prior year tax positions

 

 

84

 

Decreases due to lapse of statute of limitations

 

 

(20

)

Decreases related to Nutrisystem divestiture

 

 

(1,125

)

Unrecognized tax benefits at December 31, 2020

 

$

 

We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions.  Tax years remaining subject to examination in the U.S. Federal jurisdiction include 2017 to present.

9.

Leases

On January 1, 2019, we adopted ASC 842 using the modified retrospective approach. Therefore, the comparative information for periods ended prior to January 1, 2019 was not restated. With the exception of two finance leases related to a network server and office equipment, all of our leases are classified as operating leases.  We maintain lease agreements principally for our office spaces and certain equipment. We maintain 2 sublease agreements with respect to one of our office locations, each of which continues through the initial term of our master lease agreement.  Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability.  In the aggregate, our leases generally have remaining lease terms of one to 45 months, some of which include options to extend the lease for additional periods.  Such extension options were not considered in the value of the right-of-use asset or lease liability because it is not probable that we will exercise the options to extend.  If applicable, allocations among lease and non-lease components would be achieved using relative standalone selling prices.

Upon adoption of ASC 842, we determined our estimated discount rate for existing leases as of January 1, 2019 based on the incremental borrowing rate that most closely aligned with the remaining lease term and payment schedule, as provided by our financial institution. The discount rates for leases entered into after January 1, 2019 were determined based on similarly secured borrowings available to us as of lease inception.  

The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet:

 

December 31, 2020

 

 

December 31, 2019

 

(In thousands)

 

 

 

 

 

 

 

Right-of-use assets:

 

 

 

 

 

 

 

Operating

$

17,145

 

 

$

23,895

 

Finance

 

994

 

 

 

1,680

 

Total leased assets

$

18,139

 

 

$

25,575

 

 

 

 

 

 

 

 

 

Lease liabilities:

 

 

 

 

 

 

 

Current

 

 

 

 

 

 

 

  Operating

$

7,408

 

 

$

7,274

 

  Finance

 

644

 

 

 

624

 

Non-current

 

 

 

 

 

 

 

  Operating

$

11,097

 

 

$

18,505

 

  Finance

 

397

 

 

 

1,080

 

Total lease liabilities

$

19,546

 

 

$

27,483

 

61


The following table shows the components of lease expense:

 

Year Ended December 31,

 

 

Year Ended December 31,

 

(In thousands)

2020

 

 

2019

 

Finance lease cost:

 

 

 

 

 

 

 

Amortization of leased assets

$

686

 

 

$

298

 

Interest of lease liabilities

 

86

 

 

 

51

 

Operating lease cost

 

7,872

 

 

 

8,817

 

Total lease cost before subleases

$

8,644

 

 

$

9,166

 

Sublease income

 

(5,452

)

 

 

(5,479

)

Total lease cost, net

$

3,192

 

 

$

3,687

 

The following provides information related to the lease term and discount rate as of December 31, 2020:

 

Weighted Average Remaining Lease Term (years)

Operating leases

(1)

2.6

Finance leases

1.6

Weighted Average Discount Rate

Operating leases

4.8

%

Finance leases

5.9

%The value realized upon vesting is calculated based on the closing price of our Common Stock on the applicable vesting date. Such value may differ from the actual value realized upon distribution.

As of December 31, 2020, maturities of lease liabilitiesEmployment Agreements for each ofNEOs

Messrs. Ashworth and Holland are currently employed pursuant to written employment agreements with the next five years and thereafter were as follows:

 

 

Operating Leases

 

 

Financing

 

(In thousands)

 

Lease Payments

 

Sublease Receipts

 

Net

 

 

Leases

 

2021

 

 

8,115

 

 

(5,699

)

 

2,416

 

 

 

686

 

2022

 

 

7,957

 

 

(5,732

)

 

2,225

 

 

 

403

 

2023

 

 

2,518

 

 

(957

)

 

1,561

 

 

 

 

2024

 

 

1,083

 

 

 

 

1,083

 

 

 

 

Total lease payments

 

 

19,673

 

$

(12,388

)

$

7,285

 

 

 

1,089

 

Less: interest

 

 

(1,168

)

 

 

 

 

 

 

 

 

(48

)

Present value of lease liabilities

 

$

18,505

 

 

 

 

 

 

 

 

$

1,041

 

62


Supplemental cash flow information related to leases was as follows:

 

 

Year Ended December 31,

 

 

Year Ended December 31,

 

(In thousands)

 

2020

 

 

2019

 

Cash paid for amounts included in the measurement of lease liabilities

 

 

 

 

 

 

 

 

Operating cash flow attributable to operating leases

 

$

(3,492

)

 

$

(4,626

)

Operating cash flow attributable to finance leases

 

 

(86

)

 

 

(51

)

Financing cash flow attributable to finance leases

 

 

(622

)

 

 

(274

)

 

 

 

 

 

 

 

 

 

Supplemental noncash information:

 

 

 

 

 

 

 

 

Right-of-use assets obtained in exchange for operating lease liabilities (1)

 

 

 

 

 

31,538

 

Right-of-use assets obtained in exchange for finance lease liabilities (2)

 

 

 

 

 

1,978

 

Company effective on the following dates:

 

(1)

No new operating leases were entered into during the year ended December 31, 2019.  Amount shown is due to the adoption of ASC 842 and one lease modification that resulted in a noncash remeasurement of the related right-of-use asset and operating lease liability. Amount shown reflects balance as of January 1, 2019, adjusted for lease modification.Mr. Ashworth – May 20, 2020

 

(2)

Amount shown is due to the adoption of ASC 842 and one new finance lease for $1.8 million entered into during the year ended December 31, 2019. In addition to such lease, amount shown reflects balance as of January 1, 2019.

10.

DebtMr. Holland – May 22, 2017

Collectively, the employment agreements with Messrs. Ashworth and Holland are referred to as the “NEO Employment Agreements”.  The Company's debt, netemployments of unamortized deferred loan costseach of Messrs. Lewis, Bilbao, and original issue discount, consistedWagers were subject to offer of employment letters executed on the following at December 31, 2020 and 2019:

(In thousands)

 

December 31,

2020

 

 

December 31,

2019

 

Term Loan A

 

$

124,035

 

 

$

288,750

 

Term Loan B

 

 

372,240

 

 

 

786,250

 

Revolving credit facility

 

 

 

 

 

19,850

 

 

 

 

496,275

 

 

 

1,094,850

 

Less: deferred loan costs and original issue discount

 

 

(29,569

)

 

 

(46,723

)

Total debt

 

 

466,706

 

 

 

1,048,127

 

Less: current portion (1)

 

 

(7,456

)

 

 

 

Total long-term debt

 

$

459,250

 

 

$

1,048,127

 

dates (the “NEO Offer Letters”), which do not contain a stated term, constituting at-will employment:  

 

(1)

Represents additional term loan principal due upon final settlement of the sale of Nutrisystem based on the estimated post-Closing adjustments.  

Credit Facility

In connection with the consummation of our merger with Nutrisystem (the “Merger”), on March 8, 2019, we entered into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, (“Credit Suisse”), as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, (“SunTrust”), as revolving facility agent and swing line lender. The Credit Agreement provides us with (i) a $350.0 million term loan A facility (“Term Loan A”), (ii) an $830.0 million term loan B facility (“Term Loan B” and, together with Term Loan A, the “Term Loans”), (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit (the “Revolving Credit Facility”; Term Loan A, Term Loan B and the Revolving Credit Facility are sometimes herein referred to collectively as the “Credit Facilities”), and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four

63


fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements.  As of December 31, 2020, outstanding debt under the Credit Agreement was $466.7 million, and availability under the Revolving Credit Facility totaled $124.5  million as calculated under the most restrictive covenant.

We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full.

We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full.  

We are permitted to make voluntary prepayments of borrowings under the Term Loans at any time without penalty.  From March 8, 2019 through December 31, 2020, we made voluntary prepayments of $164.7 million on the Term Loans, which prepaid all scheduled quarterly installments due through December 31, 2021.  In addition, in December 2020 we used the significant majority of net proceeds from the divestiture of Nutrisystem to pay $519.0 million of principal on the Term Loans, which was applied to the amount due and payable at maturity.  

We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024.  In addition, the Credit Agreement contains provisions that, beginning with fiscal 2019, may require annual excess cash flow (as defined in the Credit Agreement and generally designed to equal cash generated by our business in excess of cash used in the business) to be applied towards the Term Loans.  We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages based on our Net Leverage Ratio (as defined in the Credit Agreement) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1.  Any such potential mandatory prepayments are reduced by voluntary prepayments.  We were not required to make an Excess Cash Flow Payment for fiscal 2020.

The Credit Agreement contains a financial covenant that requires us to maintain maximum ratios or levels of consolidated total net debt to consolidated adjusted EBITDA, calculated as provided in the Credit Agreement (the “Net Leverage Ratio”), of 5.75:1.00 for all test dates occurring on or after December 31, 2019 but prior to December 31, 2020, 5.25:1.00 for all test dates occurring on or after December 31, 2020 but prior to December 31, 2021, and 4.75:1.00 for all test dates occurring on or after December 31, 2021.  As of December 31, 2020, we were in compliance with all of the covenant requirements of the Credit Agreement, and our Net Leverage Ratio was equal to 2.36.

Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, the outstanding principal on the term loans under our Credit Agreement following the repayment of $519 million in December 2020, our fitness partner locations reopening and/or remaining open, and the average monthly total participation levels of our members at such locations, we currently believe we will be in compliance with the Net Leverage Ratio covenant over the next 12 months.  We will continue to monitor our projected ability to comply with all covenants under the Credit Agreement, including the Net Leverage Ratio.

Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than 0, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25% and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total Net Leverage Ratio. The Base Rate margin for Term Loan A loans is 3.25%, the Base Rate margin for Term Loan B loans is 4.25% and the Base Rate margin for revolving loans varies between 2.75% and 3.25%, depending on our total Net Leverage Ratio. In May 2019, we entered into 8 amortizing interest rate swap agreements, each of which matures in May 2024.  Under these agreements, we

64


receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread, as described in the preceding sentences.  As further explained in Note 13, during the fourth quarter of 2020 we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we de-designated these derivatives.  As of December 31, 2020, the eight interest rate swap agreements had current notional amounts totaling $700.0 million, of which $388.9 million related to effective hedges. For the year ended December 31, 2020, the effective interest rates related to continuing operations for Term Loan A and Term Loan B (exclusive of payments related to de-designated interest rate swaps, which we do not classify as interest expense) were 6.64% and 7.08%, respectively. For the year ended December 31, 2019, the effective interest rates related to continuing operations for Term Loan A and Term Loan B were 5.47% and 6.27%, respectively.

The Credit Agreement also provides for annual commitment fees ranging between 0.250% and 0.500% of the unused commitments under the Revolving Credit Facility, depending on our total Net Leverage Ratio, and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin for the Revolving Credit Facility, depending on our total Net Leverage Ratio. During the each of the years ended December 31, 2020 and 2019, we incurred total such commitment fees of $0.5 million.

Extensions of credit under the Credit Agreement are secured by guarantees from substantially all of the Company’s active material domestic subsidiaries and by security interests in substantially all of the Company’s and such subsidiaries’ assets.  

The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on us and certain of our subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year.

The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter:

(In thousands)

 

 

 

 

 

Year ending December 31,

 

 

 

 

 

2021

 

$

7,456

 

(1)

2022

 

 

59,900

 

 

2023

 

 

59,900

 

 

2024

 

 

77,071

 

 

2025

 

 

24,900

 

 

2026 and thereafter

 

 

267,048

 

 

Total

 

$

496,275

 

 

(1)

The total term loan principal due during 2021 reflects $7.5 million of additional debt repayment required upon estimated final settlement ofMr. Lewis – October 4, 2018 (and subsequent amendments dated April 1, 2019 and October 30, 2020) (collectively, the Nutrisystem sale.“Lewis Offer Letter”)

11.

Commitments and Contingencies

Shareholder Lawsuits: Weiner Lawsuit and Consolidated Derivative Lawsuit

On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of common stock, par value $0.001 per share (“Common Stock”) dropped on that same day. In connection with the United Press Release, 4 lawsuits were filed against the Company. Of the four lawsuits, 1 has been dismissed, 2 were dismissed and after plaintiffs appealed, now have a final settlement pending court approval, and 1 remains actively contested.   We

65


are currently not able to predict the probable outcome of the remaining matter or to reasonably estimate a range of potential loss, if any.  We intend to vigorously defend ourselves against the remaining complaint.

On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between February 24, 2017 and November 3, 2017 (“Weiner Lawsuit”).  The Weiner Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming as defendants the Company, the Company's chief executive officer, chief financial officer and a former executive who served as both chief accounting officer and interim chief financial officer.  The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release.  The complaint seeks monetary damages on behalf of the purported class.  On April 3, 2018, the Court entered an order appointing the Oklahoma Firefighters Pension and Retirement System as lead plaintiff, designated counsel for the lead plaintiff, and established certain deadlines for the case.  On June 4, 2018, plaintiff filed a first amended complaint.   The Court denied the Company’s Motion to Dismiss on March 18, 2019 and the Company’s Motion to Reconsider on May 22, 2019. On January 29, 2020, the Court granted lead plaintiff’s motion to certify the class. On July 23, 2020, the United States Court of Appeals for the Sixth Circuit denied the Company’s application for permission to appeal the class certification ruling.  The Company filed a motion to decertify the class and a motion for summary judgment on December 11, 2020.  The case is currently set for trial on May 18, 2021.

On January 26, 2018 and August 24, 2018, individuals claiming to be stockholders of the Company filed shareholder derivative actions, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and certain current and former executives and directors as defendants.  On October 15, 2018, the two complaints were consolidated (the “Consolidated Derivative Lawsuit”).  On May 15, 2019, a consolidated amended complaint was filed. The consolidated amended complaint asserts claims for violation of Section 10(b), 14(a), and 29(b) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. Plaintiffs seek to recover damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief. On June 14, 2019, the defendants filed a Motion to Dismiss all claims and the plaintiffs filed their opposition to the Motion to Dismiss on July 17, 2019. On October 22, 2019, the Consolidated Derivative Lawsuit was dismissed with prejudice. On November 20, 2019, plaintiffs filed a notice of appeal with the United States Circuit Court for the Sixth Circuit.  After the parties entered into a Memorandum of Understanding (“MOU”) to resolve the Consolidated Derivative Lawsuit,  the case was remanded to the District Court. The parties filed a joint stipulation of settlement based on the terms set forth in the MOU and plaintiffs filed a motion to approve settlement on October 9 and October 12, 2020, respectively. The Court granted final approval to the settlement on February 19, 2021.

Shareholder Lawsuits: Strougo, Cobb, and Delaware Lawsuits

On February 25, 2020, Robert Strougo, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between March 8, 2019 and February 19, 2020 (the "Strougo Lawsuit").  The Strougo Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming the Company, the Company's chief financial officer and former chief executive officer as defendants.  The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the performance of the Nutrisystem business that the Company acquired on March 8, 2019.  The complaint seeks monetary damages on behalf of the purported class.  On August 18, 2020, the Court appointed Sheet Metal Workers Local No. 33, Cleveland District, Pension Fund as lead plaintiff. Plaintiff filed its amended complaint on November 13, 2020. The Company filed a motion to dismiss the amended complaint on December 4, 2020.

On April 9, 2020, John Cobb, claiming to be a stockholder of the Company, filed a derivative complaint in the United States District Court for the Middle District of Tennessee naming the Company as a nominal defendant and certain directors and the Company’s former chief executive officer and current chief financial officer as defendants (the “Cobb Lawsuit”). The complaint asserted claims for breach of Section 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, failure of internal controls, and unjust enrichment, largely tracking the factual allegations in the Strougo Lawsuit. The plaintiff seeks monetary damages on behalf of the Company, restitution, and certain corporate governance and internal procedural reforms. On June 9, 2020, the United States Magistrate Judge approved the parties’ stipulation to stay the case pending the resolution of defendants’ motion to dismiss in the Strougo Lawsuit.

66


In July 2020, three putative derivative complaints were filed in the United States District Court for the District of Delaware by the following individuals claiming to be stockholders of the Company: Patrick Yerby, Thomas R. Conte, Melvyn Klein, and Mark Ridendour (the “Delaware Derivative Lawsuits”).  The complaints largely track the allegations, named defendants, asserted claims, and requested relief of the Cobb Lawsuit. The three Delaware Derivative Lawsuits have been consolidated and stayed on terms similar to those entered in the Cobb Lawsuit.

Given the uncertainty of litigation and the preliminary stage of  the Strougo Lawsuit, Cobb Lawsuit, and Delaware Derivative Lawsuits, we are not currently able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any.  We intend to vigorously defend ourselves against these lawsuits.

Trademark Lawsuit: Pacific Packaging Lawsuit

On May 31, 2019, Pacific Packaging Concepts, Inc. (“Pacific Packaging”) filed a complaint in the U.S. District Court for the Central District of California, Western Division, naming as defendants two subsidiaries of the Company; Nutrisystem, Inc. and Nutri/System IPHC, Inc. In its complaint, Pacific Packaging alleged that the defendants’ use of Pacific Packaging’s federally registered trademark, Fresh Start, in advertisements for its weight management program and shakes constitutes federal trademark infringement, counterfeit trademark infringement, false designation of origin, federal trademark dilution, unfair competition, false advertising, common law unfair competition, and common law trademark infringement. The complaint seeks injunctive relief and monetary damages in an unspecified amount.  On August 29, 2019, the defendants filed their Answer to Complaint. The case is currently set for trial on April 20, 2021.  In connection with the sale of Nutrisystem, the Company agreed to indemnify Kainos for losses arising out of this matter and retained the right to control the defense thereof.  Given the uncertainty of litigation and the preliminary stage of the case, we are currently not able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against this complaint.

Other

Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise in the ordinary course of our business.  Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies.  As these matters are subject to inherent uncertainties, our view of these matters may change in the future.  We expense legal costs as incurred.

12.

Fair ValueMeasurements

We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

Fair Value Hierarchy

The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1:

Quoted prices in active markets for identical assets or liabilities;

 

Level 2:

Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; andMr. Bilbao – October 30, 2020 (the “Bilbao Offer Letter)

 

Level 3:

Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.Mr. Wagers – September 14, 2018 (the “Wagers Offer Letter”)

67Mr. Ashworth’s employment agreement expires on June 1, 2023 and renews for successive one-year periods thereafter, unless either party gives written notice to the other party of its intention not to renew the agreement at least 90 days prior to the end of the then current term.  A non-renewal of the CEO’s employment agreement by the Company will be treated as a termination without “cause”, and a non-renewal of the employment agreement by Mr. Ashworth will be treated as a termination without “good reason.”


Mr. Holland’s employment agreement provides for an initial term of one year (which expired on June 14, 2018) and thereafter renews for continuous periods of one year each.  

Each NEO Employment Agreement and NEO Offer Letter provides for an annual base salary as well as participation in all applicable benefit plans maintained by the Company. Base salary payable under each


AssetsNEO Employment Agreement is subject to annual review and Liabilities Measured at Fair Value onmay be increased by the Board, or a Non-Recurring Basiscommittee thereof, as it may deem advisable.  The NEO Employment Agreements and NEO Offer Letters generally provide for the participation of each NEO in short-term and long-term incentive awards, if any, as determined by the Board, or a committee thereof comprised solely of independent directors.  

We measureThe NEO Employment Agreements and NEO Offer Letters provide for certain assets at fair value onpotential severance and change in control benefits.  In addition, in September 2021, the Compensation Committee adopted a nonrecurring basisseparation benefits program (the “Separation Benefits Program”) that provides for severance and change in control benefits and is applicable to the Company’s NEOs. The NEOs are not entitled to participate in the fourth quarterSeparation Benefits Program to the extent they are entitled to any severance payments or benefits from another program or agreement with the Company (for example, an employment agreement or offer of employment letter) that provides greater severance payments or more favorable terms than the Separation Benefits Program. As such, Mr. Bilbao is the only NEO entitled to participate in the Separation Benefits Program.  The potential severance and change in control benefits to which the NEOs are entitled under the NEO Employment Agreements, the NEO Offer Letters, or the Separation Benefits Program, as applicable, are discussed in detail under “Potential Payments Upon Termination or Change in Control of the Company.”

Potential Payments Upon Termination or Change in Control ofthe Company

Potential payments for each year, includingof the following:NEOs upon termination or a change in control of the Company are discussed below.  

Each of the NEO Employment Agreements contain restrictive provisions relating to the use of confidential information, competing against the Company and soliciting any customers or employees of the Company during the term of employment and for a period up to 24 months thereafter (in the case of Mr. Ashworth) or 12 months thereafter (in the case of Mr. Holland).  The NEO Employment Agreements provide that employment may be terminated at any time by the mutual written agreement of the Company and the NEO.  The employment of the NEOs also could have been terminated as of December 31, 2021 under the following circumstances:

 

1)

Involuntary without Cause – the Company may terminate each NEO’s employment without cause at any time by delivery of a written notice of termination to the executive.

2)

Voluntary for Good Reason – the NEO may resign by delivery of a written notice of resignation to the Company within 60 days (or, in the case of Mr. Bilbao, 30 days) of the occurrence of any of the following events:

a.

Reduction in base salary - (i) in the case of Mr. Ashworth, a reduction in his base salary unless such reduction is part of an across the board reduction affecting all senior officers of the Company; (ii) in the case of Messrs. Holland, Lewis and Wagers, a material reduction in the NEO’s base salary unless such reduction is part of an across the board reduction affecting all Company executives with a comparable role or title; or (iii), in the case of Mr. Bilbao, a material reduction in his base salary unless all Section 16 officers of the Company are required to take a salary reduction that is equal to or less than 25% of their base salary;

b.

Relocation -  (i) in the case of Messrs. Ashworth and Holland, a requirement by the Company to relocate the NEO to a location that is more than 25 miles from the location of the NEO’s current office (except for relocation to the Nashville, Tennessee metropolitan area in the case of Mr. Ashworth); (ii) in the case of Messrs. Lewis and Wagers, a requirement by the Company to relocate his residence, unless such relocation is mutually agreed upon by him


and the Company; or (iii) in the case of Mr. Bilbao, a requirement by the Company to move more than 50 miles from his home address as of September 22, 2021;

c.

Change in control - in connection with a change in control (as defined below), the failure by the successor or the Company’s Board to honor the NEO’s employment agreement or offer such NEO an employment agreement containing substantially similar or otherwise satisfactory terms, in the case of Messrs. Ashworth and Holland; or

d.

Change in status or responsibilities - in the case of Mr. Ashworth, a material reduction in his title, or a material and adverse change in his status and responsibilities, or the assignment to him of duties or responsibilities which are materially inconsistent with his title and responsibilities, including following a change in control, if Mr. Ashworth no longer serves as the CEO of the acquiring or successor company reporting to the board of directors (or other governing body) of such entity.

Upon receipt of an NEO’s written notice that one or more of the above-identified events has occurred, the Company shall have a 60-day period (30 days in the case of Mr. Bilbao) to cure the good reason event. If such event is cured, the NEO shall no longer have the right to resign for Good Reason.

3)

Involuntary for Cause

a.

the Company may, at any time, terminate the employment of Mr. Ashworth by delivery of a written notice of termination to Mr. Ashworth specifying the event(s) relied upon for such termination upon the occurrence of any of the following:

i.

continued failure by Mr. Ashworth to substantially perform his duties after written notice and failure to cure within 60 days;

ii.

conviction of a felony or engaging in misconduct that is materially injurious to the Company, monetarily or to its reputation or otherwise, or that would damage Mr. Ashworth’s ability to effectively perform his duties; or

iii.

willful violation of Company policies and procedures after written notice and failure to cure within 30 days.

b.

the Company may, at any time, terminate the employment of Messrs. Holland, Lewis, Bilbao or Wagers by delivery of a written notice of termination to the executive specifying the event(s) relied upon for such termination upon the occurrence of any of the following:

i.

continued failure by the NEO to substantially perform his duties after written notice and failure to cure within 60 days;

ii.

conviction of a felony (or arrest relating to a felony, in the case of Messrs. Lewis and Wagers) or engaging in misconduct that is materially injurious to the Company, monetarily or to its reputation or otherwise, or that would damage the NEO’s ability to effectively perform his duties;

iii.

theft or dishonesty by the NEO;

iv.

intoxication while on duty; or

v.

willful violation of Company policies and procedures after written notice and failure to cure within 30 days.

4)

Voluntary without Good Reason – each NEO may terminate his employment at any time by delivery of a written notice of resignation to the Company no less than 60 days and no more than 90 days prior to the effective date of such executive’s resignation, except that such advance notice provision does not apply with respect to Messrs. Lewis, Bilbao, and Wagers.


5)

Change in Control – “Change in control” is defined in each of the NEO Employment Agreements as any of the following events:

(i)

when any person or entity, including a “group” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, other than the Company or a wholly owned subsidiary thereof or any employee benefit plan of the Company or any of its subsidiaries, becomes the beneficial owner of the Company’s securities having 35% (or 50%, in the case of the CEO Agreement) or more of the combined voting power of the then outstanding securities of the Company that may be cast for the election of directors of the Company (other than as a result of an issuance of securities initiated by the Company in the ordinary course of business); or

(ii)

as the result of, or in connection with, any cash tender or exchange offer, merger or other business combination, sales of assets or contested election, or any combination of the foregoing transactions, less than a majority of the combined voting power of the then outstanding securities of the Company or any successor corporation or entity entitled to vote generally in the election of the directors of the Company or such other corporation or entity after such transaction is held in the aggregate by the holders of the Company’s securities entitled to vote generally in the election of the directors of the Company immediately prior to such transaction.

6)

Involuntary Without Cause or Voluntary for Good Reason On or Within 12 Months Following a Change in Control – each NEO Employment Agreement entitles the NEO to severance benefits in connection with a termination of his employment within 12 months following a change in control for good reason or in the event the Company terminates such NEO’s employment within 12 months following a change in control without cause, except that in the case of Mr. Ashworth, the preceding provisions apply if the termination of his employment occurs upon or within 12 months following a change in control.

7)

Disability – the NEO Employment Agreements may be terminated by either the NEO or the Company upon written notice to the other party when:

a.

the NEO suffers a physical or mental disability entitling the NEO to long-term disability benefits under the Company’s long-term disability plan, if any, or

b.

in the absence of a Company long-term disability plan, the NEO is unable, as reasonably determined by the Board, or any designated Committee of the Board (or, in the case of Mr. Holland’s agreement, as determined by the Company) to perform the essential functions of the NEO’s regular duties and responsibilities, with or without reasonable accommodation, due to a medically determinable physical or mental illness which has lasted (or can reasonably be expected to last) for a period of six consecutive months.

8)

Death – the NEO Employment Agreements terminate upon death.

9)

Retirement – under the Second Amended and Restated 2014 Plan, “normal retirement” occurs upon the retirement from active employment of the NEO on or after the date upon which the NEO reaches the age of 65.

Under the Second Amended and Restated 2014 Plan, “early retirement” occurs where (i) the sum of the NEO’s age plus years of employment at the Company as of the proposed retirement date is equal to or greater than 70, (ii) the NEO has given written notice to the Company at least one year prior to the proposed early retirement date of his intent to retire and (iii) the CEO has approved in writing such early retirement request prior to the proposed early retirement date, provided that in the event the CEO does not approve the request for early retirement or the CEO is the NEO giving notice of his intent to retire, then in both cases, the Compensation Committee shall make the determination of whether to approve or disapprove such request.


None of the NEOs were eligible for normal or early retirement at December 31, 2021 based on the terms of the Second Amended and Restated 2014 Plan or the award agreements.  Consequently, no information is provided with respect to any of the NEOs for amounts payable in connection with a normal or early retirement.

Following is the treatment of outstanding equity awards upon certain events:

reporting units measured at fair valueDeath or Disability - Generally, all outstanding equity awards granted to NEOs fully vest in the event of death or disability; provided, however, that (i) in the case of unvested RSUs awarded in connection with the CEO RSU Award, the number of RSUs scheduled to vest on the nearest future vesting date will be accelerated to vest, and all RSUs that have not vested following such acceleration will be forfeited; and (ii) in the case of the CEO MSU Award, a number of MSUs will vest equal to the product of (x) a fraction, the numerator of which is the number of full calendar months during the performance period that the CEO was employed by the Company, and the denominator of which is 36, multiplied by (y) the number of MSUs that would vest pursuant to the award agreement if the performance goals set forth in the award agreement that had been achieved as partof the vesting date were in fact achieved on the end date of the performance period (i.e., based on actual performance).

Change in Control - All outstanding, unvested equity awards granted to NEOs will not vest upon the occurrence of a goodwill impairment test;change in control unless the acquirer does not assume the outstanding equity awards (or, in the case of stock options granted under the Second Amended and Restated 2014 Plan, substitute an equivalent award). In the event the acquirer does not assume the awards:

o

RSUs granted under the Second Amended and Restated 2014 Plan will vest in full;

o

MSUs will vest based onthe actual number of MSUs that would vest pursuant to the award agreement if the performance goals set forth in the award agreement that had been achieved as of the vesting date (i.e., the date of the change in control) were in fact achieved on the end date of the performance period; and

 

o

indefinite-lived intangible assets measured at fair valuethe discretion of the Committee, stock options granted under the Second Amended and Restated 2014 Plan may be accelerated, purchased for impairment assessment.cash, or otherwise adjusted as the Committee deems appropriate.  

EachIn the event the acquirer assumes the equity awards, these equity awards will only be entitled to accelerated vesting if:

o

the NEO is involuntarily terminated, other than for cause, within 12 months following the occurrence of the change in control;

o

the NEO terminates for good reason within 12 months following the change in control (provided the NEO is party to an employment agreement or offer of employment letter with the Company that provides rights to the NEO upon a termination for good reason); or

o

in the case of RSUs and stock options granted under the Second Amended and Restated 2014 Plan, the NEO’s employment has previously terminated by reason of retirement as of the date of the change in control.  

Following the occurrence of any of these assets above is classified as Level 3 within the fair value hierarchy.

The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date.  Following the sale of Nutrisystem effective December 9, 2020, we have a single reporting unit.    

The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company.  In March 2020, we experienced a significant decline in our market capitalization and in our actual and forecasted operating results, in addition to the unfavorable change in market conditions.  As a result, management concluded that there were triggering events, during the first quarter of 2020 necessitating an impairment evaluation of our goodwill(i) RSUs and indefinite-lived intangible assets (which consist of the Nutrisystem tradename and the SilverSneakers tradename).  Following these evaluations, we recorded a total impairment loss of $199.5 million related to the Nutrisystem goodwill and tradename during the first quarter of 2020, which amount is reflected in loss from discontinued operations.  We determined there was 0 impairment related to the SilverSneakers tradename or the carrying value of goodwill related to continuing operations.

On October 18, 2020, we entered into the Purchase Agreement providing for the sale of the Nutrition business unit for $575.0 millionstock options will become fully vested (subject to the termsNEO’s execution of any release of claims as set forth in such NEO’s employment agreement or equity award agreement, if applicable), and conditions(ii) the number of MSUs that will vest (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement or MSU award agreement, if applicable) will be equal to the actual number of MSUs that would vest pursuant to the award agreement if the performance


goals set forth in the Purchase Agreement), which indicatedaward agreement that the fair value for the Nutrition business unit was below its carrying valuehad been achieved as of September 30, 2020.  We performedthe vesting date (i.e., the date of the change in control) were in fact achieved on the end date of the performance period.

Normal or Early Retirement - Following a termination in connection with normal or early retirement, unvested equity awards (other than the CEO Inducement Award, CEO RSU Award, and CEO MSU Award) generally will not be forfeited but will continue vesting in accordance with the applicable award agreements; provided, however, that upon a change in control, some equity awards will become fully vested if the executive has retired as of the date of a change in control event (as discussed above).

Without Cause or for Good Reason - In the event the NEO’s employment is terminated without cause or if the NEO resigns for good reason (as defined in his/her employment agreement):

o

For unvested RSUs granted in April 2019, a portion will vest on the date of termination equal to the number of shares that were scheduled to vest on the next soonest vesting date (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement or award agreement, if applicable).  

o

For the CEO Inducement Award granted in June 2020, unvested RSU awards will vest in full (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement).

o

For the CEO RSU Award granted in June 2020, a portion of the unvested RSUs will vest on the date of termination equal to the number of shares that were scheduled to vest on the next soonest vesting date (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement).

o

For the CEO MSU Award granted in June 2020, unvested MSU awards will vest on a pro rata basis (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement) based on the number of whole months that the NEO was employed during the performance period multiplied by the actual number of MSUs that would vest pursuant to the award agreement if the performance goals set forth in the award agreement that had been achieved as of the vesting date were in fact achieved on the end date of the performance period.

o

For unvested RSU and stock option awards granted in November 2020 and March 2021, a pro rata portion of the RSUs or stock options will vest (subject to the NEO’s execution of any release of claims as set forth in such NEO’s employment agreement or award agreement, if applicable) based on the number of days that the NEO was employed during the vesting period (less any RSUs or stock options from the same award that have previously vested).

The following tables reflect the potential payments to be made by the Company to each of the NEOs upon termination or a change in control of the Company. These benefits are in excess of those usually provided to salaried employees.  The payment amounts assume an impairment assessmenteffective change in accordance withcontrol date or termination date of December 31, 2021.  These amounts include earnings through the heldeffective change in control date or termination date and used model and determinedare estimates of compensation that the fair values of all assets and liabilities allocatedwould be paid to the Nutrition segment approximated their carrying amounts as of September 30, 2020, except for goodwill.  As a result, we recorded an impairment loss of $66.2 million for the third quarter of 2020 related to goodwill allocated to the former Nutrition segment, which amount is reflected in loss from discontinued operations.  Effective December 9, 2020, we completed the sale of Nutrisystem to Kainos for an aggregate purchase price, after giving effect to customary indebtedness and cash adjustments, of approximately $558.9 million, which amount is subject to a customary working capital adjustment post-Closing.  We estimate such working capital adjustment will result in additional proceeds to be received in 2021 of $2.8 million. AtNEOs at the time of disposition,change in control or termination.  The exact amounts of compensation can only be determined on the carrying valueactual date that each NEO separates from the Company or that there is a change in control of the disposal group of $585.7 million exceededCompany.

In addition to the estimated gross proceeds (excluding our transaction costs) of $561.7 million.  As a result, we recorded an additional impairment loss of $24.0 millionCompany compensation outlined in the fourth quartertables below, third party insurance companies will provide life insurance and disability benefits if the NEOs separate for reasons of 2020 related to goodwill allocated to the former Nutrition segment, which amount is reflected in loss from discontinued operations.

During the fourth quarter of 2020, we reviewed goodwill for impairment related to our single reporting unit.  We estimated the fair value of thereporting unit based on our market capitalization and compared such fair value to the carrying valuedeath or disability. If any of the reporting unit. Because the fair valueNEO’s employment had terminated as of the reporting unit exceeded its carrying amount, we determined that the carrying value of goodwill was not impaired.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

68


The following table presents our financial instruments measured at fair value on a recurring basis at December 31, 2020 and 2019.  

(In thousands)

 

 

 

 

 

 

 

 

Level 2

 

 

December 31,

2020

 

 

December 31,

2019

 

Derivatives designated as effective hedging instruments

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

Interest rate swap agreements

$

20,377

 

 

$

16,238

 

 

 

 

 

 

 

 

 

Non-designated derivatives

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

Interest rate swap agreements

$

16,260

 

 

$

 

The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads.

Fair Value of Other Financial Instruments

The estimatedfair value of eachclass of financial instruments at December 31, 2020 was as follows:

Cash and cash equivalents – The carrying amount of $100.4 million approximates fair value because of the short maturity of those instruments (less than three months).

Debt – The estimated fair value of outstanding borrowings under the Credit Agreement, which includes a revolving credit facility and a term loan facility (see Note 10), are determined based on the fair value hierarchy as discussed above.

The Term Loans are activelytradedandthereforeareclassifiedasLevel1valuations.Theestimatedfair valueisbasedon quotes as of December 31, 2020 from dealers who stand ready and willing2021 due to transact at those prices. The Revolving Credit Facility is not actively traded and therefore is classified as a Level 2 valuation based on the market for similar instruments.  The estimated net fair value and net carrying amount of outstanding borrowings under the Term Loans at December 31, 2020 were $463.2 million and $466.7 million, respectively.  There were 0 outstanding borrowings under the Revolving Credit Facility at December 31, 2020.

13.

Derivative Instruments and Hedging Activities

We use derivative instruments to manage differences in the amount, timing, and duration of our known or expected cash payments related to our outstanding debt (i.e., interest rate risk).  Some of these derivatives are designated and qualify as a hedge of the exposure to variability in expected future cash flows and are therefore considered cash flow hedges.  We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet at fair value as either an asset or liability.  The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. We classify cash flows from settlement of our effective cash flow hedges in the same category as the cash flows from the related hedged items, generally within the operating activities in the consolidated statements of cash flows. We classify cash flows from settlement of our non-designated derivatives within the investing section of the consolidated statements of cash flows.

Cash Flow Hedges of Interest Rate Risk and Non-Designated Derivatives

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish these objectives, we primarily use interest rate swaps as part of our interest rate risk management strategy.  The counterparties to the interest rate swap agreements expose us to credit risk in the event of nonperformance by such counterparties. However, at December 31, 2020, we do not

69


anticipate nonperformance by these counterparties.  Our interest rate swap agreements with each of the counterparties contain a provision whereby if we either default or are capable of being declared in default on any of our indebtedness, whether or not such default results in repayment of the indebtedness being accelerated by the lender, then we could also be declared in default on our derivative obligations.

Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in accumulated other comprehensive income or loss ("accumulated OCI") associated with such derivative instruments are reclassified into earnings in the period of de-designation.  

Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for our making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.  In May 2019, we entered into 8 amortizing interest rate swap agreements, each of which matures in May 2024.  Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread (see Note 10).  Upon entering into the Purchase Agreement with Kainos on October 18, 2020, we determined that some of our hedged transactions would not materially occur in the initially identified time period since we expected to use the majority of the net proceeds from the sale to pay down a significant portion of outstanding debt. As a result, we concluded that 5 of our 8 interest rate swaps no longer qualified for hedge accounting treatment. Accordingly, in the fourth quarter of 2020 we de-designated these 5 derivatives (“de-designated swaps”) and accelerated the reclassification of deferred gains and losses in accumulated OCI to earningsdeath as a result of natural causes, the hedged forecasted transactions becoming probable not to occur. Asbeneficiaries of Messrs. Ashworth, Holland, Lewis, Bilbao, and Wagers would have received a resultlump sum payout from a third-party insurance provider of such acceleration upon de-designation, we recognized a pre-tax loss of $14.3 million in income (loss) from discontinued operations.$750,000, $1,750,000, $750,000,


Additionally, upon de-designation in October 2020, we froze $3.2 million of previously deferred losses in accumulated OCI related to forecasted payments that are probable of occurring. We reclassify such deferred losses from accumulated OCI into earnings as an adjustment to interest expense during periods in which the forecasted transactions impact earnings, consistent with hedge accounting treatment.$1,236,000, and $600,000, respectively.  In the event thatof an accidental death, the related forecasted payments are no longer probable of occurring,beneficiaries for Messrs. Ashworth, Holland, Lewis, Bilbao, and Wagers would have received an additional $1,750,000, $1,750,000, $750,000, $1,618,000, and $600,000, respectively, in a lump sum payout from a third-party insurance provider. If the related loss in accumulated OCI will be recognized in earnings immediately.

We continue to maintain the effective hedging relationship between 3 interest rate swap agreements and the portion of our forecasted payments that is expected to remain highly probable of occurring. During the fourth quarter of 2020 we evaluated the likelihood and extent of potential future losses from the de-designated swaps. Such potential future losses are capped since the variable interest rate of our swaps is subject to a floor of 0%. Based on the LIBOR rates in effect at the time of de-designation, we decided to hold the de-designated swapsNEOs’ employment had terminated as derivative instruments requiring mark-to-market accounting treatment, with any change in fair value recognized each period in current earnings.

At December 31, 2020, our interest rate swap agreements designated as effective cash flow hedges had current notional amounts totaling $388.9 million, and our de-designated interest rate swap agreements had current notional amounts totaling $311.1 million.

We record all derivatives at estimated fair value in the consolidated balance sheet. Gains and losses on derivatives designated as effective cash flow hedges are recorded in accumulated OCI and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings.  Amounts reported in accumulated OCI related to cash flow hedge derivatives will be reclassified to interest expense as we make interest payments on our variable-rate debt.  As of December 31, 2020, we expect to reclassify $8.8 million from accumulated OCI as an increase to interest expense within the next 12 months2021 due to disability, each of the scheduled paymentNEOs would have been entitled to receive a monthly benefit of interest associated with our debt.  Gains and losses on derivatives de-designated$12,000 until approximately age 67 from a third-party insurance provider.  This benefit could be offset by other sources of income, such as effective cash flow hedges are recorded in the consolidated statement of operations.

70


The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at December 31, 2020 and 2019 were as follows:Social Security or other disability benefits.

 

(In thousands)

 

December 31,

2020

 

 

December 31,

2019

 

Liabilities:

 

 

 

 

 

 

 

 

Derivatives designated as effective hedging

   instruments:

 

 

 

 

 

 

 

 

Current portion of long-term liabilities

 

$

8,205

 

 

$

4,947

 

Other long-term liabilities

 

 

12,172

 

 

 

11,291

 

 

 

$

20,377

 

 

$

16,238

 

 

 

 

 

 

 

 

 

 

Non-designated derivatives:

 

 

 

 

 

 

 

 

Current portion of long-term liabilities

 

$

6,548

 

 

$

 

Other long-term liabilities

 

 

9,712

 

 

 

 

 

 

$

16,260

 

 

$

 

Richard Ashworth, Chief Executive Officer

The following table presentsshows the effectpotential payments upon termination or a change in control of cash flow hedge accountingthe Company for Mr. Ashworth if his employment had terminated on accumulated OCI as of December 31, 2020 and 2019:2021.  The amounts in the table below assume execution of full release of claims in favor of the Company.

 

(In thousands)

 

For the Year Ended

 

 

 

December 31, 2020

 

 

December 31,

2019

 

Derivatives designated as effective hedging instruments:

 

 

 

 

 

 

 

 

Loss related to effective portion of derivatives

   recognized in accumulated OCI, gross of tax effect

 

 

33,247

 

 

 

16,930

 

Loss related to effective portion of derivatives reclassified

   from accumulated OCI to interest expense, gross of tax

   effect

 

 

(11,556

)

 

 

(692

)

 

 

 

 

 

 

 

 

 

Non-designated derivatives:

 

 

 

 

 

 

 

 

Loss related to de-designation of ineffective portion of

   derivatives, gross of tax effect

 

 

(14,336

)

 

 

 

Previously deferred loss reclassified from accumulated

   OCI to interest expense, gross of tax effect

 

 

(239

)

 

 

 

 

 

 

 

 

 

 

 

 

Total other comprehensive loss, gross of tax

 

 

7,116

 

 

 

16,238

 

 

 

Involuntary

Without

Cause or

Voluntary

For Good Reason

on 12/31/21

 

Involuntary

For Cause

on 12/31/21

 

Voluntary

Without Good

Reason

on 12/31/21

Cash Severance

 

 

$

1,800,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

25,143

 

(3)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

1,036,894

 

(4)

 

 

 

 

 

 

 

 

1,036,894

 

(4)

Restricted Stock Units

 

 

 

7,932,000

 

(5)

 

 

 

 

 

 

 

 

 

 

Market Stock Units

 

 

 

3,671,220

 

(5)

 

 

 

 

 

 

 

 

 

(5)

Total

 

 

$

14,465,257

 

 

 

 

$

 

 

 

 

$

1,036,894

 

 

 

The following table presents the impact that non-designated derivatives had on our consolidated statement of operations:

 

 

Change in

Control

on 12/31/21

 

 

Involuntary

Without

Cause or

Voluntary For

Good Reason

On or Within 12

Months following a

Change in Control

on 12/31/21

 

 

Disability

on 12/31/21

 

 

Death

on 12/31/21

 

 

Cash Severance

 

$

 

 

$

2,250,000

 

(2)

$

1,800,000

 

(6)(1)

$

 

 

Group Medical Benefits

 

 

 

 

 

25,143

 

(3)

 

25,143

 

(3)

 

 

 

Annual Incentive Award

 

 

1,036,894

 

(4)

 

2,073,788

 

(4)

 

1,036,894

 

(4)

 

1,036,894

 

(4)

Restricted Stock Units

 

 

9,254,000

 

(5)

 

9,254,000

 

(5)

 

7,932,000

 

(5)

 

7,932,000

 

(5)

Market Stock Units

 

 

6,955,994

 

(5)

 

6,955,994

 

(5)

 

3,671,220

 

(5)

 

3,671,220

 

(5)

Total

 

$

17,246,888

 

 

$

20,558,925

 

 

$

14,465,257

 

 

$

12,640,114

 

 

 

(In thousands)

 

Statement of

Operations

Classification

 

Year Ended December 31, 2020

 

Loss related to de-designation of ineffective

   portion of derivatives, gross of tax effect

 

Income from discontinued operations, net of

   income tax

 

$

(14,336

)

Net loss related to ineffective portion of

   derivatives, gross of tax effect

 

Selling, general and administrative expenses

 

 

(226

)

Previously deferred loss related to

   de-designated swaps reclassified from

   accumulated OCI, gross of tax effect

 

Interest expense

 

 

(239

)

 

 

 

 

$

(14,801

)

(1)

Represents 24 months of NEO’s base salary to be paid periodically at the regular payroll dates commencing as of the date of termination.

(2)

Represents 30 months of NEO’s base salary to be paid in a lump sum following the NEO’s termination.  Following a change in control, the payments would be paid in a lump sum no later than 30 days following the date of termination.

(3)

Represents 24 months of the Company’s portion of premiums for group medical benefits to be paid in a lump sum no later than 30 days following the date of termination.


14.(4)

RestructuringFollowing a termination (a) without cause, (b) for good reason, or (c) because of disability, the NEO was entitled to receive a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination.  Following a termination because of death, the NEO was entitled to any earned, but unpaid, short-term incentive as of the date of termination.  Following a termination without cause or for good reason on or within 12 months following a change in control, the NEO was entitled to receive (i) a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination, measured at the greater of target or actual Company performance, plus (ii) an amount equal to the greater of actual bonus for the year in which the termination occurs or actual bonus for the year prior to the occurrence of the change in control. The short-term incentive award program for 2021 provided that all eligible individuals were required to be employed through December 31, 2021 in order to receive the award.  Therefore, if the NEO’s employment had terminated for any reason other than cause on December 31, 2021, he would have been entitled to a short-term incentive award payment.  No additional bonus amounts would be paid during the severance period.

(5)

Following a change in control or a termination (a) without cause, (b) for good reason, (c) without cause or for good reason within 12 months following a change in control, or (d) because of disability or death, outstanding stock options, RSUs, MSUs, and Related Chargesother unvested equity incentives would be treated solely in accordance with the terms of the applicable award agreements.  The table above assumes that such awards are not assumed by the acquiring corporation or other successor to the Company in a change in control.  The values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share.    

(6)

Although not reflected in this table, this amount would be reduced by any disability insurance payments paid by the insurance company to the NEO as a result of the NEO’s disability.  In the event of disability, the NEO would receive $12,000 per each month of disability from the insurance company until reaching age 67.

 

2019 Restructuring PlanAdam Holland, Chief Financial Officer

The following table shows the potential payments upon termination or a change in control of the Company for Mr. Holland.

 

 

 

 

Involuntary

Without

Cause or

Voluntary

For Good

Reason

on 12/31/21

 

 

 

 

Involuntary

For Cause

on 12/31/21

 

 

 

Voluntary

Without Good

Reason

on 12/31/21

 

 

Cash Severance

 

 

$

424,360

 

(1)(8)

 

 

$

 

 

 

$

16,322

 

(2)

Group Medical Benefits

 

 

 

14,794

 

(3)(8)

 

 

 

 

 

 

 

569

 

(2)

Annual Incentive Award

 

 

 

243,495

 

(4)

 

 

 

 

 

 

 

243,495

 

(4)

Stock Options

 

 

 

176,017

 

(5)

 

 

 

 

 

 

 

 

 

Restricted Stock Units

 

 

 

244,385

 

(5)(8)

 

 

 

 

 

 

 

 

 

Additional Severance

 

 

 

 

 

 

 

 

212,180

 

(6)(8)

 

 

 

 

Total

 

 

$

1,103,051

 

 

 

 

$

212,180

 

 

 

$

260,386

 

 


During

 

 

 

Change in

Control

on 12/31/21

 

 

 

Involuntary

Without

Cause or

Voluntary For

Good Reason

Within 12 Months

following a

Change in Control

on 12/31/21

 

 

 

 

Disability

on 12/31/21

 

 

 

 

Death

on 12/31/21

 

 

Cash Severance

 

 

$

 

 

 

$

424,360

 

(1)

 

 

$

424,360

 

(1)(7)(8)

 

 

$

 

 

Group Medical Benefits

 

 

 

 

 

 

 

14,794

 

(3)

 

 

 

14,794

 

(3)

 

 

 

 

 

Annual Incentive Award

 

 

 

243,495

 

(4)

 

 

243,495

 

(4)

 

 

 

243,495

 

(4)

 

 

 

243,495

 

(4)

Stock Options

 

 

 

386,555

 

(5)

 

 

386,555

 

(5)

 

 

 

386,555

 

(5)

 

 

 

386,555

 

(5)

Restricted Stock Units

 

 

 

816,335

 

(5)

 

 

816,335

 

(5)

 

 

 

816,335

 

(5)

 

 

 

816,335

 

(5)

Total

 

 

$

1,446,385

 

 

 

$

1,885,539

 

 

 

 

$

1,885,539

 

 

 

 

$

1,446,385

 

 

(1)

Represents 12 months of NEO’s base salary to be paid at regular payroll dates commencing within 60 days following the date of termination.  Following a change in control, the payments would be paid in a lump sum no later than 60 days following the date of termination.

(2)

For termination by the NEO without good reason, the NEO is entitled to base salary and benefits through the next payroll date following termination.

(3)

Represents the Company’s portion of premiums for group medical benefits to be paid for 12 months following the NEO’s termination.

(4)

Following a termination (a) without cause, (b) for good reason, (c) without cause or for good reason within 12 months following a change in control, or (d) because of disability or death, the NEO is entitled to receive a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination.  The short-term incentive award program for 2021 provided that all eligible individuals were required to be employed through December 31, 2021 in order to receive the award.  Therefore, if the NEO’s employment had terminated for any reason other than cause on December 31, 2021, he would have been entitled to a short-term incentive award payment.  No additional bonus amounts would be paid during the severance period.

(5)

Following a change in control (to the extent the awards are not assumed by the acquiring corporation or other successor to the Company) or a termination (a) without cause, (b) for good reason, (c) without cause or for good reason within 12 months following a change in control, or (d) because of disability or death, outstanding stock options and unvested RSUs will be treated solely in accordance with the terms of the applicable award agreements.  The table above assumes that such awards are not assumed by the acquiring corporation or other successor to the Company in a change in control and, in the case of stock options, the Committee exercises its discretion to accelerate the vesting of such stock options.  For stock options, the values in the table are based upon the difference between the closing price of the Common Stock on December 31, 2021 of $26.44 per share and the exercise price of the awards, including only those awards whose exercise price was below the market price on December 31, 2021.  For RSUs, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share.  

(6)

Represents six months of the NEO’s base salary to be paid at regular payroll dates commencing within 60 days following the NEO’s termination.

(7)

Although not reflected in this table, this amount would be reduced by any disability insurance payments paid by the insurance company to the NEO as a result of the NEO’s disability.  In the event of disability, the NEO would receive $12,000 per each month of disability from the insurance company until reaching age 67.


(8)

Assumes execution of full release of claims in favor of the Company.

Thomas Lewis, Chief Operating Officer

The following table shows the first quarterpotential payments upon termination or a change in control of 2019, the Company for Mr. Lewis.  The amounts in the table below assume execution of full release of claims in favor of the Company.

 

 

 

Involuntary

Without

Cause or

Voluntary

For Good Reason

on 12/31/21

 

 

 

 

Involuntary

For Cause

on 12/31/21

 

 

 

 

Voluntary

Without Good

Reason

on 12/31/21

 

 

Cash Severance

 

 

$

425,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

15,394

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

241,333

 

(3)

 

 

 

 

 

 

 

 

241,333

 

(3)

Stock Options

 

 

 

108,429

 

(4)

 

 

 

 

 

 

 

 

 

 

Restricted Stock Units

 

 

 

124,770

 

(4)

 

 

 

 

 

 

 

 

 

 

Total

 

 

$

914,926

 

 

 

 

$

 

 

 

 

$

241,333

 

 

 

 

 

Change in

Control

on 12/31/21

 

 

 

 

Involuntary

Without

Cause or

Voluntary For

Good Reason

Within 12 Months

following a

Change in Control

on 12/31/21

 

 

 

 

Disability

on 12/31/21

 

 

 

 

Death

on 12/31/21

 

 

Cash Severance

 

 

$

 

 

 

 

$

425,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

 

 

 

 

 

15,394

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

241,333

 

(3)

 

 

 

241,333

 

(3)

 

 

 

241,333

 

(3)

 

 

 

241,333

 

(3)

Stock Options

 

 

 

238,304

 

(4)

 

 

 

238,304

 

(4)

 

 

 

238,304

 

(4)

 

 

 

238,304

 

(4)

Restricted Stock Units

 

 

 

507,436

 

(4)

 

 

 

507,436

 

(4)

 

 

 

507,436

 

(4)

 

 

 

507,436

 

(4)

Total

 

 

$

987,073

 

 

 

 

$

1,427,467

 

 

 

 

$

987,073

 

 

 

 

$

987,073

 

 

(1)

Represents 12 months of NEO’s base salary to be paid at regular payroll dates following the NEO’s termination.  

(2)

Represents the Company’s portion of premiums for group medical benefits to be paid for 12 months following the NEO’s termination.  

(3)

Following a termination (a) without cause, (b) for good reason, or (c) without cause or for good reason within 12 months following a change in control, the NEO is entitled to receive a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination.  The short-term incentive award program for 2021 provided that all eligible individuals were required to be employed through December 31, 2021 in order to receive the award.  Therefore, if the NEO’s employment had terminated for any reason other than cause on December 31, 2021, he would have been entitled to a short-term incentive award payment.  No additional bonus amounts would be paid during the severance period.  

(4)

Following a change in control (to the extent the awards are not assumed by the acquiring corporation or other successor to the Company) or a termination (a) without cause, (b) for good reason, (c) without cause or for


good reason within 12 months following a change in control, or (d) because of disability or death, unvested RSUs will be treated solely in accordance with the terms of the applicable award agreements.  The table above assumes that such awards are not assumed by the acquiring corporation or other successor to the Company in a change in control.  For stock options, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share and the exercise price of the awards, including only those awards whose exercise price was below the market price on December 31, 2021.  For RSUs, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share.

we beganRaymond Bilbao, Chief Legal Officer

The following table shows the potential payments upon termination or a reorganization primarily relatedchange in control of the Company for Mr. Bilbao.  The amounts in the table below assume execution of full release of claims in favor of the Company.

 

 

 

Involuntary

Without

Cause or

Voluntary

For Good Reason

on 12/31/21

 

 

 

 

Involuntary

For Cause

on 12/31/21

 

 

 

 

Voluntary

Without Good

Reason

on 12/31/21

 

 

Cash Severance

 

 

$

309,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

12,886

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

177,302

 

(3)

 

 

 

 

 

 

 

 

177,302

 

(3)

Stock Options

 

 

 

66,349

 

(4)

 

 

 

 

 

 

 

 

 

 

Restricted Stock Units

 

 

 

69,643

 

(4)

 

 

 

 

 

 

 

 

 

 

Total

 

 

$

635,180

 

 

 

 

$

 

 

 

 

$

177,302

 

 

 

 

 

Change in

Control

on 12/31/21

 

 

 

 

Involuntary

Without

Cause or

Voluntary For

Good Reason

Within 12 Months

following a

Change in Control

on 12/31/21

 

 

 

 

Disability

on 12/31/21

 

 

 

 

Death

on 12/31/21

 

 

Cash Severance

 

 

$

 

 

 

 

$

309,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

 

 

 

 

 

12,886

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

177,302

 

(3)

 

 

 

177,302

 

(3)

 

 

 

177,302

 

(3)

 

 

 

177,302

 

(3)

Stock Options

 

 

 

145,702

 

(4)

 

 

 

145,702

 

(4)

 

 

 

145,702

 

(4)

 

 

 

145,702

 

(4)

Restricted Stock Units

 

 

 

285,235

 

(4)

 

 

 

285,235

 

(4)

 

 

 

285,235

 

(4)

 

 

 

285,235

 

(4)

Total

 

 

$

608,239

 

 

 

 

$

930,125

 

 

 

 

$

608,239

 

 

 

 

$

608,239

 

 

(1)

Represents 12 months of NEO’s base salary to be paid at regular payroll dates following the NEO’s termination.  

(2)

Represents the Company’s portion of premiums for group medical benefits to be paid for 12 months following the NEO’s termination.  

(3)

Following a termination (a) without cause, (b) for good reason, or (c) without cause or for good reason within 12 months following a change in control, the NEO is entitled to receive a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination.  The short-term incentive award program for 2021 provided that all eligible individuals were required to be employed through


December 31, 2021 in order to receive the award.  Therefore, if the NEO’s employment had terminated for any reason other than cause on December 31, 2021, he would have been entitled to a short-term incentive award payment.  No additional bonus amounts would be paid during the severance period.  

(4)

Following a change in control (to the extent the awards are not assumed by the acquiring corporation or other successor to the Company) or a termination (a) without cause, (b) for good reason, (c) without cause or for good reason within 12 months following a change in control, or (d) because of disability or death, unvested RSUs will be treated solely in accordance with the terms of the applicable award agreements.  The table above assumes that such awards are not assumed by the acquiring corporation or other successor to the Company in a change in control.  For stock options, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share and the exercise price of the awards, including only those awards whose exercise price was below the market price on December 31, 2021.  For RSUs, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share.

Ryan Wagers, Chief Accounting Officer

The following table shows the potential payments upon termination or a change in control of the Company for Mr. Wagers.  The amounts in the table below assume execution of full release of claims in favor of the Company.

 

 

 

Involuntary

Without

Cause or

Voluntary

For Good Reason

on 12/31/21

 

 

 

 

Involuntary

For Cause

on 12/31/21

 

 

 

 

Voluntary

Without Good

Reason

on 12/31/21

 

 

Cash Severance

 

 

$

300,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

14,794

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

137,213

 

(3)

 

 

 

 

 

 

 

 

137,213

 

(3)

Stock Options

 

 

 

47,389

 

(4)

 

 

 

 

 

 

 

 

 

 

Restricted Stock Units

 

 

 

62,901

 

(4)

 

 

 

 

 

 

 

 

 

 

Total

 

 

$

562,297

 

 

 

 

$

 

 

 

 

$

137,213

 

 

 

 

 

Change in

Control

on 12/31/21

 

 

 

 

Involuntary

Without

Cause or

Voluntary For

Good Reason

Within 12 Months

following a

Change in Control

on 12/31/21

 

 

 

 

Disability

on 12/31/21

 

 

 

 

Death

on 12/31/21

 

 

Cash Severance

 

 

$

 

 

 

 

$

300,000

 

(1)

 

 

$

 

 

 

 

$

 

 

Group Medical Benefits

 

 

 

 

 

 

 

 

14,794

 

(2)

 

 

 

 

 

 

 

 

 

 

Annual Incentive Award

 

 

 

137,213

 

(3)

 

 

 

137,213

 

(3)

 

 

 

137,213

 

(3)

 

 

 

137,213

 

(3)

Stock Options

 

 

 

104,075

 

(4)

 

 

 

104,075

 

(4)

 

 

 

104,075

 

(4)

 

 

 

104,075

 

(4)

Restricted Stock Units

 

 

 

216,887

 

(4)

 

 

 

216,887

 

(4)

 

 

 

216,887

 

(4)

 

 

 

216,887

 

(4)

Total

 

 

$

458,175

 

 

 

 

$

772,969

 

 

 

 

$

458,175

 

 

 

 

$

458,175

 

 

(1)

Represents 12 months of NEO’s base salary to be paid at regular payroll dates following the NEO’s termination.  


(2)

Represents the Company’s portion of premiums for group medical benefits to be paid for 12 months following the NEO’s termination.  

(3)

Following a termination (a) without cause, (b) for good reason, or (c) without cause or for good reason within 12 months following a change in control, the NEO is entitled to receive a pro-rata portion of any short-term incentive to which the NEO is otherwise entitled as of the date of termination.  The short-term incentive award program for 2021 provided that all eligible individuals were required to be employed through December 31, 2021 in order to receive the award.  Therefore, if the NEO’s employment had terminated for any reason other than cause on December 31, 2021, he would have been entitled to a short-term incentive award payment.  No additional bonus amounts would be paid during the severance period.  

(4)

Following a change in control (to the extent the awards are not assumed by the acquiring corporation or other successor to the Company) or a termination (a) without cause, (b) for good reason, (c) without cause or for good reason within 12 months following a change in control, or (d) because of disability or death, unvested RSUs will be treated solely in accordance with the terms of the applicable award agreements.  The table above assumes that such awards are not assumed by the acquiring corporation or other successor to the Company in a change in control.  For stock options, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share and the exercise price of the awards, including only those awards whose exercise price was below the market price on December 31, 2021.  For RSUs, the values in the table are based upon the closing price of the Common Stock on December 31, 2021 of $26.44 per share.  

CEO to integrating the Nutrisystem business and streamlining our corporate and operations support (the "2019 Restructuring Plan"). The 2019 Restructuring Plan concluded during the first quarter of 2020.  For the years ended December 31, 2020 and 2019, we incurred restructuring charges from continuing operations of $0.5 million and $1.9 million, respectively, relatedMedian Employee Pay Ratio

Under rulesadopted pursuant to the 2019 Restructuring Plan.  To date,Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”), we have incurred restructuring charges from continuing operationsare required to calculate and disclose the total compensation paid to our median employee, as well as the ratio of $2.4 million relatedthe total compensation paid to the 2019 Restructuring Plan. These expenses consist entirely of severance and other employee-related costs. 

2020 COVID Restructuring Plan

During the second quarter of 2020, we began a reorganization plan primarily related to eliminating certain compensation costs in responsemedian employee compared to the COVID-19 pandemic in ordertotal compensation paid to preserve our liquidity and manage ourthe CEO.  The following provides details on the methodology used to identify the median employee for 2021, as well as the results of the analysis.

Under the relevant rules, we were required to identify the median employee by use of a “consistently applied compensation measure.”  The consistently applied compensation measure we used to identify the median employee was gross cash flows (“2020 COVID Restructuring Plan”). The 2020 COVID Restructuring Plan was completed during the third quarter of 2020. To date andcompensation paid to employees for the year ended December 31, 2020, we incurred restructuring charges from continuing operations2021, which included base salary, incentive awards (including bonuses, short-term incentive awards, and sales incentives), and other miscellaneous cash awards or payments.  We included all active employees (whether full-time, part-time, or seasonal) as of $0.8 million relatedDecember 31, 2021.  We did not make adjustments to the 2020 COVID Restructuring Plan. These expenses consist entirelycompensation paid to part-time employees to calculate what they would have been paid on a full-time basis.  In addition, for any full-time employees who were hired during 2021, we used their annual salaries when calculating their gross cash compensation.  We believe the use of severancetotal cash compensation (rather than total compensation, which would include equity awards) for all employees is a consistently applied compensation measure because we do not widely distribute annual equity awards to employees.  As of December 31, 2021, approximately 16% of our employees were eligible to receive regular annual equity awards.

After identifying the median employee based on total cash compensation and other employee-related costs.the methodology described above, we calculated annual total compensation for such employee using the same methodology we use for our NEOs as set forth in the Summary Compensation Table.    The 2020 COVID Restructuring Plan is expected to result in2021 total annualized savings at target performance of approximately $6.0 million.

2020 Restructuring Plan

During the third quarter of 2020, we began a reorganization plan primarily related to optimizing our businesscompensation for growth and executing on our new strategy (“2020 Restructuring Plan”).  To dateMr. Ashworth and for our median employee were $1,947,673 and $103,398, respectively, resulting in a ratio of 19:1.  

This information is being provided for the year ended December 31, 2020, we incurred restructuring charges from continuing operationspurpose of $3.1 million relatedcomplying with the provisions of the Dodd-Frank Act.  Neither the Committee nor management of the Company used the pay ratio measure in making compensation decisions.Additionally, as a result of the flexibility permitted when identifying the median employee and the Company’s specific pay practices and workforce composition, the Company’s pay ratio may not be comparable to the 2020 Restructuring Plan, which consisted entirelypay ratios of severance and other employee-related costs.  Actions taken to date under the 2020 Restructuring Plan are expected to result in total annualized savings at target performance of approximately $6.7 million.companies.


Director Compensation

 

The following table shows Nominating and Corporate Governance Committee (the activity from continuing operations“NCG Committee”) reviews on an annual basis director compensation in accrued restructuringrelation to other comparable companies and related chargesin light of other factors that the NCG Committee deems appropriate and discusses director compensation with the Board.

From January 1, 2021 until the 2021 Annual Meeting of Stockholders, each non-employee director (excluding the Chairman) earned an annual cash retainer of $75,000; the annual cash retainer for the year ended December 31, 2020 related toChairman was $200,000.  In addition, the restructuring plans described above.  The activity set forth below consists entirely of severance and other employee-related costs that have been or will be settled in cash.  We also incurred $0.8 million of non-cash restructuring charges during 2020 related to share-based compensation.annual committee retainers were as follows:

 

(In thousands)

 

2019 Restructuring Plan

 

 

2020 COVID Restructuring Plan

 

 

2020 Restructuring Plan

 

 

Total

 

Accrued restructuring and related charges liability as of January 1, 2020

 

$

242

 

 

$

 

 

$

 

 

$

242

 

Restructuring charges

 

 

475

 

 

 

816

 

 

 

2,327

 

 

 

3,618

 

Payments

 

 

(606

)

 

 

(816

)

 

 

(514

)

 

 

(1,936

)

Accrued restructuring and related charges liability as of December 31, 2020

 

$

111

 

 

$

 

 

$

1,813

 

 

$

1,924

 

Jan. 1, 2021 until 2021 Annual Meeting of Stockholders

 

Annual Retainer

 

Committee

 

Member

 

Chair

 

Audit

 

 

$

15,000

 

 

 

 

$

30,000

 

Compensation

 

 

$

10,000

 

 

 

 

$

20,000

 

Nominating and Corporate Governance

 

 

$

10,000

 

 

 

 

$

20,000

 

 

15.

Earnings (Loss) Per Share

Beginning in March 2019, we use the two-class method to calculate earnings per share as the unvested restricted stock awards outstanding under our equity incentive plan are participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (currently not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period.  In applying the two-class method, we allocate undistributed earnings to both shares of common stock and participating securities basedEffective beginning on the number of weighted average shares outstanding during

72


the period. During periods of net loss, no effect is given to the participating securities because they do not share in the lossesdate of the Company.  Thefollowingisareconciliation2021 Annual Meeting of Stockholders, thenumeratoranddenominatorofbasicanddilutedearnings(loss)persharefor NCG Committee approved theyears ended December 31, 2020, 2019, and 2018:

(In thousands except per share data)

 

Year Ended December 31,

 

Numerator:

 

2020

 

 

2019

 

 

2018

 

Income from continuing operations attributable to Tivity

   Health, Inc. - numerator for earnings (loss) per share

 

$

56,869

 

 

$

45,217

 

 

$

97,902

 

Net income (loss) from discontinued operations attributable to

   Tivity Health, Inc. - numerator for earnings (loss) per share

 

 

(280,500

)

 

 

(332,038

)

 

 

901

 

Net income (loss) attributable to Tivity Health, Inc. - numerator for

   earnings (loss) per share

 

$

(223,631

)

 

$

(286,821

)

 

$

98,803

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Shares used for basic income (loss) per share

 

 

48,746

 

 

 

46,509

 

 

 

40,078

 

Effect of dilutive stock options and restricted stock units

   outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Non-qualified stock options

 

 

29

 

 

 

90

 

 

 

264

 

Restricted stock units

 

 

412

 

 

 

489

 

 

 

299

 

Performance-based stock units

 

 

29

 

 

 

15

 

 

 

 

Warrants related to Cash Convertible Notes

 

 

 

 

 

 

 

 

2,013

 

Market stock units

 

 

1

 

 

 

 

 

 

419

 

Shares used for diluted income (loss) per share

 

 

49,217

 

 

 

47,103

 

 

 

43,073

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share attributable to Tivity Health, Inc. - basic:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.17

 

 

$

0.97

 

 

$

2.44

 

Discontinued operations

 

$

(5.75

)

 

$

(7.14

)

 

$

0.02

 

Net income (loss) (1)

 

$

(4.59

)

 

$

(6.17

)

 

$

2.47

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share attributable to Tivity Health, Inc. -

   diluted:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.16

 

 

$

0.96

 

 

$

2.27

 

Discontinued operations

 

$

(5.70

)

 

$

(7.05

)

 

$

0.02

 

Net income (loss)

 

$

(4.54

)

 

$

(6.09

)

 

$

2.29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dilutive securities outstanding not included in the computation of

   earnings (loss) per share because their effect is anti-dilutive:

 

 

 

 

 

 

 

 

 

 

 

 

Non-qualified stock options

 

 

186

 

 

 

70

 

 

 

56

 

Restricted stock units

 

 

242

 

 

 

192

 

 

 

36

 

Performance-based stock units

 

 

24

 

 

 

 

 

 

 

Restricted stock awards

 

 

26

 

 

 

102

 

 

 

 

following revisions to non-employee director compensation:

 

(1)

Figures may not add dueThe annual cash retainer for each non-employee director (excluding the Chairman) decreased from $75,000 to rounding.$60,000;

Market stock units and performance-based stock units outstanding are considered contingently issuable shares, and certain of these market stock units and performance-based stock units were excluded from the calculations of diluted earnings per share for all periods presented because the performance criteria had not been met as of the end of the reporting periods.

73


16.

Accumulated OCI

The following tables summarize the changes in accumulated OCI, net of tax, for the years ended December 31, 2019 and 2020.

(In thousands)

 

Interest

Rate Swaps

 

Accumulated OCI, net of tax, as of January 1, 2019

 

$

 

Other comprehensive income (loss) before reclassifications, net of tax of

   $4,324

 

 

(12,606

)

Amounts reclassified from accumulated OCI, net of tax of $177

 

 

515

 

Accumulated OCI, net of tax, as of December 31, 2019

 

$

(12,091

)

Other comprehensive income (loss) before reclassifications, net of tax of

   $8,491

 

 

(24,756

)

Amounts reclassified from accumulated OCI, net of tax of $6,674

 

 

19,458

 

Accumulated OCI, net of tax, as of December 31, 2020

 

$

(17,389

)

The following table presents details about reclassifications out of accumulated OCI for the years ended December 31, 2020 and 2019:

(In thousands)

 

Year Ended

December 31, 2020

 

 

Year Ended

December 31, 2019

 

 

Statement of

Operations

Classification

Interest rate swaps

 

$

11,795

 

 

$

692

 

 

Interest expense

 

 

 

(3,012

)

 

 

(177

)

 

Income tax

 

 

 

10,675

 

 

 

 

 

Income from discontinued

   operations, net of income tax

Total amounts reclassified from

   accumulated OCI

 

$

19,458

 

 

$

515

 

 

Net of tax

17.

Segment Disclosures and Concentrations of Risk

Following the sale of Nutrisystem in December 2020, the results of which have been classified as discontinued operations for all periods presented, we have 1 operating and reportable segment. Therefore, all required segment information can be found in the Consolidated Financial Statements. Our determination that we operate as a single segment is consistent with the financial information regularly viewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.

Geographic Information

Long-lived assets and revenue from external customers attributable to our operations in the United States accounted for 100% of our consolidated long-lived assets and revenues as of and for the years ended December 31, 2020 and 2019.

Major Customers

During 2020, we had 3 customers that each accounted for 10% or more of our revenues from continuing operations and individually comprised approximately 18%, 11%, and 10% of our revenues for 2020. NaN other customer accounted for 10% or more of our revenues in 2020. In addition, at December 31, 2020, we had 2 customers that each accounted for 10% or more of our accounts receivable, net and individually comprised approximately 26% and 33% of our consolidated accounts receivable, net at December 31, 2020.

During 2019, we had 3 customers that each accounted for 10% or more of our revenues from continuing operations and individually comprised approximately 23%, 11%, and 11% of our revenues for 2019.  NaN other customer accounted for 10% or more of our revenues in 2019. In addition, at December 31, 2019, we had 3 customers that each accounted for 10% or more or our accounts receivable, net and individually comprised approximately 36%, 19%, and 11% of our accounts receivable, net at December 31, 2019.

74


18.

QuarterlyFinancial Information (unaudited)

The following tables contain selected unaudited statements of operations for each quarter of 2020 and 2019. As further discussed in Note 1, our results from continuing operations do not include the results of Nutrisystem, which we sold effective December 9, 2020.

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2020

 

First

 

 

Second

 

 

Third

 

 

Fourth (1)

 

Revenues

 

$

159,692

 

 

$

81,923

 

 

$

95,481

 

 

$

100,617

 

Gross margin

 

 

42,713

 

 

 

45,879

 

 

 

45,382

 

 

 

44,168

 

Income before income taxes

 

 

11,411

 

 

 

23,959

 

 

 

23,236

 

 

 

15,793

 

Income from continuing operations

 

 

8,275

 

 

 

17,202

 

 

 

16,750

 

 

 

14,642

 

Income (loss) from discontinued operations,

   net of income tax

 

 

(206,381

)

 

 

11,309

 

 

 

(59,168

)

 

 

(26,260

)

Net income (loss)

 

 

(198,106

)

 

 

28,511

 

 

 

(42,418

)

 

 

(11,618

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – basic:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations (2)

 

$

0.17

 

 

$

0.35

 

 

$

0.34

 

 

$

0.30

 

Discontinued operations (2)

 

$

(4.25

)

 

$

0.23

 

 

$

(1.21

)

 

$

(0.54

)

Net income (loss) (2) (3)

 

$

(4.08

)

 

$

0.59

 

 

$

(0.87

)

 

$

(0.24

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations (2)

 

$

0.17

 

 

$

0.35

 

 

$

0.34

 

 

$

0.29

 

Discontinued operations (2)

 

$

(4.22

)

 

$

0.23

 

 

$

(1.20

)

 

$

(0.53

)

Net income (loss) (2) (3)

 

$

(4.05

)

 

$

0.58

 

 

$

(0.86

)

 

$

(0.23

)

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2019

 

First (4)

 

 

Second

 

 

Third

 

 

Fourth (5)

 

Revenues

 

$

156,527

 

 

$

157,480

 

 

$

159,979

 

 

$

159,080

 

Gross margin

 

 

42,303

 

 

 

44,903

 

 

 

46,852

 

 

 

47,271

 

Income before income taxes

 

 

3,486

 

 

 

15,743

 

 

 

22,864

 

 

 

23,417

 

Income (loss) from continuing operations

 

 

(161

)

 

 

10,837

 

 

 

16,688

 

 

 

17,853

 

Income (loss) from discontinued operations,

   net of income tax

 

 

4,375

 

 

 

7,299

 

 

 

(2,769

)

 

 

(340,943

)

Net income (loss)

 

 

4,214

 

 

 

18,136

 

 

 

13,919

 

 

 

(323,090

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – basic:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations (2)

 

$

 

 

$

0.23

 

 

$

0.35

 

 

$

0.37

 

Discontinued operations (2)

 

$

0.10

 

 

$

0.15

 

 

$

(0.06

)

 

$

(7.06

)

Net income (loss) (2)

 

$

0.10

 

 

$

0.38

 

 

$

0.29

 

 

$

(6.69

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations (2)

 

$

 

 

$

0.22

 

 

$

0.34

 

 

$

0.37

 

Discontinued operations (2)

 

$

0.10

 

 

$

0.15

 

 

$

(0.06

)

 

$

(6.97

)

Net income (loss) (2) (3)

 

$

0.10

 

 

$

0.37

 

 

$

0.29

 

 

$

(6.61

)

 

The annual cash retainer for the Chairman decreased from $200,000 to $135,000;

The annual committee retainers were as follows:

2021 Annual Meeting of Stockholders through Dec. 31, 2021

 

Annual Retainer

 

Committee

 

Member

 

Chair

 

Audit

 

 

$

15,000

 

 

 

 

$

35,000

 

Compensation

 

 

$

10,000

 

 

 

 

$

25,000

 

Nominating and Corporate Governance

 

 

$

10,000

 

 

 

 

$

25,000

 

In addition, on the date of the 2021 Annual Meeting of Stockholders, non-employee directors received an annual grant of RSUs with a grant date fair value of approximately $125,000.  Equity awards to non-employee directors during 2021 were made pursuant to the Company’s Second Amended and Restated 2014 Stock Incentive Plan (the “Second Amended and Restated 2014 Plan”).  Directors who are also our employees (e.g., Mr. Ashworth) receive no additional compensation for their Board service.

Director Deferred Compensation Plan

In December 2020, the Board approved a deferred compensation program for non-employee directors, which took effect January 1, 2021. Non-employee directors can defer all or a portion of the retainer and fee payments that would otherwise be paid or granted to them in cash or equity and may elect to convert any cash payments into RSUs or unrestricted shares based on the fair market value of the Common Stock at the time the cash payments would otherwise have been made.  For RSUs, dividend equivalents are credited to non-employee directors as if the RSUs are outstanding shares of Common Stock. Such dividend equivalents are deemed invested in additional RSUs.  Alternatively, non-employee directors may elect to defer their cash compensation into a cash account that will earn interest at the long term “applicable federal rate” established by the IRS from time to time.

At such distribution date as specified in the election form, the director will receive a distribution of the deferred compensation then credited to him or her under the program. If the director elected to defer


RSUs (either the RSUs issued in lieu of cash pursuant to the election under the program or RSUs granted as an equity retainer), then shares of Common Stock equal to the number of RSUs (including those issued as dividend equivalents) will be distributed to the director per his or her deferral election. Shares of Common Stock issued for RSUs are issued under the Second Amended and Restated 2014 Plan. Upon a change in control of the Company, the period of deferral for any of such deferred amounts shall end, and payments shall be made to the director in accordance with the director’s election and the program.

2021 Director Compensation

The following table summarizes the compensation to each non-employee director during 2021.

Name

 

Fees Earned

or Paid in Cash

($)

 

 

Stock

Awards

($)

 

 

Option

Awards

($)

 

 

Total

($)

 

 

 

 

(1)

 

 

(2)

 

 

(3)

 

 

 

 

 

 

Sara J. Finley

 

$

 

 

$

213,830

 

 

 

 

 

$

213,830

 

 

Robert J. Greczyn, Jr.

 

 

85,766

 

 

 

124,988

 

 

 

 

 

 

210,754

 

 

Peter A. Hudson, M.D. (4)

 

 

34,597

 

 

 

 

 

 

 

 

 

34,597

 

 

Beth M. Jacob

 

 

90,766

 

 

 

124,988

 

 

 

 

 

 

215,754

 

 

Bradley S. Karro

 

 

88,844

 

 

 

124,988

 

 

 

 

 

 

213,832

 

 

Benjamin A. Kirshner (4)

 

 

 

 

 

32,667

 

 

 

 

 

 

32,667

 

 

Erin L. Russell

 

 

26,250

 

 

 

203,746

 

 

 

 

 

 

229,996

 

 

Anthony M. Sanfilippo

 

 

 

 

 

294,200

 

 

 

 

 

 

294,200

 

 

(1)

Income from continuing operationsThe following directors elected to receive all or a portion of their cash retainer fees earned for their service on the fourth quarterBoard in the form of 2020 includes strategic project costs, CEO transition costs,stock awards, pursuant to the Company’s director deferred compensation program: Ms. Finley, Mr. Kirshner, Ms. Russell, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.Mr. Sanfilippo.

 

(2)

WeReflects the aggregate grant date fair value of RSUs and deferred stock units granted during 2021 calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.  in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718.  

(3)

Figures may not add due to rounding.


(4)

The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.

(5)

Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

Item 9. Changes inDuring 2021, non-employee directors (except for Messrs. Hudson and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company's principal executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of December 31, 2020. Based on that evaluation, the principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures are effective as of December 31, 2020.  They are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Management's Annual Report on Internal Control over Financial Reporting

Management, including the principal executive officer and principal financial officer, is responsibleKirshner, who did not stand for establishing and maintaining adequate internal control over financial reporting.  Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Management has performed an assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2020 based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO framework"), and believes that the COSO framework is a suitable framework for such an evaluation.  Based on this assessment, management has concluded that the Company's internal control over financial reporting was effective as of December 31, 2020.

PricewaterhouseCoopers, LLP, the independent registered public accounting firm that audited the Company's consolidated financial statements for the year ended December 31, 2020, has audited the effectiveness of the Company's internal control over financial reporting, as stated in their report which appears herein.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal controls over financial reporting during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Item 9B. Other Information

Not applicable.

76


PART III

Item 10. Directors, Executive Officers and Corporate Governance

Information concerning our directors, director nomination procedures, audit committee, audit committee financial experts, code of ethics, and compliance with Section 16(a) of the Exchange Act will be included under the headings "Election of Directors," "Code of Conduct," "Corporate Governance," and "Delinquent Section 16(a) Reports" in our Proxy Statement forre-election at the 2021 Annual Meeting of Stockholders to be heldStockholders) received an annual grant of RSUs with a grant date fair value of approximately $125,000.  Each such director received 5,048 RSUs having a grant date fair value of $24.76 per share on May 20, 2021.  

In addition, Ms. Finley and is incorporated herein by reference.

PursuantMr. Kirshner received deferred stock units (DSUs) issued pursuant to General Instruction G(3)the Company’s director deferred compensation program, in lieu of Form 10-K, information concerning our executive officers is included in Part Ian election portion of this report, under the caption "Information about our Executive Officers."

Item 11. Executive Compensation

Information required by this itemcash retainer fees earned for the director’s service on the Board.  Such DSUs are fully vested and will be included underdistributed on a date elected by the headings "Executive Compensation"director. On March 31, 2021, Ms. Finley and "Director Compensation"Mr. Kirshner received 1,064 and 952 DSUs, respectively, having a grant date fair value of $22.32 per share.  On June 30, 2021, Ms. Finley and Mr. Kirshner received 858 and 434 DSUs, respectively, having a grant date fair value of $26.31 per share. On September 30, 2021 and December 31, 2021, Ms. Finley received 922 and 804 DSUs, respectively, having a grant date fair value per share of $23.06 and $26.44, respectively.

Ms. Russell and Mr. Sanfilippo received fully vested shares of common stock issued pursuant to the Company’s director deferred compensation program, in our Proxy Statementlieu of an election portion of the cash retainer fees earned for the director’s service on the Board. On March 31, 2021, Annual MeetingMs. Russell and Mr. Sanfilippo received 882 and 2,240 shares of Stockholders to be heldcommon stock, respectively, having a grant date fair value of $22.32 per share.  On June 30, 2021, Ms. Russell and Mr. Sanfilippo received 748 and 1,681 shares of common stock, respectively, having a grant date fair value of $26.31 per share. On September 30, 2021, Ms. Russell and Mr. Sanfilippo received 854 and 1,626 shares of common stock, respectively, having a grant date fair value of $23.06 per share. On December


31, 2021, Ms. Russell and Mr. Sanfilippo received 745 and 1,418 shares of common stock, respectively, having a grant date fair value of $26.44 per share.

The following directors and former directors who served on May 20,the Board during 2021 had unvested stock awards outstanding as of December 31, 2021 as follows: Ms. Finley (5,048); Mr. Greczyn (5,048); Ms. Jacob (5,048); Mr. Karro (5,048); Ms. Russell (5,048); and is incorporated herein by reference.Mr. Sanfilippo (5,048).

(3)

Mr. Karro had 15,000 stock option awards outstanding as of December 31, 2021.

(4)

Dr. Hudson and Mr. Kirshner did not stand for re-election at the 2021 Annual Meeting of Stockholders, and their terms ended at the 2021 Annual Meeting of Stockholders.



Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information required

Security ownership of certain beneficial owners and management

The following table sets forth certain information with respect to those persons that we know to be the beneficial owners (as defined by this item will be includedRule 13d-3 under the headings "Security OwnershipSecurities Exchange Act of Certain Beneficial Owners1934, as amended) of more than 5% of the outstanding shares of our Common Stock, our only voting security, and Management"with respect to the beneficial ownership of our Common Stock by all directors and nominees, each of the named executive officers (“NEOs”) included in the Summary Compensation Table and all of our Proxy Statement forexecutive officers, directors, and director nominees as a group.  The information set forth below is based on ownership information we received as of April 8, 2022 (except as otherwise noted below) and the 2021 Annual Meetingnumber of Stockholdersshares of Common Stock outstanding as of April 8, 2022.  Unless specified otherwise, the shares indicated are presently outstanding, and each of the stockholders listed below has sole voting and investment power with respect to be held on May 20, 2021 andthe shares beneficially owned.  Unless otherwise noted, the address of each beneficial owner is incorporated herein by reference.c/o Tivity Health, Inc., 701 Cool Springs Blvd., Franklin, TN 37067.


Name and Address of Beneficial Owner

 

Amount and Nature of

Beneficial Ownership (1)

 

Percent of

Class (1)

BlackRock, Inc.

 

 

 

7,153,512

 

(2)

 

 

14.34%

 

 

55 East 52nd Street

 

 

 

 

 

 

 

 

 

 

 

 

New York, NY 10055

 

 

 

 

 

 

 

 

 

 

 

 

The Vanguard Group

 

 

 

4,918,093

 

(3)

 

 

9.86%

 

 

100 Vanguard Blvd.

 

 

 

 

 

 

 

 

 

 

 

 

Malvern, PA 19355

 

 

 

 

 

 

 

 

 

 

 

 

HG Vora Capital Management, LLC.

 

 

 

4,800,000

 

(4)

 

 

9.62%

 

 

330 Madison Avenue, 20th Floor

 

 

 

 

 

 

 

 

 

 

 

 

New York, NY 10017

 

 

 

 

 

 

 

 

 

 

 

 

Hudson Executive Capital LP

 

 

 

4,795,310

 

(5)

 

 

9.62%

 

 

570 Lexington Avenue, 35th Floor

 

 

 

 

 

 

 

 

 

 

 

 

New York, NY 10022

 

 

 

 

 

 

 

 

 

 

 

 

Altaris Capital, L.P.

 

 

 

4,409,438

 

(6)

 

 

8.84%

 

 

10 East 53rd Street, 31st Floor

 

 

 

 

 

 

 

 

 

 

 

 

New York, NY 10022

 

 

 

 

 

 

 

 

 

 

 

 

Miller Value Partners, LLC.

 

 

 

3,658,303

 

(7)

 

 

7.34%

 

 

One South Street, Suite 2550

 

 

 

 

 

 

 

 

 

 

 

 

Baltimore, MD 21202

 

 

 

 

 

 

 

 

 

 

 

 

Morgan Stanley

 

 

 

3,554,685

 

(8)

 

 

7.13%

 

 

1585 Broadway New York, NY 10036

 

 

 

 

 

 

 

 

 

 

 

 

New York, NY 10036

 

 

 

 

 

 

 

 

 

 

 

 

Anthony M. Sanfilippo (a)

 

 

 

760,971

 

(9)

 

 

1.53%

 

 

Richard M. Ashworth (c)

 

 

 

348,221

 

(10)

 

 

*

 

 

Robert J. Greczyn, Jr.(a)

 

 

 

85,372

 

(11)

 

 

*

 

 

Adam C. Holland (b)

 

 

 

82,873

 

(12)

 

 

*

 

 

Bradley S. Karro (a)

 

 

 

69,142

 

(13)

 

 

*

 

 

Thomas Lewis (b)

 

 

 

46,169

 

(14)

 

 

*

 

 

Sara J. Finley (a)

 

 

 

36,201

 

(15)

 

 

*

 

 

Beth M. Jacob (a)

 

 

 

32,430

 

(16)

 

 

*

 

 

Erin L. Russell (a)

 

 

 

31,245

 

(17)

 

 

*

 

 

Ryan M. Wagers (b)

 

 

 

23,851

 

(18)

 

 

*

 

 

Raymond Bilbao (b)

 

 

 

20,872

 

(19)

 

 

*

 

 

Stephanie M. Davis (Michelman) (a)

 

 

 

423

 

 

 

 

*

 

 

All directors and executive officers as a group (12 persons)

 

 

 

1,537,770

 

(20)

 

 

3.07%

 

 

*

Indicates ownership of less than one percent of our outstanding shares of Common Stock

(a)

Director of the Company

(b)

Named Executive Officer

(c)

Director and Named Executive Officer

(1)

Pursuant to the rules of the Commission, certain shares of our Common Stock that an individual owner set forth in this table has a right to acquire within 60 days after April 8, 2022 pursuant to the exercise or vesting of options to purchase shares of Common Stock (“stock options”), restricted stock units, or other securities are deemed to be outstanding for the purpose of computing the ownership of that owner, but are not deemed outstanding for the purpose of computing the ownership of any other individual owner shown in the table.  Likewise, the shares subject to stock options, restricted stock units, or other securities held by our other directors and executive officers that are exercisable within 60 days after April 8, 2022 are all deemed outstanding for the purpose of computing the percentage ownership of all executive officers, directors, and director nominees as a group.


(2)

Information with respect to stock ownership is based on a Schedule 13G/A filed by BlackRock, Inc. (“BlackRock”) with the Commission on January 27, 2022 and includes shares held by certain of its subsidiaries.  Includes 7,081,580 shares to which BlackRock has sole voting power and 7,153,512 shares to which BlackRock has sole investment power.

(3)

Information with respect to stock ownership is based on a Schedule 13G/A filed by The Vanguard Group, Inc. (“Vanguard”) with the Commission on February 10, 2022 and includes shares held by certain of its subsidiaries. Includes 63,630 shares to which Vanguard has shared voting power, 4,817,469 shares to which Vanguard has sole investment power and 100,624 shares to which Vanguard has shared investment power.

(4)

Information with respect to stock ownership is based on a Form 13F information table filed by HG Vora Capital Management, LLC (“HG Vora”) with the Commission on February 14, 2022 and includes shares held by certain of its affiliates. Includes 4,800,000 shares to which HG Vora has sole voting power and sole investment power.

(5)

Information with respect to stock ownership is based on a Form 13F information table filed by Hudson Executive Capital LP (“Hudson”) with the Commission on February 14, 2022 and includes shares held by certain of its subsidiaries.  Includes 4,795,310 shares to which Hudson has shared voting power and shared investment power.

(6)

Information with respect to stock ownership is based on information provided to the Company by Altaris Capital, L.P. (“Altaris Capital”) as of March 22, 2021 and includes shares held by certain of its affiliates. Includes 4,409,438 shares to which Altaris Capital has shared voting power and shared investment power.

(7)

Information with respect to stock ownership is based on a Schedule 13G/A filed by Miller Value Partners, LLC (“Miller Value”) with the Commission on February 14, 2022 and includes shares held by certain of its affiliates.  Includes 3,658,303 shares to which Miller Value has shared voting power and shared investment power.

(8)

Information with respect to stock ownership is based on a Schedule 13G filed by Morgan Stanley with the Commission on February 11, 2022 and includes shares held by certain of its affiliates.  Includes 3,546,070 shares to which Morgan Stanley has shared voting power and 3,554,685 shares to which Morgan Stanley has shared investment power.

(9)

Includes the following securities to which Mr. Sanfilippo shares or may be deemed to share voting and investment power: (i) 240,000 shares held by the Vita Trust; (ii) 18,131 shares held by the Sanfilippo Family Trust; and (iii) 15,000 shares held by the Monarch Trust. Also includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(10)

Includes 175,000 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(11)

Includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(12)

Includes 10,910 shares that, as of April 8, 2022, were issuable upon the exercise of outstanding stock options. Also includes 10,173 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(13)

Includes 15,000 shares that, as of April 8, 2022, were issuable upon the exercise of outstanding stock options. Also includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(14)

Includes 4,883 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(15)

Includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022. Excludes 2,760 shares of deferred RSUs that, as of April 8, 2022, were issued under the Director Deferred Compensation Program in lieu of Ms. Finley’s annual cash retainer and will be distributed on a later date.

(16)

Includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(17)

Includes 5,048 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(18)

Includes 1,266 shares that, as of April 8, 2022, were issuable upon the exercise of outstanding stock options. Also includes 2,629 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.


(19)

Includes 1,477 shares that, as of April 8, 2022, were issuable upon the exercise of outstanding stock options. Also includes 2,984 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

(20)

Includes 28,653 shares that, as of April 8, 2022, were issuable upon the exercise of outstanding stock options. Also includes 225,957 shares issuable upon vesting of restricted stock units within 60 days after April 8, 2022.

Equity Compensation Plan Information

The following table summarizes, as of December 31, 2020,2021, certain information concerning the Company's equity compensation plans under which equity securities of the Company are currently authorized for issuance.issuance.

 

Plan Category

 

Number of Shares

to be Issued Upon

Exercise of Outstanding

Options, Warrants

and Rights,

in thousands (1)

 

 

Weighted-Average

Exercise Price of

Outstanding Options,

Warrants and

Rights (2)

 

 

Number of Shares

Remaining Available for

Future Issuance Under

Equity Compensation Plans

(Excluding Shares Reflected

in First Column),

in thousands

 

 

Number of Shares

to be Issued Upon

Exercise��of Outstanding

Options, Warrants

and Rights,

in thousands (1)

 

 

Weighted-Average

Exercise Price of

Outstanding Options,

Warrants and

Rights (2)

 

 

Number of Shares

Remaining Available for

Future Issuance Under

Equity Compensation Plans

(Excluding Shares Reflected

in First Column),

in thousands

 

Equity compensation plans approved by

stockholders

 

 

1,899

 

 

$

17.83

 

 

 

1,391

 

 

 

1,224

 

 

$

21.75

 

 

 

1,086

 

Equity compensation plans not approved

by stockholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

1,899

 

 

$

17.83

 

 

 

1,391

 

 

 

1,224

 

 

$

21.75

 

 

 

1,086

 

 

(1)

Represents 422,000493,000 stock options, 1,241,000581,000 restricted stock units, and 150,000 market stock units, and 86,000 performance-based stock units outstanding under the Company’s Amended and Restated 2014 Stock Incentive Plan.

(2)

The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding unvested market stock units, restricted stock units and performance-basedmarket stock units, which have no exercise price. The weighted average remaining contractual term of the outstanding stock options is 5.25.4 years.



Item 13. Certain Relationships and Related Transactions, and Director Independence

Information required by this item will be included

Certain Relationships and Related Party Transactions

Since the beginning of the last fiscal year, we are not aware of any related party transactions between us and our directors, executive officers, 5% stockholders or their family members that require disclosure under Item 404 of Regulation S-K under the heading "Corporate Governance" in our Proxy Statement forExchange Act (“Item 404”).

Pursuant to its written charter, the 2021 Annual Meeting of StockholdersAudit Committee reviews and either approves or disapproves all transactions between the Company and any related person that are required to be helddisclosed pursuant to Item 404.

In determining whether to approve any material related party transaction, the Audit Committee considers the relevant information and facts available to it regarding the transaction and takes into account factors such as the related party’s relationship to the Company and interest (direct or indirect) in the transaction, the terms of the transaction, and the benefits to the Company of the transaction. No director participates in the approval of an interested transaction for which he or she is a related party or otherwise has a direct or indirect interest.

Director Independence

BOARD AND COMMITTEE SUMMARY

The Board has adopted governance guidelines (“Corporate Governance Guidelines”) to assist the Board in the exercise of its duties and responsibilities and to serve in the best interests of the Company and its stockholders.  The Corporate Governance Guidelines set forth in greater detail the responsibilities of our Board and are available under “Corporate Governance” accessible through the “Investors” link on May 20,the Company’s website at www.tivityhealth.com.

Other than Mr. Ashworth, all of the members of the Board who served during 2021 and is incorporated herein by referenceare (or were, as applicable) “independent directors,” as defined under the Nasdaq Stock Market (“Nasdaq”) listing standards..

77


During 2021, each of our incumbent directors attended at least 75% of the aggregate of the total number of meetings held (i) by the Board during the period for which such director served as a member of the Board and (ii) by the committees of which such director was a member during the period for which such director served as a member of such committees.

The following table provides summary information about each committee of the Board and its members.  The duties and responsibilities of each of our committees are set forth in greater detail in each of their respective charters, which are reviewed annually and available under “Corporate Governance” accessible through the “Investors” link on the Company’s website at www.tivityhealth.com.

Audit Committee

Number of Meetings in 2021: 8

Members (1)

Primary Responsibilities

Independence

Erin L. Russell (Chair; financial expert)

Beth M. Jacob

Anthony M. Sanfilippo

The Audit Committee is responsible for, among other things,:

Assisting the Board in oversight of the quality and integrity of our accounting, auditing, and financial reporting systems and our systems of internal controls;

Meeting with our independent registered public accounting firm and management to review our consolidated financial statements; and

Overseeing the accounting, financial, legal, cybersecurity, and regulatory risks the Company faces

All of the members of the Audit Committee are “independent directors” as defined under the Nasdaq listing standards, and satisfy the heightened independence criteria applicable to members of the Audit Committee under the Nasdaq listing standards and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).


Compensation Committee

Number of Meetings in 2021: 5

Members (2)

Primary Responsibilities

Independence

Bradley S. Karro (Chair)

Robert J. Greczyn, Jr.
Erin L. Russell

The Compensation Committee is responsible for, among other things,:

Overseeing our overall compensation strategies and policies;

Annually evaluating the performance of our executive officers;

Determining the appropriate compensation of each of our executive officers; and

Reviewing, approving, and administering our equity-based incentive plans

All of the directors who serve on the Compensation Committee are “non-employee directors” as defined in Rule 16b-3 under the Exchange Act, “Outside Directors” for purposes of regulations promulgated pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), and “independent directors” as defined under the Nasdaq listing standards, in each case as determined by the Board.

Nominating and Corporate Governance Committee

Number of Meetings in 2021: 6

Members (3)

Primary Responsibilities

Independence

Sara J. Finley (Chair)

Robert J. Greczyn, Jr.

Beth M. Jacob

The Nominating and Corporate Governance Committee is responsible for, among other things,:

Identifying individuals qualified to become members of the Board;

Recommending such individuals to the Board for election to the Board;

Developing and recommending to the Board corporate governance principles applicableto the Company; and

Providing oversight for the Company’s environmental, social, and governance (ESG) practices, initiatives, and reporting.

All of the directors who serve on the Nominating and Corporate Governance Committee are “independent directors” as defined under the Nasdaqlisting standards.

(1)

Mr. Sanfilippo became a member of the Audit Committee immediately following the 2021 Annual Meeting of Stockholders.  Dr. Hudson (not shown in the table) was a member of the Audit Committee from January 1, 2021 until the 2021 Annual Meeting of Stockholders, at which time he did not stand for re-election to the Board.  We have, and will continue to have, at least one member of the Audit Committee who has past employment experience in finance or accounting and requisite professional certification in accounting or other


comparable experience that results in the individual’s financial sophistication.  The Board has determined that Ms. Russell qualifies as an “audit committee financial expert”, as defined by the regulations of the Commission.

(2)

Ms. Russell became a member of the Compensation Committee immediately following the 2021 Annual Meeting of Stockholders.  Ms. Jacob was a member of the Compensation Committee from January 1, 2021 until the 2021 Annual Meeting of Stockholders.

(3)

Ms. Jacob became a member of the Nominating and Corporate Governance Committee immediately following the 2021 Annual Meeting of Stockholders.  Mr. Kirshner (not shown in the table) was a member of the Nominating and Corporate Governance Committee from January 1, 2021 until the 2021 Annual Meeting of Stockholders, at which time he did not stand for re-election to the Board.



Item 14. Principal Accounting Fees and Services

Principal Accounting Fees and Services

The aggregate fees billed for each of the last two fiscal years for professional services rendered to us by PwC are shown in the table below.

Information required

Type of Service

 

Fiscal Year Ended

December 31, 2021

 

Fiscal Year Ended

December 31, 2020

Audit Fees

 

 

$

1,049,573

 

 

 

 

$

1,586,013

 

 

Audit-Related Fees

 

 

 

 

 

 

 

 

 

 

Tax Fees (1)

 

 

 

40,000

 

 

 

 

 

 

 

All Other Fees (2)

 

 

 

988

 

 

 

 

 

988

 

 

Total

 

 

$

1,090,561

 

 

 

 

$

1,587,001

 

 

(1)

Tax fees for 2021 relate to tax advisory services.

(2)

All other fees for 2021 and 2020 relate to a software license.

The Audit Committee has considered and concluded that the provision of the non-audit services is compatible with maintaining auditor independence.

Policy Regarding Pre-Approval of Service Provided by this item will be included under the heading "Ratification ofOur Independent Registered Public Accounting Firm" inFirm

The Audit Committee has adopted policies and procedures for pre-approving all audit and permissible non-audit services performed by our Proxy Statement for the 2021 Annual Meeting of Stockholdersindependent registered public accounting firm.  The Audit Committee may delegate its responsibility to pre-approve services to be held on May 20, 2021performed by our independent registered public accounting firm to one or more of its members, but the Audit Committee may not delegate its pre-approval authority to management.

Under these policies, the Audit Committee pre-approves the use of audit and is incorporated hereinaudit-related services following approval of our independent registered public accounting firm’s engagement.  Tax and other non-audit services that are not prohibited services, provided that those services are routine and recurring services and would not impair the independence of our independent registered public accounting firm, may also be performed by reference.our independent registered public accounting firm if those services are pre-approved by the Audit Committee.  Pre-approval fee levels for all services to be provided by our independent registered public accounting firm will be established periodically by the Audit Committee.  Our independent registered public accounting firm must provide detailed back-up documentation to the Audit Committee for each proposed service.  The Audit Committee has pre-approved all audit and audit-related services provided by our independent registered public accounting firm.

78



PART IV

Item 15. Exhibits, Financial Statement SchedulesStatement Schedules

(a)

The following documents are filed as part of this report:

1.

The financial statements filed as part of this report are included in Part II, Item 8 of this report.the Original Form 10-K.

2.

We have omitted all Financial Statement Schedules because they are not required under the instructions to the applicable accounting regulations of the SEC or the information to be set forth therein is included in the financial statements or in the notes thereto.

3.

Exhibits

 

  2.1

 

Membership Interest Purchase Agreement dated July 27, 2016 by and among Sharecare, Inc., Healthways SC, LLC and Healthways, Inc. [incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K dated August 2, 2016, File No. 000-19364]

 

  2.22.2

 

Agreement and Plan of Merger, dated as of December 9, 2018, by and among the Company, Nutrisystem, Inc. and Sweet Acquisition, Inc. [incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated December 10, 2018, File No. 000-19364]

 

 

 

  2.32.3

 

Stock Purchase Agreement, dated as of October 18, 2020, by and among Tivity Health, Inc., Kainos NS Holdings LP, and KNS Acquisition Corp. [incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated October 19, 2020, File No. 000-19364]

 

 

 

  3.1

 

Restated Certificate of Incorporation, as amended [incorporated by reference to Exhibit 3.1 to Form 10-Q of the Company's fiscal quarter ended February 29, 2008, File No. 000-19364]

 

 

 

  3.2

 

Certificate of Amendment to Restated Certificate of Incorporation, as amended, dated as of October 10, 2013 [incorporated by reference to Exhibit 3.2 to Form 10-Q of the Company's fiscal quarter ended September 30, 2013, File No. 000-19364]

 

 

 

  3.3

 

Certificate of Amendment to Restated Certificate of Incorporation, as amended, dated as of January 4, 2017 [incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated January 10, 2017, File No. 000-19364]

 

 

 

  3.4

 

Second Amended and Restated Bylaws of the Company [incorporated[incorporated by reference to Exhibit 3.4 to Form 10-K of the Company’s fiscal year ended December 31, 2019, File No. 000-19364]

 

 

 

  3.5

 

Amendment No. 1 to Second Amended and Restated Bylaws [incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K dated February 25, 2020, File No. 000-19364]

 

 

 

  3.6

 

Amendment No. 2 to Second Amended and Restated Bylaws [incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K dated April 20, 2020, File No. 000-19364]

 

 

 


  4.1

 

Article IV of the Company's Restated Certificate of Incorporation (included in Exhibit 3.1)

 

 

 

  4.2

 

Description of Securities [incorporated by reference to Exhibit 4.2 to Form 10-K of the Company’s fiscal year ended December 31, 2019, File No. 000-19364]

 

 

 

10.1

 

Office Lease dated as of May 4, 2006 between the Company and Highwoods/Tennessee Holdings, L.P. [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated May 5, 2006, File No. 000-19364]

 

 

 

10.2

 

Credit and Guaranty Agreement, dated March 8, 2019,June 30, 2021, by and among Tivity Health,the Company, certain subsidiaries of Tivity Health,the Company as guarantors, the lenders party thereto, Credit Suisse AG, Cayman Islands BranchMorgan Stanley Senior Funding, Inc., as general administrative agent, term loan facility administrative agent and SunTrustcollateral agent, and Truist Bank, as revolving facility agent and swingline lender [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated March 8, 2019,June 30, 2021, File No. 000-19364]

 

 

79


10.3

Cooperation Agreement among the Company, Altaris Capital, L.P., Altaris Partners, LLC, George Aitken-Davies and Daniel Tully, dated August 7, 2019 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated August 7, 2019, File No. 000-19364]

10.4

Amendment to Cooperation Agreement among the Company, Altaris Capital, L.P., Altaris Partners, LLC, George Aitken-Davies and Daniel Tully, dated August 7, 2019 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated February 19, 2020, File No. 000-19364]

10.5

Cooperation Agreement by and between the Company and HG Vora Capital Management, LLC, dated February 25, 2020 [incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated February 25, 2020, File No. 000-19364]

 

Management Contracts and Compensatory Plans

 

 

 

10.6

Employment Agreement dated July 29, 2012 between the Company and Mary Flipse [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company's fiscal quarter ended June 30, 2012, File No. 000-19364]

10.710.3

 

2014 Stock Incentive Plan [incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 dated June 25, 2014, Registration No. 333-197025]

 

 

 

10.810.4

 

2007Tivity Health, Inc. Amended and Restated 2014 Stock Incentive Plan as amended [incorporated by reference to Exhibit 10.1699.1 to Form 10-K of the Company's fiscal year ended December 31, 2012,Registration Statement on Form S-8 dated May 19, 2015, Registration No. 333-204313]

10.5

Tivity Health, Inc. Second Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Appendix A to the Company's Proxy Statement on Schedule 14A filed April 12, 2019, File No. 000-19364]

 

 

 

10.9

Form of Non-Qualified Stock Option Agreement under the Company's 2007 Stock Incentive Plan [incorporated by reference to Exhibit 10.24 to Form 10-K of the Company's fiscal year ended August 31, 2007, File No. 000-19364]

10.10

Form of Non-Qualified Stock Option Agreement (for Directors) under the Company's 2007 Stock Incentive Plan [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company's fiscal quarter ended June 30, 2010, File No. 000-19364]

10.11

Form of Non-Qualified Stock Option Agreement under the Company's 2007 Stock Incentive Plan [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company's fiscal quarter ended March 31, 2012, File No. 000-19364]

10.12

Form of Non-Qualified Stock Option Agreement under the Company's 2007 Stock Incentive Plan [incorporated by reference to Exhibit 10.28 to Form 10-K of the Company's fiscal year ended December 31, 2012, File No. 000-19364]

10.13

Form of Non-Qualified Stock Option Award Agreement (for Executive Officers) under the Company's 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.4 to Form 10-Q of the Company's fiscal quarter ended June 30, 2014, File No. 000-19364]

10.1410.6

 

Form of Restricted Stock Unit Award Agreement (for Executive Officers) under the Company's 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.5 to Form 10-Q of the Company's fiscal quarter ended June 30, 2014, File No. 000-19364]

 

 

 

10.1510.7

 

Form of Non-Qualified Stock Option Award Agreement (for Directors) under the Company's 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.8 to Form 10-Q of the Company's fiscal quarter ended June 30, 2014, File No. 000-19364]

 

 

 

10.16

Form of Restricted Stock Unit Award Agreement (for Directors) under the Company's 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.9 to Form 10-Q of the Company's fiscal quarter ended June 30, 2014, File No. 000-19364]

10.17

Form of Restricted Stock Unit Award Agreement (for Executive Officers) for November 1, 2016 under the Company's Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.46 to Form 10-K of the Company's fiscal year ended December 31, 2016, File No. 000-19364]

80


10.18

Form of Restricted Stock Unit Award Agreement (for Directors) under the Company's Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company's fiscal quarter ended June 30, 2015, File No. 000-19364]

10.19

Form of Restricted Stock Unit Award Agreement (for Directors) under the Company's Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.3 to Form 10-Q of the Company's fiscal quarter ended June 30, 2016, File No. 000-19364]

10.20

Form of Restricted Stock Unit Award Agreement (for Executive Officers) One-Year Cliff Vesting under the Company's Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.3 to Form 10-Q of the Company's fiscal quarter ended June 30, 2015, File No. 000-19364]

10.21

Tivity Health, Inc. Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 dated May 19, 2015, Registration No. 333-204313]

10.22

Form of Restricted Stock Unit Award Agreement (for Executive Officers) for July 1, 2015 under the Company's Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.1 to Form 10-Q of the Company's fiscal quarter ended September 30, 2015, File No. 000-19364]

10.23

Form of Restricted Stock Unit Award Agreement under the Company’s Amended and Restated 2014 Stock Incentive Plan (for Executive Officers and Other Senior Officers) for September 24, 2015 [incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated September 28, 2015, File No. 000-19364]

10.24

Revised Form of Restricted Stock Unit Award Agreement (for Executive Officers and Other Senior Officers) for September 24, 2015 [incorporated by reference to Exhibit 10.73 to Form 10-K of the Company's fiscal year ended December 31, 2015, File No. 000-19364]

10.25

Form of Director Indemnification Agreement [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated June 2, 2016, File No. 000-19364]

10.26

Employment Agreement, dated May 22, 2017, between Tivity Health, Inc. and Adam C. Holland [incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated May 25, 2017, File No. 000-19364]

10.2710.8

 

Form of Non-Qualified Stock Option Award Agreement (for Executive Officers) under the Company's 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.1 to Form 10-Q of the Company’s fiscal quarter ended March 31, 2018, File No. 000-19364]   

 

 

 

10.2810.9

 

Form of Restricted Stock Unit Award Agreement (for Directors) under the Company’s Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.1 to Form 10-Q of the Company’s fiscal quarter ended June 30, 2018, File No. 000-19364]

 

 

 

10.2910.10

Form of 2019 Restricted Stock Unit Award Agreement under the Company’s Amended and Restated 2014 Stock Incentive Plan [incorporated herein by reference to Exhibit 10.4 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]


10.11

Form of Director Indemnification Agreement [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated June 2, 2016, File No. 000-19364]

10.12

Employment Agreement, dated May 22, 2017, between Tivity Health, Inc. and Adam C. Holland [incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated May 25, 2017, File No. 000-19364]

10.13

 

Offer of Employment Letter between the Company and Ryan Wagers dated as of September 14, 2018 [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company’s fiscal quarter ended September 30, 2018, File No. 000-19364]

 

 

 

10.30

Amended and Restated Employment Agreement, dated March 18, 2019, between Tivity Health, Inc. and Donato Tramuto [incorporated herein by reference to Exhibit 10.1 to Tivity Health’s Current Report on Form 8-K, filed March 18, 2019, File No. 000-19364]

10.31

Offer of Employment Letter, dated August 25, 2016, by and between Tivity Health and Steve Janicak [incorporated herein by reference to Exhibit 10.10 to Form 10-Q of the Company's fiscal quarter ended March 31, 2019, File No. 000-19364]

81


10.32

Change of Control Agreement, dated September 13, 2016, by and between the Company and Steve Janicak [incorporated herein by reference to Exhibit 10.1 to Form 10-Q of the Company's fiscal quarter ended September 30, 2019, File No. 000-19364]

10.33

Nutrisystem Stock Incentive Plan [incorporated herein by reference to Exhibit 99.1 to Tivity Health’s Registration Statement on Form S-8, filed March 8, 2019, File No. 333-230173]

10.34

Form of 2019 Performance Stock Unit Award Agreement under the Company’s Nutrisystem Stock Incentive Plan [incorporated herein by reference to Exhibit 10.2 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]

10.35

Form of 2019 Restricted Stock Unit Award Agreement under the Company’s Nutrisystem Stock Incentive Plan [incorporated herein by reference to Exhibit 10.3 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]

10.36

Tivity Health, Inc. Second Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Appendix A to the Company's Proxy Statement on Schedule 14A filed April 12, 2019, File No. 000-19364]

10.37

Form of 2019 Restricted Stock Unit Award Agreement under the Company’s Amended and Restated 2014 Stock Incentive Plan [incorporated herein by reference to Exhibit 10.4 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]

10.38

Form of 2019 Performance Stock Unit Award Agreement under the Company’s Amended and Restated 2014 Stock Incentive Plan [incorporated herein by reference to Exhibit 10.5 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]

10.39

Form of 2019 Integration Bonus Performance Stock Unit Award Agreement under the Company’s Amended and Restated 2014 Stock Incentive Plan [incorporated herein by reference to Exhibit 10.6 to Form 10-Q of the Company's fiscal quarter ended June 30, 2019, File No. 000-19364]

10.4010.14

 

Employment Agreement by and between the Company and Richard M. Ashworth, dated May 20, 2020 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

 

 

 

10.4110.15

 

Form of Restricted Stock Unit Award Agreement for Richard M. Ashworth (Inducement Award), dated June 1, 2020 [incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

 

 

 

10.4210.16

 

Form of Restricted Stock Unit Award Agreement for Richard M. Ashworth, dated June 1, 2020 [incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

 

 

 

10.4310.17

 

Form of Market Stock Unit Award Agreement for Richard M. Ashworth, dated June 1, 2020 [incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K dated May 22, 2020, File No. 000-19364]

 

 

 

10.4410.18

 

Offer of Employment Letter between the Company and Thomas Lewis dated as of October 4, 2018 [incorporated by reference to Exhibit 10.1 to Form 10-Q of 2020 Restricted Stock Unit Retention Award Agreement under the Company’s Second fiscal quarter ended March 31, 2021, File No. 000-19364]

10.19

Amendment No. 1 to Offer of Employment Letter between the Company and Thomas Lewis dated as of April 1, 2019 [incorporated by reference to Exhibit 10.2 to Form 10-Q of the Company’s fiscal quarter ended March 31, 2021, File No. 000-19364]

10.20

Amendment No. 2 to Offer of Employment Letter between the Company and Thomas Lewis dated as of October 30, 2020 [incorporated by reference to Exhibit 10.3 to Form 10-Q of the Company’s fiscal quarter ended March 31, 2021, File No. 000-19364]

10.21

Amended and Restated 2014 Stock Incentive Plan.Offer of Employment Letter between the Company and Raymond Bilbao dated as of October 30, 2020 [incorporated hereinby reference to Exhibit 10.4 to Form 10-Q of the Company’s fiscal quarter ended March 31, 2021, File No. 000-19364]

10.22

Change of Control Agreement between the Company and Raymond Bilbao dated as of July 3, 2018 [incorporated by reference to Exhibit 10.5 to Form 10-Q of the Company’s fiscal quarter ended March 31, 2021, File No. 000-19364]


10.23

Tivity Health, Inc. Director Deferred Compensation Program, dated December 14, 2020 [incorporated by reference to Exhibit 10.46 to Form 10-K of the Company's fiscal year ended December 31, 2020, File No. 000-19364]

 

 

 

10.45*

Separation Agreement by and between the Company and Mary Flipse, dated November 2, 2020

10.46*

Tivity Health, Inc. Director Deferred Compensation Program, dated December 14, 2020

10.47*10.24

 

Form of Deferred Stock Unit Award Agreement (for Directors) under the Company’s Second Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.47 to Form 10-K of the Company's fiscal year ended December 31, 2020, File No. 000-19364]

10.25

Separation Benefits Program for Section 16 Officers, dated September 22, 2021 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated September 27, 2021, File No. 000-19364]

10.26

Special Incentive Bonus Award Agreement by and between Tivity Health, Inc. and Richard Ashworth, dated February 11, 2022 [incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated February 11, 2022, File No. 000-19364]

10.27

Form of 2020 Non-Qualified Stock Option Award Agreement (for Executive Officers) under the Company's Second Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.27 to Form 10-K of the Company’s year ended December 31, 2021]

10.28

Form of 2021 Non-Qualified Stock Option Award Agreement (for Executive Officers) under the Company's Second Amended and Restated 2014 Stock Incentive Plan [incorporated by reference to Exhibit 10.28 to Form 10-K of the Company’s year ended December 31, 2021]

 

 

 

21*

 

Subsidiary List

 

 

 

23*

 

Consent of PricewaterhouseCoopers LLP

82


 

 

 

31.1*

 

Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Richard M. Ashworth, Chief Executive Officer, as amended

 

 

 

31.2*

 

Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Adam C. Holland, Chief Financial Officer, as amended

31.3**

Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Richard M. Ashworth, Chief Executive Officer, as amended

31.4**

Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 made by Adam C. Holland, Chief Financial Officer, as amended

 

 

 

32*

 

Certification Pursuant to 18 U.S.C section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 made by Richard M. Ashworth, Chief Executive Officer, and Adam C. Holland, Chief Financial Officer

 

 

 

101101*

 

The following financial statements from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020,2021, formatted in Inline XBRL: (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Income; (iv) Consolidated Statement of Changes in Stockholders’ Equity; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial Statements.


 

 

 

104104**

 

The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, formattedCover Page Interactive Data File (formatted in Inline XBRL (includedand included in the interactive data files submitted as Exhibit 101 hereto)101).

 

(b)

Exhibits

Refer to Item 15(a)(3) above.

(c)

Not applicable

*

Filed or furnished as an exhibit to the Original Form 10-K

**

* Filed herewith

83



Item 16. Form 10-K Summary

None.


84


SIGNATURES

Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

TIVITY HEALTH, INC.

 

 

 

 

 

 

March 2, 2021April 29, 2022

 

 

By:

 

/s/ Richard M. AshworthAdam C. Holland

 

 

 

 

 

Richard M. Ashworth

Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

Title

Date

/s/ Richard M. Ashworth

Chief Executive Officer and Director (Principal Executive Officer)

March 2, 2021

Richard M. Ashworth

/s/ Adam C. Holland

Chief Financial Officer (Principal Financial Officer)

March 2, 2021

Adam C. Holland

/s/ Ryan M. Wagers

Controller and Chief Accounting Officer (Principal Accounting Officer)

March 2, 2021

Ryan M. Wagers

/s/ Anthony M. Sanfilippo

Chairman of the Board and Director

March 2, 2021

Anthony M. Sanfilippo

/s/ Sara J. Finley

Director

March 2, 2021

Sara J. Finley

/s/ Robert J. Greczyn, Jr.

Director

March 2, 2021

Robert J. Greczyn, Jr.

/s/ Peter A. Hudson, M.D.

Director

March 2, 2021

Peter A, Hudson, M.D.

/s/ Beth M. Jacob

Director

March 2, 2021

Beth M. Jacob

/s/ Bradley S. Karro

Director

March 2, 2021

Bradley S. Karro

/s/ Benjamin A. Kirshner

Director

March 2, 2021

Benjamin A. Kirshner

/s/ Erin L. Russell

Director

March 2, 2021

Erin L. Russell

 

85